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ABSTRACT 
Pharmaceutical aerosols are an effective method to deliver therapeutic agents to the respiratory tract. Among aerosol 
generation systems, dry powder inhalers (DPIs) have been an attractive technology for both local and systemic delivery 
of drugs. DPIs combine several advantages compared to metered dose inhalers (MDIs) and other inhalation devices: 
DPIs are breath-actuated (patients do not require hand-lung coordination), no need for environmentally damaging 
chlorofluorocarbon (CFC) propellants or solvents, improved product stability, DPIs deliver a wide range of drugs (e.g. 
traditional anti-asthmatics, proteins) in high doses via one short inhalation and increased respirable fractions compared 
to MDIs. Furthermore, DPIs often have only low inspiratory flow resistances, which is beneficial for patients suffering 
from respiratory diseases [1, 2]. Inhalation devices are designed to deliver a reproducible predefined dose of drug to 
the small airways and alveolar regions of the human lung. It has been reported that particles with a mass median 
aerodynamic diameter (MMAD) of <5 μm are effectively deposited at these sites [3, 4]. The MMAD of an aerosol 
particle depends on its geometrical diameter, density, and morphology with these properties generally being optimized 
during the manufacturing process [5]. Most commercial DPI formulations (adhesive mixtures) consist of micronized 
drug blended with coarser carrier particles (usually alpha lactose monohydrate; ca. 20-300 μm), which is used to aid 
the handling, metering and dosing of the formulation. These components are usually combined in a manufacturing 
process with high- or low-shear blending, which is used primarily to distribute the cohesive drug particles throughout 
the bulk excipient of the formulation to create a homogeneous mixture. The interactions between drug and carrier are 
a major determinant of DPI performance. Due to interparticulate forces, such as mechanical interlocking, capillary, 
electrostatic, and van der Waals, micronized powders exhibit very adhesive and cohesive behavior and form 
spontaneously agglomerates [6, 7]. The extent of the combined forces is dependent on powder properties such as 
particle size, morphology, shape, and material characteristics (e.g. amorphous content, hydrophilicity, electrical 
resistivity) [8], as well as on environmental factors, such as relative humidity and temperature [9]. Since the extent of 
agglomeration negatively affects the fraction of the inhaled powder within the respirable range [10], these 
agglomerates must be deagglomerated effectively prior to or during the processes of aerosolization and inhalation 
[11]. 
In recent years, there has been great interest in the development of ternary mixing systems because the addition of a 
ternary component into carrier-based DPI formulations can lead to improved aerosol performance due to drug-carrier 
interaction modifications [12-19]. In lactose-based DPI formulations, ternary components can be either lactose fines 
[20], sugars (e. g. micronized glucose) [21], or a variety of force control agents (FCAs) such as magnesium stearate 
(MgSt) or leucine [13, 15, 16, 18, 22]. Blending lactose together with MgSt prior to adding the active pharmaceutical 
ingredient (API) has been shown to modify the performance of pharmaceutical inhaled products [14, 15]. Also pre-
treatment of APIs with different FCAs has been shown to alter the performance and improve the drug deposition in 
the lowest impactor stages [23]. Various application processes such as mechanofusion, high- or low-shear mixing and 
particle smoothing have been used to apply different FCAs on carrier particles as very thin coating layers (<10 nm) 
[16, 22, 24, 25]. 
The current pharmacopoeial standard method for determining the aerodynamic particle size distribution (APSD) of 
APIs delivered from inhaled pharmaceutical products is to generate a size-segregated sample of the particles in a 
cascade impactor, typically the Next Generation Impactor (NGI) [26-28], followed by the dissolution of each size-
fractionated particle sample into a solvent which is then analyzed by high-performance liquid chromatography 
(HPLC). While highly quantitative for the total concentration of API delivered, this technique does not yield any 
information regarding the relationships and interactions between the various product components (API(s), excipients) 
within the formulation. Cascade impaction testing also requires mastery of a complex technique before consistent 
results can be achieved and results in a large demand on resources in terms of laboratory personnel and solvents, and 
the measurements are very time-consuming [29, 30]. The development of more rapid techniques as application for 
routine product quality testing or in product development is therefore highly desired [31]. Mass spectrometry based 
aerosol analytical techniques have been undergoing continuous development since the 1970s [32, 33]. Aerosol-
specific mass spectrometers are capable of providing both aerodynamic particle size distribution (APSD) profiles and 
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the chemical composition of particles by using a statistical sample of a high number of single particles in a very short 
timeframe (minutes). The single particle aerosol mass spectrometry (SPAMS) technique can be used to evaluate 
particle interactions/co-associations between drug product components in a way that is inaccessible via cascade 
impactor techniques. Importantly, since in recent years more complex inhaled products have become available on the 
market that deliver two (or even three) APIs within a single dose (e. g. Ultibro® Breezhaler®, Foster® NEXThaler®, 
Trelegy® Ellipta®) using highly sophisticated engineered formulation approaches with fine lactose and/or magnesium 
stearate [34-36]. Clinical research has shown that such combination inhalers provide an enhanced clinical effect 
beyond that achieved when the two drugs are administered concurrently from two separate inhalers. Preliminary tests 
using aerosol time-of-flight mass spectrometry and SPAMS determined that the respirable fraction can be composed 
of co-associated API particles, which could be the reason behind the increased effects of the combination drug inhalers 
[30, 37, 38]. 
This thesis focuses on the investigation of the complex mechanisms that affect the dispersion of drug particles during 
aerosolization and ultimately the in vitro aerosol performance of inhalation. Particular attention was paid to 
combinations of two APIs and formulations containing magnesium stearate as force control agent. Specifically 
prepared model dry powder inhaled formulations and commercial products were used. High- and low-shear blending 
techniques of lactose and magnesium stearate were explored and the effect of different storage regimes on 
physicochemical properties and performance of such dry powder inhaled formulations was assessed. Advanced 
powder characterization techniques such as single particle aerosol mass spectrometry (SPAMS) and time-of-flight 
secondary ion mass spectrometry (ToF-SIMS) were employed to improve the mechanistic understanding of particle 
interactions, drug detachment and dispersion during impaction analysis. 
In a first study, aerodynamic particle size distribution profiles (APSD) of commercial metered dose inhaler (MDI) and 
dry powder inhaler (DPI) were obtained using single particle aerosol mass spectrometry (SPAMS; Livermore 
Instruments Inc., USA) and then compared to those obtained by the Aerodynamic Particle Sizer (APS; TSI 
Incorporated, USA) and Next Generation Impactor (NGI, Copley Scientific, USA). In addition, the transmission 
efficiency of SPAMS as well as potential size bias of APSD measurements that might result from a size dependent 
transmission profile were evaluated. It was demonstrated that the SPAMS can generate useful APSD measurements 
with both pMDI and DPI products. However, a consistent difference of particle transmission in the SPAMS in the 
region of 2-3 µm was found compared to NGI measurements. 
In a second study, measurements of Advair® Diskus® and Seretide® using the SPAMS technique showed that a 
significant fraction of the emitted drug particles can form co-associated particles with other drugs (and likely 
excipients) in the same DPI or pMDI formulation. For this, unique mass spectral fragmentation patterns could be 
recognized and assigned for each API using the SPAMS data analysis software. SPAMS also revealed which particle 
size fractions are most likely forming these co-associations. In a third study it could be demonstrated that for example 
in Foster® NEXThaler® the degree of particle co-association was manipulated by the choice of formulation and 
manufacturing approach for DPIs. It is possible that in the manufacturing process APIs or carrier can be processed 
together with the force control agent magnesium stearate to improve dispersion mechanics. An explanation may be 
that the drug or the carrier receive an MgSt-coating that would prevent the co-association or agglomeration of the 
particles and moreover facilitate detachment from carrier. This results in high in vitro performance (and furthermore 
high extra fine particle fraction of particles <2 µm), as well as a relatively fine APSD profile compared to products 
not engineered in this way. Particle co-associations of API-MgSt were detected in the commercially available DPI 
product Foster® NEXThaler®. 
The intensity of the blending technique is demonstrated in a fourth study in this work to affect the distribution of MgSt 
covering the lactose carrier. This coverage of lactose by MgSt as evidenced using the ToF-SIMS technique was shown 
to significantly influence the in vitro aerosol performance. The underlying mechanism of particle interaction between 
API and the carrier seems to be substantially different for high- and low-shear formulations. This provides the basis 
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for a modification in particle interactions from drug-lactose to drug-MgSt (in high-shear), which then is responsible 
for the improved performance by enhanced particle detachment from carrier due to lower interaction forces. 
In a fifth study, the conditioning of DPI capsules at controlled temperature and humidity settings also showed to have 
a significant effect on the separation of drug and carrier particles. Significant differences were observed between 
adhesive and cohesive model compounds (with respect to lactose). This study highlights that electrostatic forces and 
interactions play a significant role in dry powder inhaled formulations. Large differences in the electrostatic charging 
behavior were observed. Fluticasone propionate seems to have a high propensity to electrostatic charging, while 
salmeterol xinafoate only showed negligible performance consequences as a result of its electrostatic charging 
behavior. Most of the common excipients used in DPI formulations, such as lactose monohydrate, do not seem to 
experience significant charge accumulation in stark contrast to MgSt, which tends to acquire high amounts of 
electrostatic charge. Other DPI drug product components such as HPMC capsules did not tend to charge significantly. 
Conditioning of certain APIs was found to be helpful to dissipate electrostatic charge which in turn increased aerosol 
performance. 
In summary, this thesis combines improvements to the analytical methodologies such as SPAMS with the systematic 
investigation of dry powder inhalation formulations to advance the understanding of in vitro aerosol characteristics of 
drug product formulations at a fundamental mechanistic level. 
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CHAPTER 1: GENERAL INTRODUCTION INTO PULMONARY DRUG 
DELIVERY & FORMULATION DEVELOPMENT 
1. General Introduction 
The respiratory tract is one of the oldest routes for the administration of drugs. Anesthetics, aerosolized drugs, smoke 
or steam have been inhaled for medical purposes for hundreds of centuries. Over the past decades inhalation therapy 
has established itself as a valuable tool in the local therapy of pulmonary diseases, such as asthma or chronic 
obstructive pulmonary disease (COPD) [39]. The benefits of local lung delivery include rapid clinical response and 
minimized systemic toxicity due to reduction of overall required doses. Regarding systemic therapy, the lungs are an 
efficient way for drugs to reach the bloodstream due to the large surface area available for absorption (ca. 100 m2), 
the very thin absorption membrane (0.1–0.2 μm) and the elevated blood flow (5 L/min), which rapidly distributes 
molecules throughout the body. Moreover, the lungs exhibit relatively low local metabolic activity, and unlike the oral 
route, pulmonary inhalation is not subject to first pass metabolism [40]. However, pulmonary administration presents 
the difficulty of achieving efficient and regular deposition of the drug in the bronchial or alveolar regions of the 
respiratory tree, an aerodynamically efficient filter that hinders the deposition of the drug. 
Historically, the evolution of inhalation therapy can be traced to India around 4000 years ago, where the leaves of the 
plant Atropa Belladonna, containing atropine as a bronchodilator, were smoked as a cough suppressant [41]. Asthma 
cigarettes containing stramonium leaves (Datura Stramonium) with atropine-like effects were widely used in the 19th 
century as “fuming asthma remedies” along with powders and cigars [42]. However, the development of modern 
inhalation therapy started in the 19th century with the invention of the glass bulb nebulizer. The development of the 
first pressurized metered dose inhaler (pMDI) for asthma therapy (Medihaler®) by Riker Laboratories Inc. (now 3M 
Drug Delivery Systems) in 1956 was a major advance in the use of (pharmaceutical) aerosols for drug delivery to the 
lungs [43]. However, the required hand-lung coordination of the patient and the use of environmentally damaging 
chlorofluorocarbon (CFC) propellants, are major drawbacks of the traditional pMDI. Dry powder inhalers (DPIs) were 
introduced to overcome these drawbacks. Since the first introduction of a DPI in 1971 (Spinhaler®) by Fisons, many 
DPIs have been marketed. DPIs represent a significant advance in pulmonary delivery technology. They are breath-
controlled and therefore coordination problems have been overcome. DPIs are also potentially suitable for the delivery 
of a wide range of drugs apart from the field of asthma and COPD, such as anti-asthmatics, peptides and proteins. 
DPIs can also deliver a wide range of doses from 6 mg to more than 20 mg via one short inhalation [40, 43]. 
This chapter gives an overall introduction to inhalation therapy with modern dry powder inhaler technology, from the 
pulmonary diseases and human anatomy of the airways to dry powder formulation development. 
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2. Pulmonary Drug Delivery 
2.1 From Inhalation to Clinical Effect 
Pulmonary delivery has gained importance in the therapeutic field because of the numerous advantages this route of 
administration offers, in comparison to the oral or parenteral routes. The active pharmaceutical ingredient (API) can 
be delivered directly to the site of action in the respiratory tract in a high concentration to treat respiratory diseases 
such as asthma, chronic obstructive pulmonary disease (COPD), and bacterial or fungal pulmonary infections. 
Furthermore, this route could also be considered for treating lung tumors. The advantages of such targeted therapy 
include a reduction in local (deposition in oropharynx) and systemic side effects and a decreased incidence of potential 
drug-drug interactions [44]. These reductions are due to the decrease in systemic drug concentrations, whilst ensuring 
a therapeutic efficiency that is similar or superior to oral or parenteral delivery. 
The major advantages of inhalation therapy are as follows [40]: 
(a) Rapid onset of the therapeutic effect (huge surface area in the lungs allows a fast uptake of drug) 
(b) Lowering of the required dose (compared to systemic administration) 
(c) Reduction in unwanted side effects 
It is well known that inhalation therapy, especially for asthma and COPD, is very successful even though only a small 
fraction of the inhaled dose (typically less than 20-30%) actually reaches the peripheral parts of the respiratory tract. 
The rest of the dose deposits in the mouth and in the upper airways [44]. The dry powder inhaler device is one of the 
types of delivery systems that enable the generation and delivery of aerosolized drug particles into the respiratory 
tract. The principle of this therapy is to transfer powdered medication into a clinical effect. However, the respiratory 
tract is a strongly branched system, which works excellently as filtering system to avoid penetration of particles into 
the lungs. To enable penetration into the lungs, the aerodynamic particle size of the inhaled medication has to be 
tailored, preferably below 5 μm [3, 4]. The particle size distribution of the drug is one of the major determinants in 
drug delivery to the respiratory tract. Special techniques, such as micronization of drugs in dry powder systems, are 
required to produce particles in this size range. Because of difficulties in powder handling of micronized particles and 
very low amounts of drug (5-500 mcg) that have to be metered in inhalation therapy, special formulations and devices 
have to be developed and applied to obtain the required clinical effect from the administered dose [7, 45]. 
2.2 Anatomy and Physiology of the Human Respiratory Tract 
The main function of the respiratory tract is the exchange of oxygen from the alveolar gas into the pulmonary capillary 
blood and carbon dioxide exchange vice versa. The respiratory tract can be separated into two main parts (upper and 
lower lung). The upper part is divided into the head airway region with the nose, mouth, pharynx and larynx, and the 
tracheobronchial region from the trachea to the terminal bronchioles. Its main functions are warming and humidifying 
of air, and to retain foreign material to protect the lower lung. The lower lung is the pulmonary or alveolar region 
where the gas exchange takes place [46, 47]. The respiratory tract is characterized by a thin epithelium, very large 
surface area (ca. 100 m2), low enzymatic activity, and a rich blood supply [48]. 
The human respiratory tract is a branching system of air channels with more than 23 bifurcations from the mouth to 
the alveoli with the appearance of an inverted tree. The human respiratory system can largely be divided into four 
regions. These regions clearly differ in structure, airflow patterns, function, and sensitivity to deposited particles. The 
most frequent used morphological model for describing the structures of the human lungs was initially given by Weibel 
(Figure 1) [49]. 
1. The first region is the upper respiratory tract, which includes the nose, mouth and pharynx. The main function 
of this region is the heating and moistening of air. Atmospheric air contains around 40-60% of moisture and 
has a temperature of ca. 20 °C. In the mouth, nose and throat the air is heated up to 37 °C and reaches 99% 
relative humidity. 
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2. The second region of the human lung is the conduction zone. This region consists of the first 16 generations 
of branching. The airways of the conducting zone are described as rigid tubes that consist primarily of 
cartilage in the walls and that symmetrically divide or bifurcate beginning with the trachea and ending with 
the terminal bronchioles. 
3. The third region is the transitional zone. This region consists of the generations 17 through 19 of the 
branching. The respiratory bronchioles each consist of a few alveoli in which limited gas exchange can occur. 
4. The fourth region is the respiratory zone. This region consists of the generations 20 through 23 of the 
branching, ending in the alveoli. Gas exchange occurs in the highly vascularized respiratory zone by adding 
oxygen, and removing carbon dioxide from the blood while passing the pulmonary capillary bed. With 
increasing generation number, the number of branches highly increases, while the distance between the 
branches and the airway diameter decrease. The summed cross sectional area from mouth to alveolar sacs 
exponentially increases and results in a tree shaped lung model, with a total surface area of up to 100 m2 [49, 
50]. 
 
Figure 1: Schematic representation of airway branching in the human lung. Adapted from [51]. 
2.3 Particle Deposition in the Lungs 
In order to achieve the desired pharmacological effect, a drug particle designed for inhalation must deposit at the site 
of action [52]. The fate of inhaled particles either as a medicine or as environmental aerosol depends mainly on the 
particle properties (size/aerodynamic diameter, shape, and density) and lung physiology (geometry, respiratory flow 
rate, tidal volume). Over 90% of particles with an aerodynamic diameter larger than 10 μm are deposited in the 
oropharynx. The critical aerodynamic diameter for reaching the lungs is known to be <5 μm (Figure 2) [3, 4]. The 
relationship between aerodynamic particle size and deposition has been studied extensively [53]. Most studies confirm 
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the computations in their predictions that the most effective particles for inhalation are indeed within the aerodynamic 
size range of 1-5 μm [54-57]. It should be noted that particles with larger geometric diameters may be useful for 
inhalation if they have low densities, e.g. as the result of porous structures [58, 59]. Such particles may have an 
aerodynamic diameter between 1 and 5 μm, although their geometric diameter is much larger (e.g. in the size range 
of 10 to 30 μm) [5, 60]. 
 
Figure 2: Relationship between particle size and lung deposition (from Labiris and Dolovich [3]). 
The three most important particle deposition mechanisms are (1) impaction due to inertia of particles, (2) 
sedimentation due to gravitational forces, and (3) Brownian diffusion (Brownian motion of surrounding gas 
molecules) (Figure 3) [61]. Interception and electrostatic deposition only play a minor role in the lungs [62, 63]. 
 
Figure 3: Schematic of particle deposition mechanisms at an airway branching site in the human lung adapted from [64]. 
Impaction takes place for particles >3 μm, sedimentation for particles with a diameter of 0.5-4 μm, and diffusion for 
particles <1 μm. 
The deposition mechanisms can be explained with fluid and particle dynamics in the respiratory tract. As a result of 
the many branchings, the cross section for air flow increases exponentially from the trachea to the alveolar sacs. 
Accordingly, the air velocity decreases from nearly 4 m/s in the trachea to less than 1 mm/s in the alveoli (at a moderate 
inspiratory flow rate of 60 L/min). This has the consequence that the air flow is turbulent in the upper tract and laminar 
further downstream. Because filtering of airborne particles in the upper tract by inertial deposition (impaction) depends 
on the particle’s aerodynamic diameter and the particle velocity, the cut-off value of the upper tract highly depends 
on the inhalation maneuver. At higher flow rates (>60 L/min), most particles larger than 3-5 μm cannot pass the 
oropharynx and the first bifurcations. In the upper tract, where the air velocity is still relatively high, particles may 
19 
collide with the inner walls of the large airways by inertial impaction. Particles with high inertia (large diameter; high 
density) are unable to follow the airflow in bifurcations and bends and deposit on the mucosa covering the inner airway 
walls. Filtering of the larger particles in the upper tract in combination with the reduced velocity decreases the 
deposition probability by inertial impaction further downstream, and increases the contribution of sedimentation to 
total deposition. 
When the flow rate is decreased (less than 30 L/min), particles in the size range up to 3-5 μm may enter the central or 
even the deep lung. If such particles are able to enter the lung periphery, their deposition efficiency will be relatively 
high due to their high sedimentation velocity (compared to particles of 1 μm or smaller). The decreasing sedimentation 
velocity with decreasing particle size is the reason why particles <1 μm are often considered unsuitable for inhalation, 
which explains why the recommended aerodynamic size range is between 1-5 μm [53, 57]. The gravitational settling 
velocity of particles in the micron range is low, whereas their residence time in the lungs is relatively short. As a result, 
the deposition efficiency decreases as particle settling becomes more dependent of sedimentation than of inertial 
impaction. Deposition efficiency under normal breathing conditions reaches a minimum of only approximately 20% 
for particles of 0.5 μm, meaning that 80% of particles of this size are exhaled again. To increase the deposition 
efficiency, the residence time can be prolonged, which explains the benefit of a breath hold period in this respect. For 
particles smaller than 0.1 μm, the efficiency may increase also due to an increasing contribution of Brownian motion 
to particle deposition. 
2.4 Pulmonary Drug Absorption 
The optimal absorption characteristics of a pulmonary drug depend on the site of drug action. For locally acting drugs, 
the drug absorption process may determine the removal and consequently the termination of action of the drug in the 
lungs, as well as the onset of any systemically mediated adverse effects. For systemically acting drugs, absorption 
from the lungs determines the therapeutic effect profile (onset, intensity, and duration of action) of the drug. Therefore, 
when designing drugs for pulmonary delivery, it is important to consider both lung–tissue retention and permeability, 
irrespective of site of action. The air-to-blood transfer always begins with an interaction between the drug and the 
surfactant: following deposition onto the mucosa of the tracheobronchial airways or alveolar region, the drug solute 
or particle encounters at least a monolayer of surface-active agents in which the fatty acid tails of lipids project into 
the air. For a drug compound of macromolecular size (e.g. peptide or protein), this lung surfactant may induce 
aggregation and, thus, potentially compromise dissolution or enhance macrophage uptake and digestion [65]. By 
contrast, lung surfactant can enhance solubility of small, lipophilic drug molecules, as demonstrated for example with 
glucocorticosteroids [66], which may potentially increase the rate and extent of absorption. Immediately below the 
molecular layer(s) of lung surfactant lies the 0.01–10 µm thick lining fluid through which drug must diffuse to get to 
the epithelium. The routes of drug absorption across the epithelium include passive and active transport mechanisms 
involving paracellular and transcellular transport, pore formation, vesicular transport, and drainage into the lymphatics 
(depending on the drug and site of absorption). The drug solute will pass through a cellular barrier that varies from a 
monolayer of thick (about 60 µm) columnar cells in the bronchi to a monolayer of thin (0.2 µm) broad cells in the 
alveoli. Drug absorbed from the air spaces into the blood must traverse a final barrier after the surfactant layer, the 
lining fluid, the epithelium, its basement membrane, and the interstitium: the cell monolayer that makes up the walls 
of the microvessels, the endothelium. The alveolar–capillary endothelium is extremely thin (0.03–0.2 µm) and has a 
relatively large number of endocytic vesicles [67]. 
2.4.1 Dissolution 
Once the drug aerosol has been deposited onto the lung surface, the immediate fate of the drug depends on its physical 
state. A free, solubilized drug will rapidly diffuse into the epithelial lining fluid and become available for absorption, 
while a drug deposited as particulate material has to be dissolved prior to absorption and may be subject to clearance 
by other mechanisms such as mucociliary clearance. The physicochemical properties of inhaled drugs vary 
considerably, from very hydrophilic to very hydrophobic (log P from −2 for the β2-agonist salbutamol sulfate and 5 
for the corticosteroid fluticasone propionate; where P is the octanol-water-partition coefficient) with low aqueous 
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solubility from sub-microgram per milliliter (0.1 mg/mL fluticasone propionate) to that of hundreds of milligram per 
milliliter (250 mg/mL for salbutamol sulfate) [67]. For compounds with high aqueous solubility, dissolution is not 
considered to impact the lung clearance rate, and no or only small differences in pharmacokinetics are expected for 
different types of formulations unless the regional deposition is substantially different and/or absorption is altered by 
excipients. The very poorly soluble compounds show fairly rapid onset of absorption followed by sustained absorption 
over time, which is thought to be dissolution limited. For micronized lipophilic drugs, time of peak concentration has 
been suggested to correlate with intrinsic solubility [68]. The solubility of a drug depends on the compound, the 
formulation and physical form of the drug, as well as on the composition of the dissolving media in the lung. The 
composition of this fluid is mainly water (96%), salts, phospholipids, proteins, and mucins with a pH about 6.6 in 
healthy individuals [69, 70], while the surface-lining layer in the alveoli is composed of a thin layer of alveolar 
surfactant (phospholipids and proteins). The lipids and proteins in the lining fluid will increase the wetting, the 
solubility, and hence the dissolution rate of poorly soluble drugs [66, 71]. Generally, the solubility, and hence 
dissolution rate, is higher for a less thermodynamically stable material (crystalline polymorph or amorphous form) 
than that of a molecular high-order crystalline state. 
The total liquid volume available for dissolution in the human lung is approximately 10–30 mL. Considering that a 
clinically relevant dose of fluticasone propionate, as an example of a poorly soluble drug, would require a volume in 
excess of 1 L for complete dissolution in a stationary system, the liquid volume in the lung is small. The thickness of 
the lining fluid varies from about 5–10 µm in the conducting airways and gradually decreases distally to about 0.01–
0.08 µm in the alveoli [65, 72]. A drug particle deposited in the conducting airways can thus be immersed in the lining 
fluid while the lining fluid film may be much thinner than the diameter of a deposited drug particle in the alveoli. 
Consequently, the area of the solid liquid interface between the particles and the fluid is proportional to particle surface 
area in the conducting airways but limited by the thickness of the fluid in the alveoli. This suggests that particles 
deposited in the upper airways could dissolve more rapidly than particles deposited in the alveoli. However, other 
factors such as greater solubility, larger total interfacial surface area, and/or more rapid absorption in the periphery 
could arguably lead to the opposite. Assessing dissolution in the lungs is very complex as each of the governing 
parameters will be different in the different regions of the lungs, leading to several different dissolution processes 
occurring in parallel. By contrast, dissolution in the gastrointestinal tract can be described as a continuous process 
over a sequence of tanks with different properties [73]. Dissolution in the lungs has not been as systematically explored 
as dissolution in the gastrointestinal tract; rather the knowledge is derived from a number of diverse studies 
investigating in vitro dissolution models in the environmental and drug research area. Hence, there are presently no 
established in vivo predictive in vitro dissolution models for pulmonary formulations, in contrast to the standardized 
dissolution test methods available for oral solid dosage forms [74-76]. 
In conclusion, the dissolution rate of formulations or compounds may affect the rate and mode of clearance from the 
lungs, and therefore influence the pharmacodynamic properties of a drug. As a result of the difficulty in accounting 
for all the confounding factors, direct evidence is scarce, which limits the ability to predict how variations in 
formulations that affect solubility and/or dissolution will affect the pharmacokinetic and pharmacodynamic properties 
of a product. 
21 
2.5 Clearance and Defense Mechanisms in the Respiratory Tract 
 
Figure 4: Possible routes of elimination of drug from the lungs. Pulmonary drug metabolism, clearance, and absorption 
depend on an interplay between factors occurring prior to target interaction (deposition, dissolution, and mucociliary 
transport), and events competing with target interaction (biotransformation, receptor interaction, and nonspecific 
retention), and following target interaction (systemic absorption). Adapted from [77]. 
Once deposited in the lungs, inhaled drugs are either cleared from the lungs, absorbed into the systemic circulation or 
degraded via drug metabolism. Drug particles deposited in the conducting airways are primarily removed through 
mucociliary clearance and, to a lesser extent, are absorbed through the airway epithelium into the blood or lymphatic 
system (Figure 5) [3, 78]. Mucociliary clearance is impaired in lung diseases such as immotile cilia syndrome, 
bronchiectasis, cystic fibrosis and asthma [79]. 
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Figure 5: Mucociliary clearance competing with particle dissolution and absorption. Particles deposited on the mucus layer 
will gradually dissolve and diffuse toward the cell layer where the drug substance eventually may get absorbed. Particles 
of slowly dissolving compounds will be partly cleared by ciliary action thus reducing the amount absorbed. Adapted from 
[77]. 
In addition to mucociliary clearance, soluble particles also can be removed by absorptive mechanisms in the 
conducting airways [3]. Lipophilic molecules pass easily through the airway epithelium via passive transport. 
Hydrophilic molecules cross via extracellular pathways, such as tight junctions, or by active transport via endocytosis 
and exocytosis [80]. From the submucosal region, particles are absorbed into either the systemic circulation, bronchial 
circulation or lymphatic system. 
Drugs deposited in the alveolar region may be phagocytosed and cleared by alveolar macrophages or absorbed into 
the pulmonary circulation. Alveolar macrophages are the predominant phagocytic cell for the lung defense against 
inhaled microorganisms, particles and other toxic agents. Macrophages phagocytose insoluble particles that are 
deposited in the alveolar region and are either cleared by the lymphatic system or moved into the ciliated airways 
along currents in alveolar fluid and then cleared via the mucociliary escalator [81]. This process can take weeks to 
months to complete [82]. Soluble drug particles deposited in the alveolar region can be absorbed into the systemic 
circulation. The rate of protein absorption from the alveoli is size dependent [83].  
Very little is known about how the drug-metabolizing activities of the lung affect the concentration and therapeutic 
efficacy of inhaled drugs. All metabolizing enzymes found in the liver are present to a lesser extent in the lung 
(CYP450 enzymes are up to 20 times lower than in liver) distributed throughout the conducting airways and alveoli 
[81, 84-86]. 
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3. Targets of Inhalation Therapy 
Inhalation of drugs has been established successfully for a local treatment of lung diseases. A number of marketed 
products contain a wide range of different drugs for the treatment of asthma or chronic obstructive pulmonary disease 
(COPD) as the lung diseases with the highest prevalence [87]. Ongoing research is further focusing on the therapy of 
cystic fibrosis, lung cancer or the vaccination via the lungs since the lung provides the bronchus associated lymphoid 
tissue that enables mucosal vaccinations [88-90]. Systemically, inhalation therapy is of great interest as active 
pharmaceutical ingredients (APIs) or proteins delivered to the lungs avoid the hepatic first-pass effect and degradation 
in the gastro intestinal tract. Some marketed products such as for example inhaled insulin (Exubera® from Pfizer; 
withdrawn from market in 2007) proved this concept and raised hope for the development of pharmaceutics objected 
to all kinds of diseases [91, 92]. 
3.1 Asthma and Chronic Obstructive Pulmonary Disease (COPD) 
Asthma is a chronic inflammatory disease of the airways characterized by reversible airway obstruction associated 
with exacerbations of coughing, wheezing, chest tightness, difficult of breathing, and airway hyper responsiveness 
[93]. Asthma has a high incidence and is a common disease among children. It is estimated, that over 235 million 
people worldwide suffer from asthma (2016 estimate by the World Health Organization). Risk factors for developing 
asthma include inhaling asthma “triggers”, such as allergens, tobacco smoke and chemical irritants. Asthma cannot be 
cured, but appropriate management can control the disorder and enable people to enjoy a good quality of life [94]. 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by chronic airway obstruction causing progressive 
loss of lung function. COPD is associated with symptoms of chronic cough and purulent sputum. COPD is strongly 
related to a history of smoking and is predominantly a disease of older patients [95]. Globally, it is estimated that 
about 3 million deaths were caused by COPD in 2015 (5% of all deaths worldwide) [94]. 
Airflow limitations and chronic inflammation are the main characteristics of both asthma and COPD. The most 
effective treatment is the administration of a medication which acts to reduce and prevent airway constriction and 
inflammation. The first-line treatments in both asthma and COPD are bronchodilators (short and long acting β2-
agonists; SABA, LABA) and anti-inflammatory therapy (inhaled corticosteroids; ICS), which are administered to aid 
bronchodilation and reduce inflammation [96-98]. Asthma differs from COPD whereas there is a greater reversibility, 
spontaneously and after treatment with bronchodilators or inhaled corticosteroids. Some patients with asthma have 
progressive irreversible airway obstruction and therefore have a form of COPD, and some patients may have coexistent 
asthma and COPD. 
Chronic respiratory diseases are not curable, however, various forms of treatment that help dilate major air passages 
and improve shortness of breath can help control symptoms and increase the quality of life for people with the disease. 
Therefore, the main goal of respiratory therapy is to improve the patient’s quality of live by achieving and maintaining 
control of symptoms, preventing exacerbations, attaining normal lung function, maintaining normal activity levels, 
including exercise, and avoiding adverse effects from respiratory medications [99]. The Global Initiative for Asthma 
(GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) release guidelines based on the latest 
state of the art and suggest the drug therapy with respect to disease severity [94, 100]. 
3.1.1 Bronchodilators 
Bronchodilators are used to relieve symptoms of bronchoconstriction [101]. They typically stimulate β-adrenoceptors 
in the smooth-muscle of the airway, producing smooth-muscle relaxation and bronchodilation (β2-agonists) [102]. 
Short-acting β2-agonists (SABA) include for example salbutamol and terbutaline, which have a duration of action of 
approximately 3-4 hours with an onset of action of 15 minutes. Long-acting β2-agonists (LABA), including salmeterol 
xinafoate (SX) and formoterol fumarate dihydrate (FF), have a duration of action of more than 12 hours and are helpful 
in controlling chronic asthma [103]. Anticholinergic quaternary ammonium compounds such as tiotropiumbromide 
or glycopyrroniumbromide are a relatively novel class of bronchodilators [104]. Anticholinergic drugs act as a 
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competitive blockage of muscarinic cholinergic receptors, inhibiting bronchoconstriction and bronchial 
hypersecretion leading to airway dilation [105]. 
3.1.2 Anti-Inflammatory Drugs 
Inhaled corticosteroids (ICS) are widely used for the treatment of asthma and COPD. ICS such as budesonide (BUD) 
and fluticasone propionate (FP) reduce airway inflammation which is the underlying pathophysiological process in 
both diseases [101]. 
3.1.3 Combination Therapy 
Both the «Global Initiative for Asthma (GINA)» guidelines for the treatment of patients with asthma and the «Global 
Initiative for Chronic Obstructive Pulmonary Disease (GOLD)» guidelines for COPD patients mention the use of 
long-acting β2-receptor agonists (LABA) in addition to inhaled corticosteroids (ICS) for patients whose treatment 
with ICS alone is insufficient. This way, two fundamental processes of the diseases can be addressed: 
bronchoconstriction and inflammation. 
It was found that the co-administration of the two types of drugs in one formulation resulted not only in increased 
patient convenience, but also showed improved β2-adrenoceptor and glucocorticoid receptor function, as well as a 
reduction in inflammation and, potentially, remodeling in the airways and lung due to synergistic effects [106]. For 
example, the co-administration of fluticasone propionate (ICS) and salmeterol xinafoate (LABA) was found to be 
superior in terms of clinical efficacy to the separate treatment with the two drugs [107]. In a Cochrane meta-analysis 
of 48 studies (including more than 15’000 patients) [108] the authors concluded that the combination therapy is 
modestly more effective in reducing the risk of exacerbations requiring oral corticosteroids than a higher dose of 
inhaled ICS alone. Combination therapy also led to a greater improvement in lung function, symptoms and use of 
rescue β2-agonists than with a higher dose of inhaled corticosteroids. For children under the age of 12, combination 
therapy did not contribute to a beneficial treatment, but rather showed a trend towards an increase in adverse effects. 
A growing body of evidence suggests that triple therapy with an antimuscarinic agent, a LABA, and an ICS is 
efficacious in patients with more severe asthma and COPD, such as those with frequent exacerbations. A variety of 
triple combinations are currently under development [109]. 
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4. Inhaler Devices 
Formulations for inhaled medicines require either dry or liquid particles (or agglomerates) with a particle size <5 μm 
to penetrate the deeper airways as described earlier. For the generation of aerosol particles in the required size range 
for deep lung deposition, three different types of inhalation devices are currently available on the market. These are 
nebulizers, pressurized metered dose inhaler (pMDI) and dry powder inhaler (DPI). MDIs are currently the most 
frequently used system worldwide [110]. Nebulizers and pMDIs will only be introduced briefly in this section as the 
main focus in this thesis is on DPI formulations. 
4.1 Nebulizers 
Nebulizer systems are applied for drug solutions or suspensions, which are aerosolized either by air jet (atomization), 
using vibrating meshes or ultrasonic nebulization to generate droplets of appropriate size. To generate the aerosol 
from an air-jet nebulizer, compressed air is forced through an orifice over the open end of a capillary tube. The drug 
solution or suspension is drawn through the capillary by means of momentum transfer. In the nozzle region, shear 
forces disrupt the liquid into small particles that are entrained by the air towards a baffle. Only the smallest droplets, 
in the desired size range, are able to follow the streamlines of the air and pass the baffle, whereas larger droplets 
impact on the baffle and are returned to the liquid reservoir. The emerging aerosol is then inhaled over a mouthpiece 
or a facemask (Figure 6) [111]. Nearly any soluble drug or mixture of different drugs and in almost any dose can be 
administered by nebulization, which favors them for infant therapy. Nebulizers can further be used for ventilated 
patients or those suffering from diseases such as dementia or Alzheimer’s since no specific coordination or device 
actuation is needed. However, such device systems are cost-intensive, bulky and require a consistent power supply, 
which limits the use in everyday life. Other major disadvantages of nebulizers are their poor deposition efficiency and 
long inhalation time [112]. 
 
Figure 6: Schematic of a pneumatic jet nebulizer [111]. 
4.2 Metered Dose Inhalers 
Pressurized metered dose inhalers (pMDIs) provide the aerosolization of drug solutions or suspensions upon actuation 
by the patient. The drugs are therefore either dispersed in a propellant to form a suspension or dissolved in a propellant 
to build a drug solution [113]. MDIs consist of four basic functional elements: container, metering valve, actuator and 
mouthpiece (Figure 7). The operation principle of pMDIs is based on a spray-can. A single dose is released from the 
inhaler device upon actuation forcing the drug solution or suspension through a spray orifice to generate an aerosol. 
The propellant evaporates rapidly to leave solid particles of adequate size (<5 μm) that are subsequently inhaled by 
the patient [114]. MDIs have been invented in the 1950s based on chlorofluorocarbon (CFC) propellants that have 
mostly been replaced by environmentally less harmful hydrofluoroalkanes (HFAs) at current stage [112, 115]. The 
inhalation maneuver for pMDIs is relevant for deposition efficacy as the hand-lung coordination is of major 
importance. For infants or elderly people, spacers are applied that help to reduce inhalation variability to improve 
hand-lung coordination during the inhalation maneuver to overcome oropharynx deposition issues. 
26 
 
Figure 7: Schematic of a pressurized metered-dose inhaler [111]. 
Soft mist inhalers (non-pressurized metered dose inhalers) as invented with Boehringer Ingelheim´s Respimat® 
generate a low velocity spray from aqueous or ethanolic drug solutions that are forced through a nozzle system. 
Administration of the drug dose is actuated by the patient and independent from the inspiratory effort. Coordination 
between inhalation and actuation is simplified due to prolonged treatment times based on lower spray velocities, which 
in turn results in higher respirable fractions and lower dose variability due to less deposition in the oropharynx 
compared to traditional pMDIs [116, 117]. 
4.3 Dry Powder Inhaler Containing Adhesive Mixtures 
Interest in DPIs for inhalation therapy grew strongly due to their potential to offer CFC-free alternatives to pMDIs 
[118]. The first single dose dry powder inhaler with a hard gelatin capsule technology (Spinhaler®, 1971) was initially 
developed for the inhalation of relatively large amounts of drug (50 mg of disodium cromoglycate) [43]. DPI devices 
combine several advantages such as prolonged long-term stability of drugs, higher drug contents per dose or increased 
respirable drug fractions compared to pMDIs [115, 119]. Most marketed DPI inhalers work breath-actuated and use 
the patients inspiratory forces for particle dispersion and deagglomeration, which results in reduced aerosol velocities 
and lower oropharyngeal drug depositions that in turn induce higher respirable fractions than exhibited for pMDIs 
[120]. However, despite better results in the overall dispersing mechanism, large differences from patient to patient 
can be observed with respect to the applied inspiratory airflow. Elderly people, younger children or patients suffering 
from severe asthma or COPD are known to not sufficiently inhale drugs with a DPI [121]. The aerodynamic 
performance of dry powder inhaler is a combination of powder properties, inhaler device and the patient’s habits. 
Most marketed DPIs contain micronized drug blended with larger carrier particles (mainly alpha lactose monohydrate, 
usually with a particle size distribution of ca. 50-300 μm), which prevents aggregation, assists in metering and helps 
flow. The dispersion of dry powder aerosols is conducted from a static powder bed. In order to generate the aerosol 
cloud, the particles have to be moved. Passive inhalers employ the inspiratory flow of the patient for fluidization and 
aerosol generation. When the patient activates the DPI by inhaling through it, the airflow within the device creates 
high shear forces and turbulence; and the generation of velocity gradients introduces air into the powder bed. Thus, 
the static powder blend is fluidized and enters the patient’s airways. At the mouthpiece, the drug particles separate 
from the carrier particles and are carried deep into the lungs while the larger carrier particles impact in the oropharynx 
and are cleared. Thus, deposition in the lungs is determined by the patient’s variable inspiratory airflow [6, 122-124]. 
One of the main reasons for the low deposition efficiency encountered with DPIs is inadequate drug/carrier separation 
[125]. Dose uniformity is a challenge in the performance of DPIs. This is a greater concern with powders than with 
liquids because of the discrete nature of particulates. 
The main advantage of utilizing a patient’s inspiratory airflow as the main source of energy is that such devices are 
breath actuated. This avoids the need to synchronize the actuation and inspiration maneuver by the patient. The 
downside of this approach is that devices currently available show a device-specific airflow resistance, and this often 
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demands a relatively high inspiratory effort [126] which might be a hurdle for patient populations suffering from 
obstructive airway diseases such as asthma or COPD, the elderly, or very young patients [127]. The extent of lung 
deposition is also highly dependent on the individual patient’s inspiratory flow rate causing a potential difference in 
the dose effectively delivered due to this variability [128]. Since often times flow properties of micronized powders 
are poor, most formulations consist of physical blends of drug particles with larger (30-300 μm) carrier particles such 
as lactose, to facilitate deagglomeration and powder flow [129]. 
 
Figure 8: Schematic drawings of marketed example dry powder inhaler systems for adhesive mixtures. A) Capsule based 
single-dose inhaler (Breezhaler®), B) multi-dose blister inhaler (Diskus®) and C) multi-dose powder reservoir inhaler 
(Turbuhaler®). Modified from [130-132]. 
DPIs commonly consist of four functional elements: (1) a powder container, (2) a dosing or metering system, (3) a 
disintegration principle and a mouthpiece (4). Based on these functional elements, DPIs can be divided into two major 
groups: single dose and multi-dose inhalers. The multi-dose inhalers are divided in two different types of design: the 
reservoir systems (such as Turbuhaler®) and the multiple unit-dose inhalers (such as Diskus®). Each of these parts 
affects the inhaler efficiency with respect to dose dispensing and powder deagglomeration, and thus the amount of 
drug particles that can theoretically reach the deeper parts of the lung for deposition. A critical factor affecting the 
reproducibility of doses delivered by multi-dose inhalers is dose metering. While single-dose and multi-unit dose 
devices use pre-metered powders packed into blisters or capsules, powder bed bulk multi-dose inhalers use powder 
reservoirs so that the dose to be delivered has to be separated from the bulk material prior to actuation [133]. For both 
types of devices, suitable powder flow properties are essential, either for accurate dosing or emptying of the single-
dose container entirely. 
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5. Challenges in the Development of Dry Powder Inhaled Formulations 
Dry powder inhalers (DPIs) have been providing effective treatments for patients worldwide for more than 50 years. 
Throughout this period, the fundamental principles of DPI formulation have remained unchanged. A drug is 
formulated as a powder in which the drug particles are sufficiently small for deposition in the lungs. The powder must 
be homogeneous on a scale commensurate with the dose, and homogeneity must be preserved during manufacture, 
shipping, and use. And, for passive DPIs, a patient’s inspiratory effort must provide sufficient energy to fluidize and 
disperse the powder. Although an inhalation product is commonly viewed as a drug and an inhaler, the formulation 
plays a critical role because it can influence both drug design and inhaler design. For example, most drugs for 
inhalation are small, highly crystalline molecules. Formulation technologies that relax or remove this constraint will 
enable development of a greater variety of drugs. Furthermore, formulation of a readily fluidizable and dispersible 
powder enables simpler device designs, benefitting both the manufacturer and, more importantly, patients. Although 
the drug substance, the formulated powder, the package, and the device are often times discussed in isolation, inhaled 
drug product development requires integration of these technologies into the drug product. A holistic approach to dry 
powder product development requires that engineering of the drug substance and particle be performed with 
consideration of how the formulated powder will be filled, packaged, and ultimately delivered to a patient’s lungs 
(Figure 9). 
 
Figure 9: Formulation of a dry powder for inhalation requires integration of multiple technologies into the final drug 
product. Adapted from Weers et al. [134]. 
The development of new DPI formulations requires the consideration of a large number of factors that might influence 
the overall pharmaceutical performance of the new product. Apart from particle properties of all components (drug 
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and excipients), particle-particle interactions between all components (drug-drug, drug-carrier, carrier-carrier, drug-
force control agent, carrier-force control agent) or particle-wall interactions between the formulation and inhaler 
device, and also the choice of inhaler device with its associated dispersing mechanism is of high importance. 
Cohesiveness of drug particles is by far the main challenge in dry powder formulations. A pronounced tendency to 
build drug agglomerates can be attributed to the sum of cohesion forces (e.g. van der Waals forces, capillary forces or 
electrostatic forces). Drug bulk flowability is dramatically decreased for those small particles, which renders adequate 
dosing impossible for pre-metered capsules or blister stripes but also for container based devices. 
 
Figure 10: Dry powder inhaler formulation processing and variables associated with each process. Adapted from Xu et al. 
[135]. 
A large number of variables and processes can have a significant impact on the aerosol performance of the final DPI 
product. Figure 10 gives an overview of these variables in particular. Interparticulate interactions occur during milling, 
mixing, filling and storage and the end point of these coordinating steps of pharmaceutical processes are the beginning 
of the interparticulate interactions as they pertain to aerosolization performance [135]. 
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6. Pulmonary Drug Delivery through Dry Powder Inhaled Formulations 
As a consequence of the need to use drug particles below 5 μm in size, powders composed of such small particles are 
often strongly cohesive and show very poor flowability. In order to achieve an accurate metering of the desired small 
quantities, the drugs are either formulated with additional excipients or processed to soft spheres through 
spheronization. The goal of both is to improve powder flowability, which is essential to allow volumetric filling of 
the device reservoir or capsules and blister cavities, respectively. The addition of coarse lactose increases the total 
mass and therefore the metering volume, leading to fewer variations in dosing. Furthermore, the formation of an 
adhesive mixture improves the flowability significantly, as the used lactose is generally larger in size. A similar effect 
can be obtained through controlled agglomeration (spheronization) of the micronized drug particles. The increase in 
agglomerate size accompanies a decrease in interagglomerate forces and, hence, an increase in flowablity [7, 136-
138]. 
In attempts to enhance the efficiency of delivery from DPIs, several techniques have been utilized to prepare particles 
of active pharmaceutical ingredients (APIs) and carriers (e.g. lactose or mannitol) under controlled conditions. These 
include simple crystallization techniques, spray-drying, freeze-drying, supercritical fluid technology and engineered 
carrier particles (adhesive mixtures). In this chapter, techniques like spray-drying, freeze-drying, supercritical fluid 
technology or crystallization techniques are only briefly introduced as the focus of this thesis is mainly on engineering 
of carrier based DPI systems (adhesive mixtures). 
6.1 Drug Substance 
Particle size is a driving factor with respect to deposition site in the lungs. The smaller the aerodynamic diameter of 
the particles, the deeper they may penetrate into the lungs [139, 140]. Target receptors are not always distributed 
uniformly throughout the lung. For example, Usmani et al. demonstrated in their study that variations to the particle 
size of inhaled salbutamol lead to a shift in deposition region and patient response [141]. Furthermore, for the treatment 
of infectious lungs diseases, or for a possible systemic uptake, it may be necessary to administer API particles 
uniformly throughout different lung regions [3]. Drug particles in the respirable size range can be generated via various 
processing methods. 
6.1.1 Micronization of Drug Substance 
The preparation of drug particles for inhalation purposes requires particles with an aerodynamic diameter <5 μm. 
Several approaches have been introduced to target this size range, but only a few are currently used for marketed 
products. Micronization techniques published in literature suggest freeze drying, micronization from supercritical 
fluids or air jet milling to be applicable for drug preparation since all techniques provide particles with a respective 
size range and appropriate aerodynamic behavior. Micronization by air jet milling is the most commonly used method 
to prepare drug particles for inhalation purposes. The process is cost-effective and is reliable with regards to batch-to-
batch variations. 
6.1.2 Air Jet Milling 
The crystalline raw materials (drug substance) are introduced into a grinding chamber and grinded with high pressure 
nozzles using an inert gas. The resulting particle size is determined by the grinding pressure chosen since fine particles 
are separated based on the inert gas velocity in the chamber. It has been reported in literature that micronized materials 
can comprise amorphous areas on the surface due to the high-energy input during the micronization process. 
Drawbacks are not only related to the amorphous areas that might recrystallize during storage due to their high free 
Gibbs energy but also due to drug particle shape [142, 143]. Most drug substances appear with unevenly shaped 
particles upon air jet milling, so that particle adhesion to carrier particles cannot be derived from distinct controlled 
product properties (Figure 11) [144, 145]. It has been reported that approaches using spray drying techniques may 
overcome such challenges as this technique is known for creating a homogeneous overall particle shape. 
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Figure 11: Scanning electron microscopy micrographs of micronized fluticasone propionate and salmeterol xinafoate by 
air jet milling. Adapted from [146]. 
6.1.3 Spray Freeze Drying 
Spray freeze drying is a two-step process, during which the feed solution is sprayed into a freezing medium (usually 
liquid nitrogen). Eventually, the liquid nitrogen evaporates and the frozen particles can be lyophilized in a subsequent 
freeze drying step [147]. The typical process yield is >95% and the obtained particles are of light and porous nature 
with improved aerosolization characteristics compared with the micronized material [147, 148]. Particle properties 
can be modified through process adjustments (atomization) or formulation set-up [149, 150]. Generally, this technique 
can be used to create powders for various treatments, however, the time consuming and very expensive process 
narrows the use down to high-cost products, such as protein or antibody formulations. Furthermore, the ability to 
formulate liposomes [148] or encapsulated particles (e.g., in polylactid-co-glycolid; PLGA) [151] opens up a new 
strategy for formulation design of inhaled therapy. Sufficient stability of the material (protein) to shear, freezing and 
dehydration stresses is essential. Protein stability may be increased by adding sugars to the liquid feed, which can then 
build a glassy matrix and protect the protein during the process [152]. 
 
Figure 12: Scanning electron microscopy image (SEM) of a spray-freeze-dried liposomal ciprofloxacin powder particle 
[148]. 
6.1.4 Supercritical Fluid Technology 
A liquid or gaseous phase can be transferred into its supercritical state by rising the pressure and temperature above 
their specific critical values. The obtained supercritical fluids (SCF) present an intermediate state that combines 
properties of both, gaseous (low viscosity) and aqueous (density) phase. Consequently, its often advantageous ability 
to serve as solvent or antisolvent for several drug substances offers a promising alternative approach for the generation 
of particles in the respirable size range [153, 154]. Supercritical carbon dioxide (above 31°C, 74 bar) is commonly 
used due to its low cost and non-toxicity. Particles can be generated mainly via three supercritical fluid techniques: 
(a) rapid expansion of supercritical solutions (RESS), (b) particles from gas-saturated solutions (PGSS) and (c) 
supercritical anti-solvent (SAS). Particles generated with such techniques are usually very uniform in size and exhibit 
a platelet-like morphology. They show improved flowability and smaller cohesive-adhesive interactions compared 
with jet-milled powders [155]. Such powders possess enhanced dispersion, which in turn generates increased 
Fluticasone propionate Salmeterol xinafoate 
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respirable particle fractions [156], especially at low airflow rates or low aerodynamic turbulent stresses [154, 155]. 
The generation via SCF precipitation has been shown to be a suitable approach for the production of low (water) 
soluble-drug and peptide particles. It is still subject of intense research and offers a promising alternative to spray 
drying and spray freeze drying methods. However, supercritical fluid technology is very complex and expensive set-
up has so far limited its use on a routine basis. 
 
Figure 13: Scanning electron microscopy photographs of micronized salmeterol xinafoate (a) and salmeterol xinafoate 
produced by precipitation in supercritical CO2 (b). Adapted from [156]. 
6.2 Spray Drying 
The generation of fine particles using spray drying techniques can help to overcome some of the drawbacks of the 
micronization process. The technique can be used to generate particles with a narrow size distribution out of a solution, 
suspension or colloidal dispersion. The obtained particles reveal a more homogenous surface energy distribution and 
generally show a reduced area of contact between particles, thus leading to increased flowability and dispersion 
efficiencies (i.e., respirable fractions) [157]. Moreover, particle properties, such as density or morphology, can be 
customized by changing the process and/or formulation parameters [157-161]. However, spray drying often leads to 
the generation of amorphous particles. Modifications to the process set-up (introduction of a secondary drying step) 
[162] or change of material (type of carrier) [158] may be suitable approaches to overcome these challenges. The first 
inhaled dry powder treatment on the market using a spray dried formulation approach of tobramycin was the TOBI® 
Podhaler® (PulmoSphere® technology [163]). In this approach, the formulation containing volatile ‘blowing agents’ 
is spray-dried to produce large porous particles out of an oil-in-water emulsion. This way, powder flowability and 
deagglomeration is improved and no additional mixing step is needed. Also, a flow rate-independent, high-dose 
deposition in the lungs has been demonstrated [163]. Furthermore, spray drying was found to be a suitable technique 
to produce dry powder protein formulations for inhalation [164], and additional excipients, such as mannitol or 
trehalose, may be added to prevent possible degradation during processing and storage [165]. 
 
Figure 14: High resolution scanning electron microscopy image (SEM) of a spray dried PulmoSphere® particle of 
tobramycin. Copyright© Novartis Pharmaceuticals [166]. 
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6.3 Adhesive Mixtures 
Most marketed DPI products apply larger carrier particles to improve powder flow and dosing accuracy as well as to 
overcome the cohesive nature of the micronized APIs. Those single excipient platforms (interactive powder blends) 
usually consist of coarse carbohydrate particles (alpha lactose monohydrate) and small drug particles, but can be 
supplemented by fine sugar particles (lactose fines) or force control agents (e. g. magnesium stearate) to become dual 
excipient platforms (ternary interactive powder blends). Carrier particles, mostly consisting of lactose monohydrate 
with sizes ranging from ca. 50–300 μm are blended with micronized drug particles (<5 μm) to evenly distribute the 
drug on the carrier surface. The improved powder flow enables accurate dosing for all kinds of inhaler devices and 
inspiratory shear forces ensure the detachment of single drug particles or small drug agglomerates from the carrier 
surface to get entrained by the airflow to penetrate the lungs (Figure 15). 
 
Figure 15: Principle of dry powder inhaler design of adhesive mixtures. The formulation, typically consisting of micronized 
drug blended with larger carrier particles is dispensed in a metering system. An active or passive dispersion system entrains 
the particles in the patient’s airways where drug particles separate from the carrier and are carried into the lung [6]. 
6.3.1 Carrier Particles in Adhesive Mixtures 
Since micronization of API crystals is still the most commonly used method to obtain particles in a respirable size 
range, further formulation steps to improve powder flowability are necessary. The aim is to use the adhesive forces of 
the micronized powder to build up agglomerates that are larger in size and, therefore, exhibit improved powder 
flowability. For such a process, the control over agglomerate strength (magnitude of interparticulate forces) is 
fundamental. Agglomerates need to be mechanically stable during storage, filling and dosing. But on the other hand, 
the thorough dispersion into single particles upon inhalation is essential to achieve reasonable respirable fractions of 
the drug. Most of the DPIs on the market contain a powder formulation with carrier material. In theory, the micronized 
drug binds to the host crystal surfaces to form an adhesive mixture [7] and gets separated again as single particles 
during the inhalation maneuver. Lactose monohydrate is currently the carrier of choice for almost all current DPIs on 
the market [167]. As carrier material, different sugars or sugar alcohols such as glucose monohydrate, mannitol, 
sorbitol, maltitol, xylitol, trehalose [168-170] and others have been tested. Nevertheless, Lactose has a well-
established safety and stability profile, production is inexpensive, various qualities are easily available on the market, 
it is less hygroscopic compared with alternative sugars and there is extensive knowledge on its physico-chemical 
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properties [6]. Lactose is a suitable carrier for the majority of API molecules, however, lactose may not be applicable 
for formulations containing substances that are incompatible with its reducing sugar function (especially peptides). A 
typical carrier size ranges between 50 and 300 μm in diameter and the payload of drug is usually between 0.1 and 5% 
by weight [171, 172]. Deagglomeration efficiency of the mixture is dependent on a large number of factors and their 
interactions such as for example the flow rate during actuation, particle size of API and carrier or the blending 
technique. Extensive research has been performed to understand the influence of particle size, particle morphology, 
physico-chemical properties (e.g., pseudopolymorphs and amorphous contents), dose and environmental conditions 
on the drug deagglomeration behavior, but the very complex relationships are still not fully understood [7, 171, 173]. 
A very important factor is the addition of a third component to binary API-carrier mixtures. There are numerous 
publications on increased respirable API fraction with the addition of a ternary fine (mostly micronized lactose) 
component [15, 16, 20]. Supposed theories for the aerosol performance enhancement are the saturation of ‘active sites’ 
on the carrier surface with excipient fines (regions of increased adhesive forces on the carrier surface are covered with 
lactose fines before the carrier mixture is blended together with the API), and the formation of drug/fine excipient 
agglomerates with beneficial overall dispersion properties [7, 174]. It has been proposed that high-energy ‘active sites’ 
exist on coarse carrier particles. The addition of ternary fines (e. g. fine lactose or force control agents) preferentially 
bind and cover these active sites, forcing the drug to weaker binding sites, thus drug particles are more easily liberated 
from the surface of the carrier particles after actuation [175, 176]. The ‘active site’ theory has a vague definition that 
covers a multitude of phenomena including surface irregularities (pores, clefts, cavities, lattice discontinuities), surface 
rugosity, adhering fines, amorphous spots, water adsorption sites and impurities [7, 177]. The ‘soft agglomerates’ 
hypothesis describes that during interactive mixing, drug particles are distributed between the surface of carrier and 
fines, forming weak agglomerates of drug and fines that can be dispersed easily. The evidence for this mechanism can 
be found by direct observation of drug and fine agglomerates using scanning electron microscopy. This can be 
explained by the fact that agglomerates of drug and lactose fines weaken the cohesive interactions between drug 
particles [7, 178-180]. 
 
Figure 16: Scanning electron microscope image of alpha lactose monohydrate carrier particles (Respitose® ML001). 
6.3.2 Blending of Adhesive Mixtures for Inhalation 
The primary goal of a mixing process is the homogeneous distribution of drug particles within the excipient matrix in 
order to achieve acceptable content uniformity by volumetric dosing or filling. In detail, for an adhesive inhalation 
mixture, agglomerates of cohesive drug particles (and excipients fines) need to be broken up and distributed evenly 
across a carrier surface. Once adhered to their host crystals, the segregation tendency of an adhesive mixture is 
comparably low. Generally, two types of mixers can be utilized to produce such blends: tumbling blenders (low-shear) 
and high-shear mixers. The extent of energy input of the type of mixer during blending varies significantly and also 
does the magnitude of the driving diffusive, convective and shear mixing effects. Consequently, appropriate mixing 
speeds and process times for the production of homogeneous blends differ significantly. Mixing is a dynamic process, 
and particles may be redistributed across the carrier surfaces, become part of newly formed agglomerates, or may even 
act as carriers themselves over the time of the mixing process [7, 171]. The mixing efficiency is affected by multiple 
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factors, such as particle size, size distribution, morphology, density and other physico-chemical properties, and needs 
to be evaluated carefully for each new drug or component. Blending as a dynamic process leads to the further 
understanding that despite a homogenous distribution, redistribution effects of the particles may also be of importance 
for the correct choice of process parameters (mixing time, blending order, energy input, equipment) [181, 182]. 
Powder homogeneity (or blend uniformity) should not be looked at exclusively for an inhalation product. In particular, 
high shear mixing exerts a high mechanical stress on the larger carrier particles and may cause breakage or attrition 
or even changes to the solid state of the drug (small amorphous areas) [15, 17, 183, 184]. In addition, prolonged mixing 
time leads to a constant redistribution of particles and may hinder the detachment of drug particles from the host 
crystal surfaces (‘press-on forces’) [15, 185]. Short mixing times may be advantageous for high-shear formulations 
compared with low shear tumble mixers, however, research about the influence of differences in energy input on 
inhalation formulations has just moved into focus in recent years [181, 182, 186]. 
When mixing powders with different properties, particle sizes and drug-carrier ratios, inadequate mixing can cause 
poor dose uniformity, something that may not be improved with increasing mixing time. The choice of blender, mixing 
speed, mixing time, capacity, order of adding the ingredients, and fill level all require optimization, as they are likely 
to affect the blend homogeneity [181, 187]. In addition, blending conditions can also influence the interparticulate 
forces, which in turn determine the aerosol performance of a DPI formulation. 
6.3.3 Magnesium Stearate as a Performance Enhancer and Force Control Agent in DPI Formulations 
Using alpha lactose monohydrate as a single excipient has been the most prevalent excipient strategy in modern 
commercial DPI products. However, the use of only a single excipient may not always be capable of achieving the 
required performance efficiency, manufacturability and scale or commercial shelf-life using well understood product 
and company specific ‘carrier’ excipient based processing steps. Additionally, the single excipient platform may not 
be readily adaptable for intellectual property reasons or for the matching the performance of generic DPIs to their 
originator products [19]. While there has been a considerable number of academic publications and patents concerning 
the use of additional (ternary) excipients as functional additives for DPIs, their use in approved products has expanded 
since 2010 with no less than 6 product approvals by 3 companies in global regional markets between 2010 and 2015, 
all of which contain lactose monohydrate and magnesium stearate (Table 1). The traditional role of magnesium stearate 
in solid dosage forms has also been expanded to DPIs where its functionality in dual excipient platform formulations 
has been described in the literature as a ‘lubricant’, ‘force control agent’, ‘water barrier’, ‘stabilizer’ and ‘chemical 
stabilizer’, suggesting multi-functional properties of this excipient in this solid dosage form [19]. 
Table 1: Approved lactose monohydrate/magnesium stearate dual excipient platform inhalation drug products after 2010. 
Adapted from [19]. 
Brand name Company Drug Therapy Inhaler type/ 
Dose container 
First 
approved 
Foster® NEXThaler® Chiesi Beclometasone dipropionate/ 
formoterol fumarate 
Combination, 
co-formulated 
Reservoir 2012 
Relvar® Ellipta®/ Breo™ 
Ellipta™ 
GSK Vilanterol trifenatate/ 
fluticasone furoate 
Combination, dual Dual blister 2013 
Anoro® Ellipta®/ Anoro™ 
Ellipta™ 
GSK Umeclidinium bromide/ 
vilanterol trifenatate 
Combination, dual Dual blister 2013 
Incruse® Ellipta® GSK Umeclidinium bromide Mono Single blister 2014 
Seebri® Breezhaler®/  
Seebri™ Neohaler® 
Novartis Glycopyrronium bromide Mono Capsule, 
HPMC 
2012 
Ultibro® Breezhaler®/  
Utibron™ Neohaler® 
Novartis Glycopyrronium bromide/ 
indacaterol maleate 
Combination, 
co-formulated 
Capsule, 
HPMC 
2013 
 
The effect of ternary materials on the properties of powders and DPI product performance has been extensively 
investigated. In terms of the use of magnesium stearate, reports by Staniforth et al. had already described the influence 
of a ternary component, magnesium stearate, on the adhesion of salicylic acid to sucrose [188]. Such observations 
were further elaborated for the potential advantages of ternary materials for DPI product performance. Scientific 
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literature is claiming that the addition of magnesium stearate may improve the fine particle dose performance 
characteristics of DPI formulations [189-191]. The use of such ternary materials in DPI products may now be 
considered to be a somewhat standard formulation approach. With the increased understanding of the surface and 
particulate interactions in DPIs [23, 171, 192, 193], the use of such ternary materials in modern DPI development has 
led to the functionality of such a performance enhancer to also now being widely referred to as a ‘force control agent’ 
[14, 23]. Where such additives were added to DPIs their function was used to modify the characteristics of the powder 
formulation by impacting the inter-particulate interactions, or ‘cohesive-adhesive balance’ resulting in improved 
powder properties and aerosolization performance. 
 
Figure 17: Scanning electron microscope images of magnesium stearate particles (Peter Greven). 
 Magnesium stearate (Figure 17), a hydrophobic, waxy fatty acid soap, has been used at low concentrations in lactose 
based formulations (MgSt content typically ca. 0.5%–3%, w/w) to improve drug delivery efficiency. Magnesium 
stearate can be mixed with the lactose carrier or the drug substance using conventional low-energy blending processes 
(for example Turbula mixer), or using energy-intensive process (“mechanofusion”) designed to produce a thin coating 
layer on the carrier surface [14, 17, 24, 194]. Guchardi et al. proposed that the magnesium stearate increases the 
cohesive forces between fine and coarse lactose, thereby reducing adhesive forces between the drug and the carrier 
particles [195]. A variety of other force control agents such as Leucine, Lecithin, Pluronic F-68, Cremophor RH 40, 
Glyceryl monostearate, Polyethylene glycol 6000 using different application techniques have also been investigated 
previously [14, 22, 23]. 
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7. Particle Interactions 
Efficient drug dispersion of dry powder aerosol particles during aerosolization is governed by several factors that can 
be described as particle-particle interactions. The energy transferred from inspiratory forces to the powder blend needs 
to exceed the energy that arises from particle-particle interactions to effectively disperse drug and carrier particles 
(and eventually fines). The fundamental attractive forces/mechanisms of interaction between drug and carrier particles 
in DPI formulations can be summarized as van der Waals, electrostatic and capillary forces [7, 196]. Besides the 
mentioned adhesive and cohesive forces, friction and mechanical interlocking also play important roles in power flow 
and deaggregation [197]. Mechanical interlocking happens when fine particles are entrapped within the asperities or 
rough particles ‘interlocked’ with each other, resulting in increased area of contact and difficulty in separation [8, 
198]. Particle aggregation is a result of interparticulate forces. The contribution of each force to the particle 
aggregation is dependent on numerous factors such as surface morphology, crystallinity, intrinsic material properties 
(e.g. amorphous content, polymorphism, hydrophilicity, electrical resistivity), and environmental conditions [8]. The 
drug-to-carrier interparticulate forces must be weak enough to allow substantial drug detachment during the 
inhalation/aerosolization process while strong enough to maintain powder blend homogeneity. The performance of 
DPI formulations is therefore a function of the relative magnitudes of cohesive (drug–drug) and adhesive (drug–
excipient) interparticulate forces (Figure 18). In general, at normal environmental conditions, the strength of van der 
Waals forces is about two orders of magnitude higher than electrostatic and capillary forces. However, capillary forces 
would dominate at condition of high relative humidity [7, 199]. 
 
Figure 18: Particle interactions between carrier (large light grey particles) and drug particles (small black particles). 
Modified from [200]. 
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Figure 19: Particle-particle interactions between carrier surface and small particles adhered to the surface. Adapted from 
Hickey et al. [201]. 
Van der Waals forces (FvdW) can be defined as below [7]: 
𝑭𝒗𝒅𝑾 =  
𝑨
𝟔𝒉𝟐
 ∗  
𝑹𝟏𝑹𝟐
𝑹𝟏+𝑹𝟐
=  
𝑨𝑹
𝟏𝟐𝒉𝟐
 (𝑹𝟏 = 𝑹𝟐 = 𝑹, 𝐟𝐨𝐫 𝐭𝐰𝐨 𝐢𝐝𝐞𝐧𝐭𝐢𝐜𝐚𝐥 𝐬𝐩𝐡𝐞𝐫𝐞𝐬) Equation 1 
𝑭𝒗𝒅𝑾 =  
𝑨𝑹
𝟔𝒉𝟐
 (𝑹𝟏 ≪  𝑹𝟐, 𝐟𝐨𝐫 𝐬𝐩𝐡𝐞𝐫𝐞 𝐚𝐧𝐝 𝐬𝐮𝐫𝐟𝐚𝐜𝐞)    Equation 2 
Where A is the Hamaker constant (typically ~10-19 J) dependent on the molecular properties of the materials, R is the 
particle radius, and h is the separation distance. As compared to van der Waals forces, gravitational forces are lowered 
greater when size of drug particles becomes small. Therefore, the dry particles, with size less than 10 μm, become 
adhesive/cohesive as van der Waals forces become predominant. Van der Waals forces are effective within a 
separation distance of <100 μm and diminish rapidly with increasing separation distance [7]. Therefore, van der Waals 
forces are sensitive to the change of particle shape and surface morphology [202]. The magnitude of van der Waals 
forces is greatly affected by the number of mutual points of contact (coordination number) [8]. The van der Waals 
forces of particles could be also influenced by surface roughness (such as kinks and defects) by several orders of 
magnitude. The surface roughness of particles can be evaluated by mathematical models (e.g. Fourier, fractal analysis) 
in terms of irregular oscillations around a mean value [203]. At distances of typical pharmaceutical powders (e.g. 
separation distance ∼5 nm), van der Waals forces are about 1-2 orders of magnitude stronger than electrostatic forces 
[8]. The force–distance curves indicate that capillary forces are significantly higher than both van der Waals and 
electrostatic forces [204], but are produced only at high RH (>65%) [8]. Electrostatic forces are ‘long’-range forces 
compared to van der Waals forces, but decay quickly at high RH [205]. 
Electrostatic forces (including contact charging, coulombic interaction, and induced charging) can be either attractive 
or repulsive. Contact charging involves the contact of a charged object to a neutral object until electron transfer reaches 
equilibrium. The contact charging force (Fc) is defined as [7]: 
𝑭𝒄 =  
𝟐𝝅𝒒𝟐
𝑨
        Equation 3 
Where q is charge detachment between two objects, A is the contact area between two objects. 
Coulombic interaction occurs in two charged objects. Dependent upon the sign of electrical charge, it could be either 
attraction or repulsion. Coulombic force (Fq) is expressed as [7]: 
𝑭𝒒 =  
𝒒𝟏𝒒𝟐
𝟒𝝅𝜺𝒉𝟐
        Equation 4 
Where q1 and q2 are the charge on two objects, respectively, ε is the permittivity, and h is the separation distance. 
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Induced charging appears when a charged object approaches an uncharged object. Induced charging (Fe) is calculated 
as [7]: 
𝑭𝒆 =  𝒒
𝟐  (𝟏 − 
𝒉
(𝑹𝟐+𝒉𝟐)
𝟎.𝟓)  ∗  
𝟏
𝟏𝟔𝝅𝜺𝒉𝟐
      Equation 5 
Where q is the charging on charged object, h is the separation distance, R is the radius of uncharged object, and ε is 
the permittivity. 
The accumulation of electrostatic charge in DPI particles can occur during formulation preparation, where the API is 
micronized, sieved and blended with coarser carrier particles, and processing, where the formulation is placed in 
storage, filled into capsules or blister strips or transferred to a powder reservoir device. During these different 
manufacturing processes as particles are disturbed and agitated they undergo collisions with themselves and the 
surfaces with which they come in contact with. During such collisions particles will become charged via the 
mechanism of triboelectrification, which may result in a bipolar charge distribution [206, 207]. Since 
triboelectrification arises from interactions between surfaces, the composition of equipment surfaces will directly 
affect charging. This is due to the fact that different materials have different abilities to transfer electrons from or to a 
surface depending on their relative abilities to donate or accept electrons. Therefore, interactions between particles 
and different material surfaces may result in different charge levels and polarity in the powder [199]. This can 
potentially affect the physical structure of the blend and result in processing problems such as adhesion to container 
surfaces, agglomeration, poor flow behavior, reduced API recovery, loss of content uniformity and manual handling 
difficulties [208]. The presence of charge on a DPI formulation, which may not decay quickly with time, can result in 
variable formulation performance. In addition to a build-up of electrostatic charge during manufacturing and 
processing, DPI formulations also undergo triboelectrification upon aerosolization within an inhaler device. During 
drug dispersion in a DPI, interactions between the powder, air turbulence and inhaler device surface build up 
electrostatic charge in the aerosol cloud. Particles deagglomerate from each other, fluidize and enter the air stream. 
The particles circulate within the internal cavity of the inhaler where they also undergo numerous interparticulate 
collisions and collisions with the device material. Other factors influencing the extent of electrostatic charge during 
DPI aerosolization include the deaggregation mechanism of the device, device material, capsule material, physico-
chemical and electrical properties of the particles, humidity and temperature [205, 209]. 
Water can interact with solid particles in three ways: adsorption, capillary condensation, and deliquescence process 
based on the relative humidity (RH) and the particle characteristics [210]. Capillary forces rise between particles 
following capillary condensation of water vapor at relatively high humidity (typically RH >65%). The Laplace 
pressure developed due to the water meniscus formed in the contact zone pulls particles together [8]. An increase in 
RH can induce profound change in particulate interactions in dry powder aerosol formulation, in most cases, resulting 
in reduced dispersion efficiency [173, 211-215]. The water vapor at or above critical RH may induce deliquescence 
followed by solid bridge formation by recrystallization. 
The capillary forces (Fcp) between two spherical particles are described as [7]: 
𝑭𝒄𝒑 = 𝟒𝝅𝑹 ∗ 𝜸𝑳𝒄𝒐𝒔𝜽 + 𝟒𝝅𝑹 ∗ 𝒚𝑺𝑳      Equation 6 
Where R is the harmonic mean of radii of the particles, γL is the surface tension of water, γSL is the solid-liquid 
interfacial energy, and θ is the contact angle of liquid film to particle surface. 
In reality, the forces of interaction between pharmaceutical particles are difficult to characterize or to be controlled 
due to the heterogeneity in particle composition and physicochemical characteristics. Therefore, it is not practical to 
consider each of these forces independently. However, key features of inhalation powders that critically influence 
interparticulate forces should be evaluated, including particle size and size distribution, particle shape, surface 
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asperities (roughness), crystallinity, particle density, and presence of impurities (Figure 20) [7]. Adhesion or cohesion 
of dry powder formulations can be indirectly estimated by using inverse gas chromatography (IGC) [136, 216-223] 
and contact angle [216], and directly measured by using atomic force microscopy (AFM) [193, 224, 225]. However, 
techniques like AFM only enable the measurement of interpaticulate or surface forces at the individual particle level, 
but due to the lack of understanding of the actual form of bodies in contact such as the contact area and coordination 
number, the exact description of the powder formulation and the correlation of measured forces with aerosol 
performance are still challenging. The efficiency of deaggregation in aerosolization is highly influenced by existing 
adhesive/cohesive forces in formulations. For instance of carrier-based dry powder formulation for inhalation, strong 
adhesive (drug-carrier) interaction may prevent the release of respirable drug particles from the surface of carriers, 
leading into a high deposition in upper airways. Therefore, the adhesive forces between respirable drug particles and 
large carrier particles strongly influences the delivered dose, since only drug particles separated from carrier surface 
are able to reach to the deep lungs. Similarly, excessive cohesive forces could lead to agglomerate formation, affecting 
powder fluidization and dispersion characteristics of formulations [193]. The balance of these forces is very critical 
in drug-carrier blending, drug particle deaggregation, and drug particle resuspension. 
 
Figure 20: Overview of factors impacting particle interactions in adhesive powder mixtures. 
A lot of work has been done earlier to discover dependencies between particle characteristics and performance during 
inhalation (Figure 20) [12, 21, 139, 219, 226-230]. Impaction analysis as a technique to study the detachment and 
dispersion of drug particles upon device actuation was introduced to investigate these dependencies and is required 
by the European Pharmacopoeia (Ph. Eur.) to assess the fine particle dose (FPD) of any formulation applied for 
inhalation [231]. 
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8. Pharmaceutical Aerosol Testing 
The fraction of the aerosol that is deposited in different locations of the respiratory tract is a function of the distribution 
of the aerodynamic particle size of the particles, the mode of inhalation and the morphology of the respiratory tract 
[139, 232]. The aerodynamic diameter (Dae) is the most appropriate measure of aerosol particle size because it 
correlates directly with the efficiency of lung delivery and ultimately the therapeutic effect [6]. 
For the assessment of the aerodynamic particle size distribution (APSD) of orally inhaled pharmaceutical aerosols, 
typically the full resolution multi-stage cascade impactor (for example Next Generation Impactor, NGI, Copley 
Scientific, UK; Figure 21) is regarded in the compendial literature as the “gold standard”-method [233, 234]. Cascade 
impactors are the instruments of choice for the in vitro assessment of delivery efficiency of inhalation products for 
three reasons. First, by using a specific drug assay, the size distribution of drug particles that is obtained is drug 
specific, not confounded with any non-drug material that may be in the sample. Second, the size distribution is 
measured of the total amount of drug that is delivered, rather than of only a sub-sample that may or may not be 
representative. Third, impactors classify particles according to their aerodynamic diameter. However, it is important 
to recognize that the cascade impactor is not a lung simulator because of many features, including the geometry at the 
point of impact, collection surface hardness and coating, and operation at constant flow rate. In particular, collection 
stages in the impactor do not correspond to any specific deposition sites in the lung [28]. 
Particles entering a cascade impactor pass through different plates containing nozzles of a well-defined size (cutoff 
stages). A collection cup located immediately beyond a plate at a defined separation distance deflects the airflow; the 
inertia of the particles causes them to cross the flow stream, with the result that those with a size greater than a critical 
value impact on the surface, whereas smaller particles remain airborne [235, 236]. Usually, such instruments size-
fractionate the incoming aerosol into eight discrete components by size, depending on the incoming air flowrate. 
About five stages in an NGI collect particles within a size range from 0-5 μm in aerodynamic diameter [26, 27, 237], 
where most information is acquired in connection with the respiratory deposition to receptors located in the human 
airways beyond the oropharynx [238, 239]. Cascade impactor measurements provide direct measures of both mass of 
active pharmaceutical ingredient (API) and aerodynamic particle size [235]. 
   
Figure 21: Next Generation Impactor equipped with a pre-separator and USP throat model (left), open NGI with collection 
cups (middle) and seal body with the eight cutoff stages (right). Adapted from [28]. 
After generating a size-segregated sample of the particles in a cascade impactor, each size fractionated particle sample 
is dissolved into a solvent which is then analyzed by high-performance liquid chromatography (HPLC). While highly 
quantitative for the total concentration of API delivered, this technique does not yield any information regarding the 
relationships between the various product components (drugs and excipients) within the formulation. 
Cascade impaction testing requires mastery of a complex technique before consistent results can be achieved. NGI-
testing results in a large demand on resources in terms of laboratory personnel and solvents, the measurements are 
very time-consuming and results are typically returned days or even weeks later [29, 30]. There is, therefore, an interest 
in the development of more rapid techniques that might have particular application for routine product quality testing 
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as well as in product development applications in which many similar impactor measurements are often necessary 
[31]. 
An alternative technique for aerosol characterization is single particle aerosol mass spectrometry (SPAMS), which 
determines both the aerodynamic diameter and the chemical composition of many individual particles in real-time. 
SPAMS is descended from other single particle characterization techniques. 
Rapid single-particle mass spectrometry (RSMS) could determine the chemical composition of each particle at a rate 
of one per second but only determined the particle size very inaccurately by measuring the light scattering intensity 
collected by a relative large diameter fiber optic perpendicular to the scattering laser [240]. In 1994, the group of 
Prather et al. improved the RSMS design into aerosol time-of-flight mass spectrometry (ATOFMS), which was the 
first analytical technique capable of the in-situ simultaneous characterization of both the chemical composition and 
aerodynamic diameter of individual aerosol particles in real-time [241]. In 1997 the first portable ATOFMS was 
constructed and commercialized later by TSI Corporation [242]. The system was primarily developed for 
environmental air sampling and monitoring but its capabilities for characterizing aerosols generated with pMDIs have 
been demonstrated [37, 243, 244]. Unfortunately, while promising, the limitations the ATOFMS instrument limited 
the effectiveness of the technique as demonstrated by their specific analytical methods. First, the tendency of the 
ATOFMS light scattering detection system to saturate at particle concentrations common to pMDIs prevented 
quantitation of the particle concentrations. Second, the ATOFMS instruments were unable to efficiently analyze 
particles across the therapeutically relevant size range. While the overall approach of using on-line single particle 
mass spectrometry was innovative and remains robust, the experiments failed to demonstrate its utility. Therefore, 
there was the need for a real-time identifier of individual aerosol particles with a higher total particle analysis 
throughput and that would degrade progressively once the level of saturation is reached at very high particle 
concentrations. The SPAMS system developed by Lawrence Livermore National Laboratory prevented the light 
scattering system saturation and added high speed mass spectral acquisition and analysis in real-time [245]. The 
SPAMS was unique in its ability to acquire mass spectra rapidly and analyze data within seconds. The SPAMS 
technology was subsequently commercialized by Livermore Instruments Inc. (SPAMS 3.0 in Figure 22) [246]. 
 
Figure 22: Livermore Instruments Inc. single particle aerosol mass spectrometer (SPAMS 3.0). 
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Aerosol-specific mass spectrometers such as the Livermore Instruments Single Particle Aerosol Mass Spectrometer 
(SPAMS 3.0) are capable of providing both aerodynamic particle size distribution (APSD) profiles of particles and 
the chemical composition of particle statistical sampling of 10’000 single particles in two minutes. The SPAMS has 
a very high rate of data acquisition (up to 250 particles per second) compared to earlier aerosol MS designs measuring 
only 1-4 particles per second. By analyzing a large number of particles and using application-specific chemometric 
software, the instrument is able to determine mass loadings for particular components (both APIs and excipients), 
which can be compared to results obtained by NGI. Previous experiments using both aerosol time-of-flight mass 
spectrometry (ATOFMS) and SPAMS have demonstrated that particle co-associations between drug product 
components could be evaluated in a way that is inaccessible via impactor techniques [30, 37, 146, 247-249]. 
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9. Outline and Aims of this Thesis 
Current marketed dry powder inhalation products generate fine particle fractions (FPF; the proportion of dose 
containing particles <5 μm in aerodynamic diameter) that are roughly between only 10-50% of the label claim [137, 
138]. Several powder inhalation products have recently been marketed of which the carrier-based formulations contain 
additional excipients such as the ‘force control agent’ magnesium stearate to obtain a satisfactory dispersion 
performance (e.g. Foster® NEXThaler®, Seebri® Breezhaler® or Anoro® Ellipta®), even though no evidence can be 
found in literature about the mechanism of action. Development and production of safer, more efficient and effective 
dry powder inhalation products is a goal worthwhile of striving towards. Understanding the dispersion performance 
of adhesive mixtures is pivotal in this respect. Therefore, the aim of this thesis is to improve the understanding of the 
relationships between particle interactions, the dispersion performance, formulation variables and inhalation variables 
of adhesive mixtures for inhalation. 
This thesis focuses on the preparation of dry powder inhaled formulations and the investigation of the complex 
mechanisms that affect the dispersion of drug particles during aerosolization. Despite several years of research on 
particle interactions that occur in carrier-based systems, there are still essential issues that remain unclear (Figure 23). 
There is only a limited understanding of how blending processes affect material properties and the resulting 
distribution of drug and excipient in the final dosage form, as well as its final aerosol performance. A great number of 
variables are considered relevant to the interfacial forces in adhesive mixtures, but their effects have mostly been 
investigated individually, without taking account of the influence they may have on each other. Currently, there is a 
strong focus on exploring techniques for the characterization of drug and carrier surface properties that are believed 
to have an influence on the interparticulate forces in adhesive mixtures. For a number of surface properties it may be 
questioned whether they are really the key parameters to investigate [134, 136, 171, 177]. 
 
Figure 23: Scheme of variables in lactose carrier-based formulations showing the effects linked to a change of in vitro aerosol 
performance. Modified from [171]. 
Advanced powder characterization techniques such as single particle aerosol mass spectrometry (SPAMS) and time-
of-flight secondary ion mass spectrometry (ToF-SIMS) were employed to improve the mechanistic understanding of 
particle interactions, drug detachment and dispersion during impaction analysis. ToF-SIMS is one of the most sensitive 
surface composition analysis techniques, with elemental detection limits ranging from parts per million to parts per 
billion. It can elucidate the microscopic structure of powders in form of an image. An introduction into ToF-SIMS 
measurements of dry powder carrier particles for inhalation is given in Jetzer et al. (Chapter 2) [146]. 
The overall objective of this PhD thesis was to improve the understanding of physical processes that determine the 
aerosol performance of dry powder inhalation drug product formulations and also to further develop the SPAMS 
analytical technique for testing pharmaceutical aerosols. 
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The objectives can be grouped in the following areas: 
 Further development of the SPAMS analytical technique and application of the technique in the investigation 
of complex dry powder inhaled drug products. The focus was on the validation of the aerosol performance 
data such as aerodynamic particle size distribution (APSD) and fine particle fraction (FPF) generated with 
SPAMS and the evaluation of the suitability of the method to identify and quantify compound/compound 
interactions of different active ingredients in dry powder blends. 
 Investigation of compound/compound (and/or excipient) interactions in dry powder blends (e.g. interactions 
between two APIs as a fixed dose combination in dry powder blends that affect aerosol performance of the 
DPI drug products when compared with the monotherapy dry powder blends). Previous experiments using 
the SPAMS technique have demonstrated that particle co-associations between drug product components can 
be evaluated in a way that is inaccessible via traditional impactor techniques 
 The functionalizing of lactose carriers with a ‘force control agent’ (magnesium stearate) was studied by using 
different blending techniques. The parameters involved in this carrier modification were elucidated, e.g. the 
degree of carrier surface coverage/distribution with MgSt, the amount of particle co-association, changes in 
the excipient carrier’s particle size distribution, physical characteristics changing on the microscopic level 
and their impact on in vitro aerosol performance. This may enable more rationale formulation process 
development and allow better control of DPI drug product critical quality attributes. 
 Identification and study of model systems where the underlying physical processes determining the aerosol 
performance (APSD and FPF) of dry powder inhalation drug products are not fully understood at the 
mechanistic level. 
 Conditioning processes of different dry powder inhaled formulations were studied. Exposure of the DPI 
capsules to specific environmental conditions such as elevated temperature or elevated humidity can alter the 
in vitro aerosol performance characteristics of a DPI drug product. The understanding of the root cause is 
limited and it is not clear if dissipation of electrostatic charge, a change in triboelectrification behavior or 
agglomeration of the APIs is the main root cause. Differences in conditioning behavior of different APIs was 
investigated. Several ways to measure electrostatic charge before, during and after conditioning as well as 
during DPI aerosolization were explored. 
 
 
 
 
 
 
 
 
 
 
 
 
47 
CHAPTER 2: PEER-REVIEWED PUBLICATIONS 
1. Comparison of Different Aerodynamic Sizing Techniques for the Evaluation 
of Metered Dose and Dry Powder Inhalers 
 
Jetzer et al. Respiratory Drug Delivery 2016. Volume 3, 2016 459-462 
Summary 
For the evaluation of the aerosol performance of inhaled pharmaceutical products, the current state of the art is the use 
of the next generation impactor (NGI, Copley Scientific, UK) [250], typically with chemical analysis using high 
performance liquid chromatography (HPLC), to characterize the aerodynamic particle size distribution (APSD). In 
this study, we compare the APSD profile of single particle aerosol mass spectrometry (SPAMS) to the aerodynamic 
particle sizer ((APS) TSI Incorporated, MN, USA) and NGI when tested with a pMDI and DPI. In addition, we 
evaluate the transmission efficiency of SPAMS as well as potential size bias of APSD measurements that might result 
from a size dependent transmission profile. 
Introduction 
SPAMS can be utilized for APSD measurements of pharmaceutical aerosols [30]. SPAMS data was found to correlate 
well with the fine particle mass (FPM) data obtained by NGI for Onbrez® and Arcapta™ dry powder inhalers (DPIs) 
as a function of dosage strength [251]. In this study, APSD data was obtained from APS and NGI to compare to 
SPAMS results. Since SPAMS samples a small fraction of the total emitted dose uniform transmission is required to 
prevent size bias. Therefore, this study also evaluates the transmission efficiency of particles of indacaterol maleate 
in a metered dose inhaler (pMDI) and DPI formulations in the SPAMS in order to better characterize the performance 
of the inlet interface and to determine if the results are closer to established standard aerodynamic sizing techniques. 
Materials and Methods 
A Livermore Instruments SPAMS 3.0 was used for this study. The experimental setup of the SPAMS instrument and 
sample testing has been described earlier by Morrical et al. [30]. For DPI formulations, a pre-separator was mounted 
between the USP throat and reservoir. In addition to the SPAMS, an APS was used with a single-stage impactor to 
take a size-segregated sample at a predefined air flow at 28.3 L/min. The NGI testing was conducted with a flow rate 
of 90 L/min for 2.7 seconds. The powder deposited on each stage was recovered via solvent extraction and analyzed 
with reverse-phased high performance liquid chromotography (HPLC). Indacaterol maleate DPI formulations 
(Arcapta™ Neohaler™ and Onbrez® Breezhaler®) and a proprietary indacaterol maleate pMDI suspension formulations 
were tested in the comparative studies. 
Results 
A comparison of APSD results from SPAMS for indacaterol maleate pMDI formulations with APS is shown in Figure 
24A. While the profiles are similar, there are differences observed in the range from 2-3 μm where the SPAMS results 
are lower than those from the APS. But when comparing DPI profiles measured by APS and SPAMS technique (Figure 
24B), it can be seen that there is a larger difference in the size distribution profile. DPI formulations are composed 
mostly of lactose carrier particles and the APS does not discriminate between lactose and API. The APS measurement 
indicates that there are more large particles > 6.7 μm, and also particles < 3.8 μm present, which are not counted by 
SPAMS because lactose is not ionized. 
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Figure 24: A) pMDI actuation with APS and calculated from SPAMS data. B) DPI actuation (Onbrez®) with APS and 
calculated from SPAMS data. 
Table 2: Aerodynamic diameter estimated from indacaterol maleate pMDI and DPI formulations for both aerodynamic 
sizing methods APS and SPAMS at 28.3 L/min. 
 
As can be seen in Table 2, there is good agreement overall between the APS and SPAMS for pMDI, while there is not 
a good agreement between APS and SPAMS for the DPI measurement. The results above indicate that the SPAMS 
does not have the same transmission efficiency for particles of all sizes. There are two potential factors that may cause 
this bias in the SPAMS APSD analysis: the sampling chamber and differences in the particle inlet interface. These 
two factors can result in differences in the settling velocity and deposition of larger particles and most likely have 
significantly different particle transmission efficiencies. SPAMS was also compared to the widely used NGI to see if 
it was possible to compare the results of a particle counting technique to one that obtains mass directly. In order to do 
this, the counted particles were summed into different size “bins” that match the impactor cup size cutoffs in the NGI 
at 90 L/min. Then the total mass of API particles was calculated for each size bin assuming unity density and a 
spherical shape. The mass was normalized to give the same relative mass scale of the NGI results. When comparing 
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NGI results with SPAMS data for DPI, it is observed that at the 6.48 and 3.61 μm stages results match well, but there 
is a consistent difference with the next stage (2.3 μm), where SPAMS results appear to be lower than these from NGI 
(Figure 25). This result mirrors what was observed for the pMDI results when comparing the SPAMS with the APS 
(Figure 24) and suggests that there is a significantly lower transmission of particles in this size range than would be 
expected from other sizing techniques. It is important to note that for the pMDI APS/SPAMS experiment only pure 
indacterol maleate particles were used and for the DPI NGI/SPAMS experiment the particles plotted are chemically 
specific to indacaterol maleate, so the interference with lactose observed in the DPI APS/SPAMS experiment is 
negated. 
 
Figure 25: Indacaterol maleate DPI NGI data compared to calculated SPAMS data. 
A potential reason for this is caused by the SPAMS interface that appears to have a discontinuity in the transmission 
of particles with the main gap centered around 2.3 μm, which will likely result in an underestimate of FPM (particles 
< 5 μm). Figure 26 shows the transmission efficiency of the SPAMS interface using calibration latex spheres. In Figure 
26, the expected number of particles is the total number of particles introduced into the system and real counts is the 
actual number counted by the SPAMS. As can be seen, the transmission of particles in the range from 2-3 μm appears 
to be lower than for particles with a size of 1 or 6 μm. This again confirms what was observed in the previous 
experiments. 
 
Figure 26: Real number of particle counts of a SPAMS compared with calculated expected number of counts. 
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Conclusions 
It was demonstrated that the SPAMS can generate useful APSD measurements with both pMDI and DPI. However, 
there is still lack of a good correlation to date because of a consistent anomaly of particle transmission in the SPAMS. 
More work characterizing the particle interface is needed, particularly in the region of 2-3 μm, based on observations 
when comparing SPAMS with APS and NGI for the characterization of particles. 
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2. Particle Interactions of Fluticasone Propionate and Salmeterol Xinafoate 
detected with Single Particle Aerosol Mass Spectrometry (SPAMS) 
 
Jetzer et al. International Journal of Pharmaceutics (2017) 532:218-228 
Abstract 
Particle co-associations between the active pharmaceutical ingredients fluticasone propionate and salmeterol xinafoate 
were examined in dry powder inhaled (DPI) and metered dose inhaled (MDI) combination products. Single Particle 
Aerosol Mass Spectrometry was used to investigate the particle interactions in Advair Diskus® (500/50 mcg) and 
Seretide® (125/25 mcg). A simple rules tree was used to identify each compound, either alone or co-associated at the 
level of the individual particle, using unique marker peaks in the mass spectra for the identification of each drug. High 
levels of drug particle co-association (fluticasone-salmeterol) were observed in the aerosols emitted from Advair 
Diskus® and Seretide®. The majority of the detected salmeterol particles were found to be in co-association with 
fluticasone in both tested devices. Another significant finding was that rather coarse fluticasone particles (in DPI) and 
fine salmeterol particles (both MDI and DPI) were forming the particle co-associations. 
Introduction 
The two most common chronic respiratory diseases are asthma and chronic obstructive pulmonary disease (COPD). 
According to the 2016 estimate by the World Health Organization, 235 million people currently suffer from asthma 
and over 3 million people die each year from COPD, accounting for an estimated 6% of all deaths worldwide [252]. 
Two major classes of drugs widely used in the treatment of these diseases are inhaled corticosteroids (ICS) and beta2-
agonists (LABA), both preferably being delivered directly to the lungs by inhalation. The active pharmaceutical 
ingredients (APIs) are typically administered to patients via either a pressurized metered dose inhaler (pMDI) or a dry 
powder inhaler (DPI) device. The two classes of compounds have very different modes of action, targeting different 
aspects of the respiratory disease process (airway inflammation in the case of ICS and smooth muscle dysfunction in 
the case of LABA). Thus these two classes of drugs in combination address complementary aspects of the disease 
pathophysiology of asthma that neither drug class is able to achieve alone [101]. 
Clinically, prescribing both classes of drugs has become a method of taking advantage of their complementarity. There 
is, however, significant clinical and in-vitro evidence to suggest that the co-association of ICS and LABA at the level 
of the single administered aerosol particle leads to a synergetic effect with improved clinical outcomes. Studies have 
shown increasing evidence of complementary and synergistic effects of LABA and ICS, interacting at the molecular 
receptor [253-257] and cellular [258-261] level. Previous studies have ruled out systemic pharmacokinetic or 
pharmacodynamic interactions between inhaled fluticasone propionate (FP) and salmeterol xinafoate (SX) when 
administered in combination [262]. One postulated reason for this synergetic increase in pharmacological efficacy is 
the co-association of APIs at the point of deposition within the lung [38, 263]. Specifically, salmeterol was observed 
to retard the transport of fluticasone across cell cultures of lung epithelial tissues, prolonging its localized anti-
inflammatory effects [38]. The co-administration of the two drugs is expected to improve the likelihood of the two 
APIs being delivered to the same location in adequate concentrations, maximizing the likelihood of these synergetic 
effects [107]. Partly for patient convenience and partly to take advantage of this synergetic phenomenon, “combination 
products” have been introduced which contain both APIs in a single formulation administered simultaneously by a 
single device. 
Interestingly, the presence of one API in these products was demonstrated to affect the delivered dose of the other that 
reached the lung [107, 263-266] but that phenomenon was ruled out as the cause of the improved clinical outcomes 
for the combination products versus the administration of two single API products [267, 268], indicating that the 
postulated synergetic phenomenon is, indeed, taking place in vivo. Previously, it was demonstrated that there is some 
52 
affinity between fluticasone and salmeterol in solution, indicating that they may also be co-associated at the level of 
the individual administered aerosol particle [269]. Attempts have been made to observe particle co-associations with 
Raman microscopy by Theophilus et al [270]. Determining the chemical composition of individual particles with a 
technique such as single particle aerosol mass spectrometry (SPAMS) should yield more definitive data. Preliminary 
runs with the SPAMS technique have already shown promising results [30]. 
The current pharmacopoeial standard method for determining the aerodynamic particle size distribution (APSD) of 
drugs delivered from inhaled pharmaceutical products is to generate a size-segregated sample of the particles in a 
cascade impactor, typically the recently developed Next Generation Impactor (NGI) [26-28], followed by dissolving 
of each size-fractionated particle sample into a solvent which is then analyzed by high-performance liquid 
chromatography (HPLC). While highly quantitative for the total concentration of API delivered, this technique does 
not yield any information regarding the relationships between the various product components (API(s), excipients) 
within the formulation. 
Mass spectrometry based aerosol analytical techniques have been undergoing continuous development since the 1970s 
[24, 32, 33, 271, 272]. Aerosol-specific mass spectrometers such as the Livermore Instruments SPAMS 3.0 are capable 
of providing both aerodynamic particle size distribution (APSD) profiles of particles and the chemical composition of 
particle statistical sampling of 10,000 single particles in two minutes. 
The SPAMS is descended from an earlier instrument, the Aerosol Time-of-Flight Mass Spectrometer, that was also 
capable of determining the aerodynamic size and chemical composition for individual particles in real-time, first 
reported by Prather et al in 1994 [32]. This instrument was initially developed for environmental and air pollution 
studies but was applied to the analysis of inhaled pharmaceutical products soon after its invention [37, 237]. 
Recently, SPAMS was developed as a more advanced instrument capable of characterizing single aerosol particles, 
providing both the aerodynamic diameter and chemical composition of each measured particle. The SPAMS has a 
very high rate of data acquisition (up to 250 particles per second) compared to earlier aerosol MS designs measuring 
only 1-4 particles per second. By analyzing a large number of particles and using application-specific chemometric 
software, the instrument is able to determine mass loadings for particular components (both APIs and excipients), 
which can be compared to results obtained by NGI. Previous experiments using both ATOFMS and SPAMS have 
demonstrated that particle co-associations between drug product components could be evaluated in a way that is 
inaccessible via impactor techniques [30, 37, 247]. A deeper understanding about product performance and 
interactions can be gained, providing valuable information for combination products. If a higher degree of co-
associated particles would indeed be beneficial for patients, product developers could design formulations with a 
greater degree of co-associated API. This makes the SPAMS technique an attractive alternative in the field of 
pharmaceutical aerosol analysis (complementary to NGI/HPLC-analysis). 
The objective of these experiments was to determine the degree of particle co-associations between fluticasone and 
salmeterol and the mass distributions of the particles containing the two different APIs across multiple size ranges in 
real-time. Axotide® and Serevent®, each a single API product containing fluticasone and salmeterol, respectively, 
were used to identify unique marker peaks from mass spectral signals of each API. 
Materials and Methods 
In the current study, commercially available inhalation drug products containing fluticasone propionate (FP) and 
salmeterol xinafoate (SX) were investigated using a SPAMS 3.0. Table 3 lists the products used in this study. The 
experimental matrix consisted of both pMDI and DPI fluticasone mono, salmeterol mono and fluticasone-salmeterol 
combination formulations. 
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Table 3: Overview of DPI and pMDI product groups used in this study. 
Brand Name Inhaler API/Dosage Strength 
Advair Diskus® DPI Fluticasone Propionate / Salmeterol Xinafoate 500/50 mcg 
Axotide Diskus® DPI Fluticasone Propionate 500 mcg 
Serevent Diskus® DPI Salmeterol Xinafoate 50 mcg 
Seretide® pMDI Fluticasone Propionate / Salmeterol Xinafoate 125/25 mcg 
Axotide® pMDI Fluticasone Propionate 125 mcg 
Serevent® pMDI Salmeterol Xinafoate 25 mcg 
 
Chemical structures for fluticasone and salmeterol are given in Table 4. 
Table 4: The structures of fluticasone propionate and salmeterol xinafoate. 
 
Fluticasone Propionate (FP) 
C25H31F3O5S 
MW 500 g/mol 
 
 
Salmeterol Xinafoate (SX) 
 
Salmeterol 
C25H37NO4 
MW 415 g/mol 
 
 
Xinofoate 
C11H8O3 
MW 188 g/mol 
 
Single Particle Aerosol Mass Spectrometry 
The SPAMS instrument has been described elsewhere previously, but a brief description will be given here [30, 273]. 
Figure 27 is a schematic of the SPAMS instrument as configured for DPI measurements. An inhalation device is fitted 
to a USP throat (UIP, MSP Corp., Minnesota, USA) which is, in turn, mated to an aerosol residence chamber. The 
chamber is necessary to mediate between the higher flow rate of the devices under actuation and the SPAMS which 
draws 1.16 liters/minute through a KF-16 port at the bottom of the chamber. The relaxation chamber is also a source 
of sampling bias due to the loss of particles from wall adhesion and from gravitational settling of particles in the size 
range of interest [274]. In these experiments, no attempt was made to scale the data according to shape or transmission 
efficiency of the SPAMS inlet interface. The devices are actuated via a vacuum pump (HCP5, Copley Scientific Ltd., 
UK) / critical flow controller (TPK-2000, Copley Scientific Ltd., UK) which are connected through a third port in the 
side of the chamber.  
The SPAMS system is maintained under vacuum. Aerosol particles are introduced from the chamber into its top 
through an inlet nozzle and proceed through a series of aerodynamic focusing lenses. The lenses collimate the particles 
into a beam and also serve to accelerate the particles in the beam to a terminal velocity that is a function of their 
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aerodynamic diameters. The SPAMS determines each particle’s size in real-time by measuring its transit time as it 
traverses a square profiled laser beam and its scattered light is detected by a photomultiplier tube (2). This transit time 
is compared to a calibration made from particles of known size and density, returning their aerodynamic diameters at 
the level of the individual particle. The light scattering event is also used to trigger the firing of a pulsed ionization 
laser which desorbs and ionizes the particle. The desorption/ionization process occurs at the center of the source region 
of a dual polarity time-of-flight mass spectrometer. Both positive and negative ion spectra are simultaneously acquired 
and stored along with that particle’s transit time. Up to 250 of these mass spectra/aerodynamic diameters can be 
acquired per second, each from an individual aerosol particle (3). 
The mass spectra are analyzed in real-time using SPAMS-specific analysis software. First, the mass spectra are 
compared to a library of known mass spectra from previous training experiments to determine the general nature of 
the particle. Subsequently, the presence and absence of specific mass peaks are confirmed according to a decision tree 
to categorize the particles more precisely [246]. 
 
Figure 27: Schematic of a SPAMS instrument with a setup for dry powder inhaler measurements. 
The first step in characterizing the acquired data is the removal of particles where a sizing event was recorded but no 
corresponding mass spectrum was observed. The remaining particles that generate both sizing and mass spectral data 
are referred to as “hit” particles, whereas particles with only sizing data acquired are referred to as “missed” particles. 
The hit rate in this work is defined as the ratio between the number of particles that generate ions detectable by mass 
spectrometry when the D/I laser has fired versus the total number of particles sized in the same time period. 
Aerodynamic Diameter and Mass Calculation 
As mentioned above, the aerodynamic diameter of the individual aerosol particles, dae was obtained from the 
correlation between transit time and an aerodynamic particle size calibration. The computation of dae, using Eq. (1) 
was based on the assumption that particles behave like spheres with a unit density in the air stream [275]. 
𝒅𝒂𝒆 = 𝒅𝒈𝒆𝒐√(
𝝆𝒑
𝝆𝟎𝝌
)     Eq. 1 
where dae is the aerodynamic diameter in micrometers; dgeo is the geometric diameter of a volumetrically equivalent 
sphere in micrometers; ρp and ρ0 are particle and unit densities; and χ is the dynamic shape factor (unity for a perfect 
sphere). The density of the polystyrene spheres was given by the manufacturer as 1.05 g/cm3.  
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By making the approximation that particles have a perfectly spherical shape (χ ≡ 1), their mass can be calculated by 
multiplying the volume of the particle by the API density, according to Eq. (2). 
𝑴 = 𝑽 × 𝝆𝟎 =
𝟒
𝟑
𝝅𝑹𝟑 × 𝝆𝟎   Eq. 2 
where M is the mass (g); V is the volume of the sphere; ρ0 is the particle density; and R is the radius. 
With the SPAMS technique, the fine particle mass can be estimated on the basis of a conversion from particle counts 
per size bin into estimated mass per bin; by contrast, the NGI mass is based directly on gravimetric measurement or 
by chemical determination per impactor stage (defined size cut-offs) using HPLC. Additionally, whereas a SPAMS 
analyzes a statistical sampling of particles which can be scaled to the total mass, an NGI theoretically samples all 
particles which are dissolved and analyzed in their entirety. 
Calibration of the SPAMS instrument 
For the calibration of the SPAMS particle sizing section over the range of 0.1-10 μm, polystyrene microspheres 
(Thermo-Fisher Scientific, USA) were used. A size calibration curve was obtained by analyzing aqueous standard 
particle solutions in proper concentration with geometric diameters of 0.1, 0.5, 1.0, 2.0, 3.2 and 6.0 µm were 
introduced into the SPAMS by using a nebulizer (Salter Labs®, USA). The nebulized droplets were dried to individual 
particles by passing the aerosol stream through a two-stage diffusion dryer (Livermore Instruments, USA), containing 
silica gel desiccant. The aerodynamic diameters of the unknown particles from the inhalers were obtained from the 
generated calibration curve by plotting the median particle transit time as determined by the SPAMS against the 
calculated aerodynamic diameter. The smaller particles (aerodynamic diameter below 0.1 µm) are traveling at the 
approximate velocity of the gas molecules and thus their sizes cannot be distinguished from each other. Additionally, 
as the particles become smaller in size, they are more difficult to focus into a tight particle beam through the 
aerodynamic lens inlet [33] and behave more like gas molecules and can be pumped away [276]. The SPAMS interface 
is designed deliberately to take advantage of this phenomenon in order to bias towards the less numerous large particles 
and against the more numerous smaller particles roughly as a function of the mass of the particle. 
Dry Powder Inhaler/pressurized Metered Dose Inhaler Testing by SPAMS 
The experimental setup of the SPAMS instrument for inhalational device testing is similar to that described by 
Morrical et al [30]. Diskus® inhaler devices were fitted to an universal induction port (MSP Corp., Minnesota, USA) 
which was in turn fitted to a pre-separator (Copley Scientific, UK) which was filled with 15 mL of water and then 
connected to the 4L relaxation chamber. This assembly of pre-separator and relaxation chamber was then fitted to the 
SPAMS inlet. The primary purpose of the pre-separator was to filter out coarse lactose carrier particles (>10 μm) to 
prevent clogging of the SPAMS inlet interface. The actuation of the DPIs was made with a 2.7 seconds draw of air 
into the relaxation chamber, at a flow rate 90 L/min (i.e. 4 liters of air drawn). The pMDIs were actuated 
simultaneously with a 1.7 second draw of air at a flow rate 30 L/min (~1 liter of air drawn) through a universal 
induction port without a pre-separator into the relaxation chamber. Approximately the same number of particles was 
analyzed for each sample run (ca. 10,000 individual particles each). SPAMS experiments were alternated with clean 
air blank runs to flush the relaxation chamber for one minute each. 
Preliminary experiments have been performed to investigate optimal parameters for pMDI and DPI measurements by 
SPAMS [30, 247, 277]. Both fluticasone and salmeterol have previously been demonstrated to generate ions well at a 
wavelength of 248 nm [278]. Therefore, the desorption/ionization laser was set to fire at a wavelength at 248 nm. In 
the configuration being operated, the SPAMS was able to analyze up to 64 particles per second (laser repetition rate 
64 Hz). The laser energy was maintained at approximately 12 mJ per pulse to obtain a high and consistent hit rate. 
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Determination of the Chemical Identity of Particles 
Determination of APIs present in a given particle of a combination product such as Advair Diskus® or Seretide® 
requires the acquired mass spectra to be analyzed. The comparison of multiple data sets of the combination product 
with the two mono products’ data sets allows for the identification of unique marker peaks that distinguish one particle 
type from another. Most APIs are significantly structurally different or have a different counter ion (for compounds 
in a specific salt form), a mass spectrum should contain an ion or multiple ions that are unique for that compound. 
Once these ions have been identified in the single component products mass spectra, then combination particles are 
identified by the observation those unique markers in combination in an individual particle mass spectrum. Analyzing 
pure lactose in the SPAMS instrument did not result in any mass spectral data (lactose does not absorb significantly 
at a wavelength of 248 nm) (Figure 30). 
A simple rules tree of mass-to-charge ratios and signal thresholds can then be applied to the single API and 
combination DPIs or pMDIs to determine which particles have either, both or neither API present (Figure 28) [30, 
277]. Most likely, these particles are agglomerations of one or both API particles possibly in aggregation with 
excipients. 
 
Figure 28: Rules tree to identify fluticasone propionate and salmeterol xinafoate in mass spectra. 
Results and Discussion 
The hit rate for the combination products was 92% for Advair Diskus® DPI and 78% for Seretide® pMDI. The hit rate 
for the mono products was at 71% for Axotide® pMDI, 87% for Serevent® pMDI, 79% for Axotide Diskus® DPI and 
92% for Serevent Diskus® DPI. The hit rate for the different device types depends on several factors. For example, 
the ionization rate of each API itself plays an important role. Also imperfect alignment between the ionization laser 
and the aerosol beam or between the ionization laser and the tracking laser may result in reduced energy being received 
by the particle. Higher dosage strength in the product will also result in an increase in the hit rate. Excipients in a 
formulation, such as lactose, will significantly decrease the hit rate. However, in Advair Diskus®, Axotide Diskus® 
and Serevent Diskus® a lactose type with a very narrow particle size distribution around 60-100 μm was determined 
to be used by the manufacturer. In our experiments, a pre-separator was used to cut off particles with an aerodynamic 
diameter above 10 μm. Thus, the hit rate for the measured DPI products was very high since nearly all of the particles 
with an aerodynamic diameter below 10 μm were API particles. A possible explanation could be that during DPI 
actuation some smaller lactose particles may be formed through particle collision, abrasion and shear forces and reduce 
the hit rate [15]. MDI products are suspensions of API in a combination with excipient and vehicle so not every particle 
created during nebulization may contain an active substance. 
Mass spectral data 
Figure 29 shows the averaged mass spectra acquired from a single dose each of Axotide®, Serevent® and Seretide® 
pMDI formulations acquired over a 3 min period from each single actuation. Per the formulations, Figure 29 shows 
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spectra of pure fluticasone (top) and salmeterol (middle) respectively, while on the bottom a spectra of co-associated 
particles of fluticasone and salmeterol is shown. A spectrum from excipient particles (lactose) from a DPI is shown in 
Figure 30. The molecular weight of fluticasone propionate is 500 g/mol, of salmeterol is 415 g/mol and of xinafoate 
is 188 g/mol. 
The molecular ion generally cannot be seen when analyzing particles by this method [30, 277] due to the extensive 
fragmentation of the molecule during the desorption and ionization process. The structures of both fluticasone and 
salmeterol contain strong chromophores, which absorb well at λ = 248 nm [278]; however, the required energy needed 
to break the crystal lattice of the particle and then to ionize the free molecules is substantially higher than the ionization 
threshold of the APIs. As a result, there is often sufficient excess energy to result in extensive fragmentation of the 
molecule into the fragment ions seen in Figure 29. 
The mass spectra were individually evaluated for the presence of unique marker peaks with optimal predictive value 
for the identity of each API. The marker peaks inferred from the two products containing a single API were used to 
discern those APIs in the combination product. Negative ions were primarily used as markers since unique peaks were 
more readily identified there. It was determined that a peak at M/Z = -19 was found in fluticasone, indicating the 
liberation of fluorine from the fluticasone structure. For salmeterol xinafoate, peaks at M/Z = -188 and -24, -25, -26 
were identified as originating for the xinafoate counter ion (M/Z=-188) and salmeterol (hydrocarbons: C2, C2H, C2H2), 
respectively. 
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Figure 29: Top: Averaged mass spectra of pure fluticasone propionate (FP) particles (M/Z = -19) from Axotide® pMDI. 
Middle: Averaged mass spectra for pure salmeterol xinafoate (SX) particles (M/Z = -188; -24, -25, -26) from Serevent® 
pMDI. Bottom: Mass spectra for co-associated single particles of fluticasone propionate (FP) (M/Z = -19) and salmeterol 
xinafoate (SX) (M/Z = -188; -24, -25, -26) from the combination products. 
It can be clearly seen that the spectra in Figure 29 at the bottom contain marker ions that correspond to those seen in 
the spectra taken from pure standards of both fluticasone and salmeterol and must therefore be agglomerates of co-
associated particles. 
Very few spectra were acquired for pure lactose and those that were acquired had an extremely weak sign for both 
positive and negative ions, presumably due to the lack of a strong chromophore in the lactose molecule capable of 
absorbing radiation at 248 nm (Figure 30). As a result, lactose does not interfere with the detection of particles 
containing an API. By eliminating all of the pure API particles and comparing them to the maximum known hit rates 
typically achieved, we estimate that less than 10% of all particles detected by mass spectrometry were pure lactose. 
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Figure 30: Averaged mass spectra for excipient (Lactose). 
Aerodynamic Particle Size Distributions 
As mentioned above, the SPAMS interface deliberately size biases in favor of larger particles and this bias was not 
accounted for in this work. Nevertheless, even the biased aerodynamic particle size distribution (APSD) histograms 
can be informative given that they all have the same bias. Those APSDs are plotted in Figure 31 and Figure 33 and 
Supplementary Figures 1-2. The histograms show the distribution of active and unassigned or excipient particles in 
10,240 measured particles. MDIs show a normal (Gaussian) distribution curve shape with a median aerodynamic 
diameter (MAD) around 2.00 μm for fluticasone (Axotide®) and 1.39 μm for salmeterol (Serevent®) as can be seen in 
Table 5 and Supplementary Figures 1-2. In Figure 31, the MAD of total API (fluticasone-salmeterol, fluticasone and 
salmeterol) in Seretide® was 1.79 μm. Salmeterol seems to be much finer than fluticasone in the tested pMDI 
formulations and, as a result, many more small salmeterol particles were detected in the range from 0-0.7 μm. 
The DPI mono products Axotide Diskus® and Serevent Diskus® had an MAD of 2.06 μm and 1.86 μm, respectively 
(as can be seen in Table 5 and Supplementary Figures 1-2). The DPI combination product Advair Diskus® had an 
MAD for both APIs combined around 2.02 μm (Figure 33, Table 5). Generally, the MAD for fluticasone, salmeterol 
and co-associated particles was found to be coarser in DPI formulations compared to corresponding pMDI products. 
However, the MAD of pure fluticasone was coarser in both the DPI mono and pMDI mono formulations than in the 
combination products. 
The particle co-associations and interactions in combination products may influence the ratio and MAD of fluticasone, 
salmeterol and fluticasone-salmeterol (co-associated particles). It is possible that a certain particle size of each API 
preferentially forms heterogeneous agglomerates. Alternatively, it is possible that the drug substance was milled to a 
different fineness by the manufacturer. DPIs also have some larger agglomerate particles compared to pMDI profiles, 
with an aerodynamic diameter around 5.9-6.7 μm (Table 5). Because DPI formulations also contain excipients such 
as lactose, it seems likely that pure particles (fluticasone or salmeterol) and co-associated particles (fluticasone-
salmeterol) are made of agglomerates of API and excipient, resulting in the larger particle size. 
Table 5: Median aerodynamic diameter (MAD) calculated from pMDI and DPI products measured by SPAMS. 
MAD [μm] Axotide® 
pMDI 
Serevent® 
pMDI 
Seretide® 
pMDI 
Axotide Diskus® 
DPI 
Serevent Diskus® 
DPI 
Advair Diskus® 
DPI 
FPSX --- --- 1.64 --- --- 2.02 
FP mono 2.00 --- 1.96 2.06 --- 1.36 
SX mono --- 1.39 2.25 --- 1.86 2.12 
Overall 2.00 1.39 1.79 2.06 1.86 2.02 
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Figure 31 shows the APSD of APIs in Seretide® pMDI, both as mono API particles and as co-associated API particles. 
The APSD histogram shows the fractionation of the “hit” particles and the collected data demonstrates that a majority 
of particles emitted from Seretide® contained both APIs in co-association. A fraction of particles (11%) could not be 
identified, most likely due to insufficient ionization. Due to the higher dosage strength of fluticasone compared to 
salmeterol in Seretide® (125/25 mcg), many more fluticasone particles were present to be detected than salmeterol 
particles. 45% of all hit particles contained fluticasone and salmeterol in co-association. A majority of salmeterol 
particles (70%) were co-associated with fluticasone. 
 
Figure 31: Aerodynamic particle size distribution of Seretide® pMDI obtained by SPAMS (n=3 pMDI actuations; error 
bars represent one standard deviation). The plot shows the distribution of number of particle co-associations of fluticasone-
salmeterol (FPSX), pure fluticasone (FP), pure salmeterol (SX) and unassigned particles. 
In Seretide® the MAD for pure fluticasone is around 1.96 μm while the MAD for salmeterol particles was found to be 
much coarser for pure SX particles (MAD 2.25 μm). The co-associated drug particles in Seretide® had an MAD around 
1.64 μm. Interestingly, pure fluticasone and salmeterol particles had a coarser MAD compared to the co-associated 
particles in the pMDI combination product. In the tested pMDI combination formulation, it appears that fine salmeterol 
particles are preferentially co-associating with fluticasone particles (Figure 32). As can be seen in Figure 32, the 
majority of salmeterol particles in the finest size fraction are nearly 100% co-associated and the distribution is very 
different compared to the salmeterol mono pMDI. 
The picture for pure fluticasone in the combination product is somewhat different. Although there is a slight shift in 
pure fluticasone in the combination product compared to the fluticasone mono pMDI, it appears that the fluticasone 
particle sizes that are involved in co-association are more evenly distributed across the entire size distribution rather 
than preferentially finer particles as observed with pure salmeterol particles in the combination product (Figure 32). 
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Figure 32: Overlay of aerodynamic particle size distribution of mono pMDI products (Axotide® and Serevent®) with pure 
fluticasone (FP) and salmeterol (SX) found in Seretide® pMDI. 
Interestingly, the two mono DPIs give very similar distributions, unlike the fluticasone and salmeterol mono pMDIs, 
which look very different in their APSD (Supplementary Figures 1-2). The lactose carrier seems to have a big influence 
on the aerodynamic particle size distribution profiles of salmeterol. 
The plot in Figure 33 illustrates the APSD of APIs in the Advair Diskus®, either as single API particles or as co-
associated API particles. The APSD histogram shows the fractionation of the “hit” particles and the collected data 
demonstrates that there are also a high number of co-associated particles emitted from the Advair Diskus®. Only a 
small fraction of particles could not be assigned probably due to insufficient ionization (5%). 41% of all the hit 
particles contained fluticasone and salmeterol in co-association. Due to the far higher dosage strength of fluticasone 
compared to salmeterol in Advair Diskus® (500/50 mcg), there are many more fluticasone particles present and 
detected than salmeterol particles. A large fraction of salmeterol (74% of total salmeterol) is in co-association with 
fluticasone. While only about 52% of fluticasone is co-associated. This could be a simple result of the statistical 
mechanics given the 10x difference in dosage strength between the APIs in the product. But the cohesive nature of 
fluticasone [279] (with regards to salmeterol) could plausibly also play a role for this occurred effect. 
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Figure 33: Aerodynamic particle size distribution of Advair Diskus® DPI obtained by SPAMS (n=3 DPI actuations; error 
bars represent one standard deviation). The plot shows the distribution of number of particle co-associations of fluticasone-
salmeterol (FPSX), pure fluticasone (FP), pure salmeterol (SX) and unassigned particles. 
In Axotide Diskus® the MAD for fluticasone is 2.06 μm whereas the MAD for fluticasone in Advair Diskus® is around 
1.36 μm. This can be seen clearly in Figure 34 where it appears that primarily larger particles of fluticasone are 
involved in co-association with salmeterol particles. 
Also shown in Figure 34 is the comparison of Serevent Diskus and the pure salmeterol particles from Advair Diskus. 
The MAD for Serevent Diskus salmeterol particles is 1.86 μm and for the pure salmeterol particles in Advair Diskus 
it is 2.12 μm, indicating the finer particles are the ones involved in co-association. This effect was also observed for 
the pMDI formulation. 
For the co-associated drug particles (fluticasone-salmeterol), the MAD is somewhat coarser than the free fluticasone 
particles at approximately 2.02 μm, also strongly indicating that those particles result from the agglomeration of fine 
salmeterol and coarser fluticasone particles. Comparing the MAD in combination products of pure fluticasone and 
salmeterol particles, there appeared to be a difference between the DPI and pMDI formulations (Table 5). It may be 
possible that the lactose is changing the adhesive/cohesive behavior of the APIs in the tested products [225]. 
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Figure 34: Overlay of aerodynamic particle size distribution of mono DPI products (Axotide Diskus® and Serevent 
Diskus®) with pure fluticasone (FP) and salmeterol (SX) found in Advair Diskus® DPI. 
MADs for co-associated particles in the DPI were found to be larger than those in the pMDI product (Table 5 and 
Supplementary Figure 3). The pure salmeterol particles were coarser than the pure fluticasone particles in both DPI 
and pMDI. The manufacturer may have formulated APIs with a different particle size distribution but a more likely 
scenario is that there may be a greater tendency of salmeterol particles with small aerodynamic diameters to co-
associate with coarser fluticasone in the DPI combination product. The mechanism and effect of the formation of co-
associated particles or agglomerates appears substantially different between the two tested inhaler types and, in light 
of the synergetic effects of the two APIs, merits further investigation. 
Theophilus et al. [270] made an attempt to investigate particle co-associations of fluticasone and salmeterol with 
Raman microscopy in 2006 and found interesting results. However, their sampling method likely biased their results. 
Collecting a sample on stage 4 of the Andersen Cascade Impactor at particle concentrations similar to those reported 
is expected to result in powder piles accumulating under the nozzles on the plate. Therefore it is impossible to 
disambiguate whether particle co-associations were formed before or after impaction on the plate. Nevertheless, if 
their detected particle co-associations of fluticasone and salmeterol are correct, one can assume, as in our own 
observations, that there is a greater tendency of smaller particles to form co-associations. The higher rate of diffusion 
for smaller particles could influence the phenomenon. But it is important to note that the particle size of salmeterol 
was found to be smaller than that of fluticasone and therefore many more small salmeterol particles are present in the 
formulation, suggesting statistical mechanics as a rival hypothesis. 
Looking at the aerosol populations in their entireties, significant levels of API particle co-associations were detected 
in both of the tested combination products. 45% of all particles in the pMDI and 41% of all particles measured from 
the DPI were found to contain both APIs. The levels of particle co-association of fluticasone and salmeterol in DPIs 
and pMDIs were found to be different (Table 6 and Table 7). The adhesive API salmeterol [225] (with respect to 
fluticasone) was found to be highly co-associated with fluticasone for both inhaler types. A high fraction of salmeterol 
seemed to be in co-association with fluticasone, while only a smaller fraction of salmeterol seemed to be free (14% in 
DPI and 20% in pMDI, Table 6). Meanwhile, a significantly higher fraction of pure fluticasone could still be found in 
the tested formulations. Fluticasone is a cohesive compound (with respect to salmeterol) and agglomerates primarily 
with itself [279]. At a sufficiently high fluticasone to salmeterol ratio, all available salmeterol particles are used up in 
co-association and there is an excess of fluticasone particles given the far higher dosage strength of fluticasone in the 
analyzed formulations. 
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Table 6: Percentage of individual particles measured in the DPI and pMDI formulations (10’240 particles per run). 
[%] Axotide® 
pMDI 
Serevent® 
pMDI 
Seretide® 
pMDI 
Axotide Diskus® 
DPI 
Serevent Diskus® 
DPI 
Advair Diskus® 
DPI 
FPSX --- --- 44.9 --- --- 41.3 
FP 71.3 --- 24.6 79.1 --- 38.8 
SX --- 87.0 19.5 --- 91.5 14.4 
Unassigned 28.7 13.0 11.1 20.9 8.5 5.4 
 
Comparing the percentage of distribution of fluticasone and salmeterol particles in the formulation in either pure or 
co-associated state, it seems that overall more fluticasone and salmeterol is in co-association in the pMDI formulation 
(Table 7). 
Table 7: Percentage distribution of total fluticasone propionate (FP) and salmeterol xinafoate (SX) in the formulation in 
co-associated or pure state in the tested DPI and pMDI combination products. 
[%] Advair Diskus® 
DPI 
Seretide® 
pMDI 
FP co-associated 51.6 64.6 
SX co-associated 74.1 69.7 
FP pure 48.4 35.4 
SX pure 25.9 30.3 
 
Overall, higher levels of API co-association were found in the pMDI combination product than in the DPI (Table 7). 
This may be explained by the different dosage strengths of the inhalers used in this study. Advair Diskus® contains a 
dosage strength of 500/50 mcg while Seretide® is only 125/25 mcg of fluticasone and salmeterol, respectively so the 
fluticasone to salmeterol ratio in the DPI was twice that of the pMDI. On the one hand, there are more total salmeterol 
particles available for co-association in the DPI and a higher percentage of observed particles were co-associated; on 
the other hand, there was less salmeterol initially and so a smaller percentage of particles were observed as pure 
salmeterol. This phenomenon was mitigated to some degree via the division of the API mass among a larger number 
of smaller salmeterol particles as the salmeterol particles were significantly smaller than the fluticasone particles 
(Table 5) [167]. Further studies with different dosage strengths and controlled particle sizes could clarify the statistical 
mechanical effects influencing the level of co-association. 
Since, the pMDI and DPI formulations were considerably different, the mechanisms by which co-association of APIs 
may occur could also be different. In the pMDI, co-association can to occur between the two types of solid particles 
(fluticasone and salmeterol particles) while still in the suspension within the inhaler [269]. Depending on the dosage 
strength, multiple particles will be emitted within individual droplets to a greater or lesser degree upon the actuation 
[280]. When an emitted droplet collapses in the air stream through propellant evaporation, these particles can remain 
associated [281]. If both, fluticasone and salmeterol particles are within the droplet then they may remain co-
associated. Alternatively, coalescence of droplets within the plume could also lead to particle co-association. API co-
associations in DPIs can arise from interactions between different API-containing particles as a result of high shear 
forces during the blending process or via the formation of weak agglomerates of API with lactose fines [7]. In the case 
of the Advair Diskus®, the APIs were processed together and could furthermore also mix in the aerosol plume 
following the actuation of the device. Soft agglomerates of API and fine lactose formed during device actuation that 
could effectively co-associate the two APIs without direct binding of the one API to the other. Nevertheless, this co-
association could well deliver both APIs to the same site in the patient. Adding lactose to the blend as an excipient 
would presumably reduce the level of co-association by acting as a diluent. These and other mechanisms contributing 
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to the levels of API co-association in inhaled products merit further study to optimize that co-association for increased 
pharmacological efficacy [38, 281]. 
SPAMS Mass Estimates 
Mass estimates were made by multiplying the number of particles with active ingredient counted in each size bin by 
the mass of the average particle found in that bin (Figure 35 and Figure 36). This estimate was based on assuming all 
counted particles to be spheres with a density of 1 g/mL and to be pure API. In the mass spectra of the combination 
products, if both ions were present, the mass of the particle was assumed to be split evenly between each API, while 
if only one or the other were found then the mass of the particle was assumed to result entirely from that API. It is 
possible to use NGI data to develop a scaling factor for the SPAMS data for each size bin [247]. 
 
Figure 35: Computed masses of particles of the combination product Advair Diskus® DPI which contain either, both or 
neither active ingredients as determined by the SPAMS 3.0 (n=3; error bars represent one standard deviation).  
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Figure 36: Computed masses of particles of the combination product Seretide® pMDI which contain either, both or neither 
active ingredients as determined by the SPAMS 3.0 (n=3; error bars represent one standard deviation). 
The mass distribution profiles differ for dry powder formulations (Figure 35) from metered dose inhaled formulations 
(Figure 36). Particle mass is shifted to larger sizes in the DPI most likely due to the fact that insufficient de-
agglomeration of the powders may occur [45]. This is often the case with formulations with strong adhesive forces 
[193, 282]. For the pMDI formulation the mass distribution plot is similar to a normal (Gaussian) distribution. 
Furthermore, co-association of APIs will also increase the particle size by simple virtue of the fact that multiple smaller 
particles are necessarily agglomerated. 
Conclusions 
The collected data confirms that high levels of co-associated particles are emitted from both fluticasone-salmeterol 
DPI and pMDI combination products examined after actuation of the device. Using the SPAMS technique reveals that 
approximately 41% of the respirable particles in the tested DPI product and 45% of the respirable particles in the 
pMDI product contained both fluticasone and salmeterol. Unique mass spectral fragmentation patterns were 
recognized and assigned for each API using software that has been specifically designed for the analysis of SPAMS 
data. A large fraction of the detected salmeterol was found in co-association with fluticasone in both DPI and pMDI 
devices while a large fraction of pure fluticasone particles was also detected. A significant finding was also that rather 
coarse fluticasone particles (in DPI) and fine salmeterol particles (both MDI and DPI) were forming the particle co-
associations. The underlying mechanism for the formation of co-associated particles seems to be different between 
the DPI and pMDI. There is high potential for the association of fluticasone or salmeterol or both with lactose or other 
excipients present in a formulation and future work should involve the development of techniques to further 
differentiate, identify and quantify both APIs and excipients at the level of the individual particle. SPAMS was able 
to reveal particle co-associations successfully in combination pMDI and DPI products and provides an interesting tool 
for formulation design. 
Future Outlook 
In an effort to avoid extensive fragmentation and make the identification of the analyte compounds easier, a 
modification to the SPAMS to allow for a two-step laser desorption/ionization would potentially make identification 
of analytes less problematic than the current single laser system. This was successfully demonstrated for single particle 
0
1E-08
2E-08
3E-08
4E-08
5E-08
0.54 0.83 1.36 2.3 3.99 6.4 11.72 More
Es
ti
m
at
e
d
 m
as
s 
[g
]
Aerodynamic diameter [µm]
SX FP FPSX Unassigned
67 
mass spectrometry by Morrical et al [283], who successfully coupled a “soft” two-step laser desorption/ionization 
technique (L2MS) with ATOFMS. L2MS decouples the desorption process from the ionization process by using a 
different laser for each step. By decoupling desorption from ionization, L2MS permits the independent optimization 
both laser energy and wavelength for each step. For the desorption process, it has been shown that an infrared laser, 
typically a CO2 laser, efficiently thermally desorbs most molecules. The ionization step is performed subsequently 
with a UV laser at typical wavelengths of 193, 248, 266, or 308 nm [284, 285]. Such an upgrade to the SPAMS 
instrument would be highly valuable for the analysis of pharmaceutical aerosols. An upgraded SPAMS with separate 
desorption and ionization lasers firing at a different wavelength could potentially detect co-associations not only 
between APIs, but also between API and excipients (lactose or force control agents) in the future if an appropriate 
ionization wavelength were selected. 
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Supplementary Data 
 
Supplementary Figure 1: Aerodynamic particle size distribution of fluticasone propionate (FP) particles in Axotide® pMDI 
and Axotide Diskus® obtained by SPAMS (n=3 pMDI actuations; error bars represent one standard deviation). 
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Supplementary Figure 2: Aerodynamic particle size distribution of salmeterol xinafoate (SX) particles in Serevent® pMDI 
and Serevent Diskus® DPI obtained by SPAMS (n=3 pMDI actuations; error bars represent one standard deviation). 
 
Supplementary Figure 3: Overlay of aerodynamic particle size distribution of co-associated particles of fluticasone-
salmeterol (FPSX) in the combination products (Advair Diskus® and Seretide®). 
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3. Probing the Particulate Microstructure of the Aerodynamic Particle Size 
Distribution of Dry Powder Inhaler Combination Products 
 
Jetzer et al. International Journal of Pharmaceutics (2018) 538:30-39 
Abstract 
The in vitro aerosol performance of two combination dry powder inhaler (DPI) products, Foster® NEXThaler® and 
Seretide® Diskus® were investigated with single particle aerosol mass spectrometry (SPAMS). The in-vitro 
pharmaceutical performance is markedly different for both inhalers. Foster® NEXThaler® generates a higher fine 
particle fraction (FPF <5 μm) and a much higher relative extra fine particle fraction (eFPF <2 μm). In terms of the 
composition of the aerodynamic particle size distribution (APSD), it could be verified with SPAMS that overall 
Foster® NEXThaler® emits a significantly higher number of fine and extra fine particles with a median aerodynamic 
diameter (MAD) of 2.1 μm while Seretide® Diskus® had a larger MAD of 3.1 μm. Additionally, the interactions 
between the two active pharmaceutical ingredients (APIs) in both products are different. While Seretide® emits a 
significant (37%) number of co-associated API particles, only a negligible number of co-associated API particles were 
found in Foster® NEXThaler® (<1%). A major difference with Foster® NEXThaler® is that it contains magnesium 
stearate (MgSt) as a second excipient besides lactose in a so-called ‘dual excipient’ platform. The data generated using 
SPAMS suggested that nearly all of the beclomethasone dipropionate particles in Foster® NEXThaler® also contain 
MgSt and must therefore be co-associated with this additional excipient. This may help explain why beclomethasone 
dipropionate in Foster® NEXThaler® forms less particle co-associations with the second API, formoterol fumarate, 
shows a lower cohesive strength in respect to beclomethasone itself and why both APIs exhibit superior detachment 
from the carrier as evidenced by the increased eFPF and smaller MAD. 
Introduction 
Dry powder inhalers (DPIs) are used to deliver an efficacious dose of active pharmaceutical ingredients (API) to a 
target region of the lung. DPIs are available as capsule, blister and reservoir based products, most of which employ 
excipients as carriers. The delivery of an efficacious dose to the target region of the lung is dependent on the fine 
particle dose (FPD), or more precisely, the aerodynamic particle size distribution (APSD) of the API emitted from the 
DPI during its use by the patient. Aerodynamic particle sizes of <5 microns are usually considered optimal for drug 
delivery to the lungs [286]. 
There is an increasing interest in the development and use of the so-called ‘extrafine’ aerosols to target the small 
airways in the treatment of peripheral airways in asthma and chronic obstructive pulmonary disease (COPD) [141, 
287-289]. It has been reported that the inhalation of very small drug particles (<2μm) leads to an increased total lung 
deposition, improved distal airway penetration and a higher peripheral lung deposition [140]. Leach et al. used imaging 
single-photon emission computed tomography (scintigraphy) to compare the lung deposition of inhaled drugs from 
pressurized metered dose inhalers (pMDIs) with different particle size formulations. It was observed that up to 77% 
of the ‘non-extrafine’ fluticasone/salmeterol HFA-suspension pMDI was deposited in the oropharynx and about 16% 
in the lungs compared with 35% and 58% of the ‘extrafine’ HFA-solution of beclomethasone/formoterol [36, 290]. 
The development of DPIs now appears to follow somewhat ‘standard’ processes and analytical control methodologies 
with many DPI products being granted marketing authorization. In terms of the efficacious dose, the APSDs of DPIs 
are typically characterized using cascade impaction methods, which involve aerosolizing the powder in the DPI under 
standard conditions. For example, for the uniformity of delivered dose of DPIs, the European Pharmacopoeia requires 
testing 4 L of air at a flow rate, which generates a pressure drop across the device of 4 kPa [291]. The aerosolized 
particles are then fractionated in the impactor based on their aerodynamic particle size and collected on the 
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plates/stages of the impactor. The API deposited on the plates/stages of the impactor is then assayed to obtain the mass 
of fractionated API and ultimately the APSD. 
There is one important aspect to consider for any assessment of the aerodynamic particle size of DPIs, namely that 
such techniques assume that the total mass of an API on any impactor stage/plate has been deposited as ‘API only’ 
particles/particulates. If the mass of the API is not deposited as ‘API only’ particles then this would mean that any 
generated APSD may not represent the true APSD of the idealized ‘API only’ particles, but instead the APSD would 
be API-excipient assemblies, such as agglomerates. This means that in reality, the pure API particles would be smaller 
than the agglomerates and therefore theoretically able to penetrate deeper in the respiratory system. The situation is 
even more complex for combination products, where two or more APIs and/or excipients are present. The physical 
association of API particles with any excipient particles and/or any of the secondary API particles (in the case of 
combination products) would constitute an apparent ‘growth’ of the API particle(s), but without any increase in API 
mass. Consequently, the aerodynamic particle size of an API-excipient or API(1)-API(2) assembly would be expected 
to be greater, albeit sometimes only marginally, than that of the discrete API particle(s). 
The presence of other components in the APSD of mono therapy DPIs evaluated by Srichana and co-workers 
suggested that lactose was detected in the lower stage of a twin stage impinger from Rotahaler® and Diskhaler® 
commercial Ventolin® formulations [292]. Thalberg et al. confirmed the presence of both lactose and MgSt in the 
Next Generation Impactor (NGI) stages by investigating the “total fines” in their formulations [15]. This suggests that 
the excipient in these formulations is indeed aerosolized and emitted from the device. However, the nature of this 
mass of excipient was not further elaborated in terms of particulate structure i.e., whether the excipient particles were 
present as discrete excipient only entities, or as some form of API-excipient ‘assembly’. 
One way to determine the morphology of the API particulates in the APSD of DPIs is the use of Raman chemical 
imaging to study particles aerosolized from DPIs. For example, it was reported that API-lactose agglomerates were 
identified as being deposited on NGI impaction plates from DPI formulations [270, 293, 294]. Whilst such studies 
begin to shed light on the qualitative chemical nature of the particles in the APSD they do not provide quantitative 
information concerning the nature and composition of any individual particles/particulates, for example, whether 
particles are single entities or co-associated agglomerates. Indeed, the main challenge to any such investigations is 
that there is no way to demonstrate that such identified particulate assemblies were not created during impaction, or 
that, due to the scale of analytical scrutiny particulate assembles are truly co-associated or simply geographically co-
located. 
Recent scientific advances in aerosol measurement technology are now allowing real possibilities to better understand 
the aerosol particles, which comprise the APSD and the fate of particles in the lung, for example by scintigraphy [295]. 
Additionally, it is now possible to visualize, in real time, the fluidization and aerosolization of DPI formulations [296] 
and to model their behavior using computational fluid dynamics [297]. However, even though such techniques offer 
further insight into the understanding of behavior of the fluidized and aerosolized powder, they do not provide any 
information concerning the chemical compositions of the particulates, which could be of particular relevance for any 
in vivo observations and correlations. 
The chemical characterization of DPI particulates is achievable using mass spectrometry. The use of mass 
spectrometry to study aerosols has undergone continual development since the 1970s [33, 241]. These techniques 
have, like impaction methods, focused on attempting to characterize aerosols by generating the aerodynamic particle 
size distribution (APSD) profiles of particles. However, advances in technology are providing an increasing level of 
information about the chemical composition of single aerosolized particles. The first instrument capable of generating 
aerodynamic particle size and chemical composition for single particles for real-time analysis, the aerosol time-of-
flight mass spectrometer (ATOFMS), was initially developed for environmental and air pollution studies [241]. The 
possibility of utilizing the technique to analyze pharmaceutical inhaled products was investigated by New et al. who 
studied the detection and assessment of co-association in inhalable drug particles using ATOFMS [37]. More recently, 
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the technique was further developed and improved for the specific characterization of single aerosol particles, namely 
single particle aerosol mass spectrometry (SPAMS). SPAMS has, in contrast to ATOFMS, a very high data acquisition 
rate and when coupled with chemometric analysis, allows the determination of the chemical composition for the 
particulates. Importantly for DPIs, the technique is also capable of studying APIs and excipients. The APSD results 
generated using SPAMS can be transformed and compared to APSD data generated using cascade impactors. But 
importantly, SPAMS allows the possibility to evaluate the chemical nature of the particulates in the APSD without 
the need for offline chemical analysis, such as HPLC [30]. 
Even though excipients have been detected in the lower stages of impactors, the physical morphology of the deposited 
excipient is not fully known. For example, it is not clear whether any excipient is present as discrete particles or 
aggregated with other excipients or to what degree, if any, co-association exists between particles of a mono API and 
excipient. This is a complex situation, especially when considering that the APSD impacts the efficacious dose of a 
DPI and any interpretation of the nature of APSD may have both in vitro and in vivo implications. In the case of 
combination products, or formulations where more than one excipient is present, the situation is even more complex 
since multiple particulate interactions are possible. For single excipient based DPI mono therapies, any API detected 
in the impactor stages/plates could be present as: API only (single API particles or API particle aggregates) or API-
excipient assemblies (single or multiple API particle/single or multiple excipient particles; so called “soft-
agglomerates”). 
In the case of combination products, it has been reported that the addition of another API to a mono formulation can 
affect the in vitro and, importantly, in vivo performance of one or both APIs [107, 263, 265, 266]. The mechanism for 
how any potential interactions may impact apparent in-vitro performance has not, so far been elucidated using cascade 
impaction studies. Preliminary investigations of DPI mono and combination products have suggested that SPAMS is 
a useful tool for the evaluation of any particle co-associations between APIs (and possibly excipients) and that such 
approaches may generate results that would otherwise not be available using impactor techniques in terms of the 
APSD and chemical composition of aerosolized particles [30, 37, 277]. Recently, the possibility of using SPAMS was 
further expanded to study mono DPI formulations containing a second excipient, a so-called force control agent, 
namely magnesium stearate [18]. The SPAMS technique allows characterization of the particulate 
interactions/compositions of the APIs in the APSD of such products, by clearly determining a chemical signature for 
each component in the agglomerate. 
There has been great interest in the development of ternary mixing systems because the addition of a ternary 
component into carrier-based DPI formulations can lead to improved aerosol performance due to drug-carrier 
interaction modifications [12-19]. In lactose-based DPI formulations, ternary components can be either lactose fines 
[20], (other) sugars [21], or force control agents (FCAs) such as magnesium stearate or leucine [13, 15, 16, 18, 22]. 
Blending lactose together with MgSt prior to adding the API has been shown to modify the performance of 
pharmaceutical inhaled products [14, 15]. Also pre-treatment of APIs with different FCAs has been shown to alter the 
performance and improve the drug deposition in the lowest impactor stages [23]. Various application processes such 
as mechanofusion and particle smoothing have been used to apply different FCAs on carrier particles as very thin 
coating layers (<10 nm) [22, 24, 25]. Furthermore it has been published recently that a co-milled formulation of BDP 
and MgSt (5% w/w) led to a significant reduction in agglomerate size and strength after storage at elevated humidity 
compared to a formulation without MgSt. In addition to an enhanced pharmaceutical performance, another benefit of 
adding an FCA can be an enhanced stability and therefore a potentially longer shelf life of the product [19, 22]. 
To investigate particle interactions between API and carrier, Jones et al. [225] examined the drug-carrier cohesive-
adhesive balance (CAB) ratio in DPI formulations containing different APIs. It was reported in this study that 
fluticasone propionate is strongly adhesive and salmeterol xinafoate is strongly cohesive with respect to lactose. On 
the other hand, formoterol fumarate is only slightly cohesive with respect to lactose (the cohesive-adhesive balance 
for beclomethasone dipropionate has not been published so far). The results of this study suggested that carrier-based 
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DPI formulation performance is optimized when the drug-carrier CAB ratio is slightly cohesive. A more cohesive 
drug-carrier CAB ratio would represent a stronger drug-drug cohesion, and relatively weaker drug-carrier adhesion. 
In order to investigate product performance and interactions in DPIs and to test the applicability of SPAMS for the 
study of different DPIs, this study reports the particulate and chemical composition of the emitted particles from two 
DPI combination products: one containing a single excipient (lactose monohydrate), Seretide® Diskus®, and one 
containing two excipients (lactose and MgSt), Foster® NEXThaler®, with particular focus on the interactions of the 
two APIs. It should be noted that in each product two totally different sets of APIs are contained (Foster® NEXThaler®: 
beclomethasone dipropionate (BDP)/ formoterol fumarate (FF) and Seretide® Diskus®: fluticasone propionate (FP)/ 
salmeterol xinafoate (SX)). Particle interactions might have a significant influence on the performance of inhaled 
formulations as for example fine particles show a much faster dissolution in vitro [76]. Another aim of this work was 
to determine the fate of the aerosolized MgSt in Foster® NEXThaler® and whether it also interacts with the APIs in 
the formulation. The effect on the aerosol performance of the force control agent MgSt in commercial combination 
DPI formulations was further investigated. 
Materials and Methods 
Seretide® Diskus® (250/50 mcg) and Foster® NEXThaler® (100/6 mcg) were used for the study. Seretide® Diskus® 
contains the APIs fluticasone propionate (FP) and salmeterol xinafoate (SX) in a blister and Foster® NEXThaler® 
contains the APIs beclomethasone dipropionate (BDP) and formoterol fumarate (FF) in a reservoir. The products were 
stored at room temperature prior to opening the blister pouches and studied at ambient conditions. The analysis was 
performed within the instruction for use expiry date in the product information documentation. Chemical structures 
for the APIs FP, SX, BDP and FF; and for the excipients lactose monohydrate and MgSt are given in Table 8. 
Table 8: The chemical structures of fluticasone propionate (FP), salmeterol xinafoate (SX), beclomethasone dipropionate 
(BDP), formoterol fumarate (FF), lactose monohydrate and magnesium stearate (MgSt). 
 
Fluticasone propionate (FP) 
C25H31F3O5S 
MW 500 g/mol 
 
 
Salmeterol xinafoate (SX) 
 
Salmeterol 
C25H37NO4 
MW 415 g/mol 
 
Xinafoate 
C11H8O3 
MW 188 g/mol 
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Beclomethasone dipropionate (BDP) 
C22H29ClO5 
MW 521 g/mol 
 
Formoterol fumarate (FF) 
Formoterol 
C19H24N2O4 
MW 344 g/mol 
 
Fumaric acid 
C4H4O4 
MW 116 g/mol 
 
Lactose monohydrate 
C12H22O11 
MW 342 g/mol 
 
Magnesium stearate (MgSt)  
Mg(C18H35O2)2 
MW 591 g/mol 
 
Single Particle Aerosol Mass Spectrometry / DPI Testing by SPAMS 
A SPAMS 3.0 (Livermore Instruments Inc., USA) was used for this study. The experimental setup of the SPAMS 
instrument and sample testing has been described earlier by Morrical et al [30] and Jetzer et al [248]. For the 
calibration of the SPAMS instrument in the region of 0.1-10 μm, polystyrene (PLS) microspheres (Thermo-Fisher 
Scientific, USA) were used. The DPI samples were acquired by actuating the inhaler device via an induction port 
through a pre-separator into the relaxation chamber. The induction port was connected to a pre-separator (Copley 
Scientific, UK), which was filled with 15 mL of water and then connected to the 4 L relaxation chamber. This assembly 
of pre-separator and relaxation chamber was then fitted to the SPAMS inlet. The primary purpose of the pre-separator 
was to filter out coarse lactose carrier particles (>10 μm) to prevent clogging of the SPAMS inlet interface. The 
sampling chamber allows for dilution of the particles and flow rate matching. The NEXThaler® and Diskus® have 
similar device resistances, and at a 4 kPa pressure drop and a 4 L test volume would require test flow rates of 55 L/min 
and 67 L/min respectively [35]. Since it is reported that Seretide® and NEXThaler® are relatively unaffected by flow 
rate, a test flow rate of 60 L/min was used for both devices [35]. The actuation of both DPI devices was made three 
times with a 4 sec. draw of air into the relaxation chamber, at a flow rate 60 L/min (i.e. 4 L of air drawn). The same 
number of particles was analyzed for each sample run (ca. 10’000 individual particles each). SPAMS experiments 
were alternated with background blank runs for one minute each. 
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Previous studies have been performed to investigate optimal parameters for pMDI and DPI measurements by SPAMS 
[30, 247, 277]. Based on these studies, the desorption/ionization laser was set to fire at a wavelength at 248 nm. In the 
configuration being operated, the SPAMS is able to analyze up to 64 particles per second (laser repetition rate 64 Hz). 
The laser energy was maintained at approximately 12 mJ per pulse to obtain a high and consistent acquisition rate of 
particles with mass spectral data. It is important to note that the SPAMS interface is known to size bias in favor of 
larger particles and that that bias was not accounted for in this work. Nevertheless, the relative differences in the 
aerodynamic particle size distribution (APSD) histograms can be evaluated for all tested formulations with SPAMS. 
Results and Discussion 
The Foster® NEXThaler® and Seretide® Diskus® are both co-formulated multi-dose combination product DPIs, 
containing two APIs, with the Foster® NEXThaler® being a reservoir product, and the Seretide® Diskus® consisting 
of a single blister strip containing single dose blisters of the formulation. Both products contain the excipient lactose 
monohydrate; however, the Foster® NEXThaler® contains the additional excipient MgSt as force control agent, the 
so-called ‘dual excipient platform’ [19]. Foster® NEXThaler® is equipped with a breath-actuated mechanism while 
Seretide® Diskus® is a regular device (contains no such feature). Additionally, the products have shelf-lives of 18 
months and 36 months for Seretide® Diskus® and Foster® NEXThaler® respectively and can be stored at room 
temperature, suggesting they are stable pharmaceutical products. 
Figures 1-8 show mass spectra of particles acquired from the tested combination DPI formulations Seretide® Diskus® 
and Foster® NEXThaler® acquired with SPAMS. Lactose and MgSt are not easily ionized at a wavelength of 248 nm 
using the SPAMS technique, therefore pure lactose and MgSt will not give a mass spectrum (Figures 7 and 8). 
However, it was found that if MgSt is co-associated with certain APIs, a large peak at M/Z=+24 (for Mg+) will be 
detected in the mass spectral data (Figure 40 and Figure 44). For sizing, the majority of excipient particles is larger 
than 10 μm and thus is not analyzed. The relative number of excipient particles <10 μm depends on the lactose grade 
and dosage strength of the API(s). 
The first step in characterizing the acquired data is the removal of particles where a sizing event was recorded but no 
corresponding mass spectrum was observed. The remaining particles that generate both sizing and mass spectral data 
are referred to as “hit” particles, whereas particles with only sizing data acquired are referred to as “missed” particles. 
The hit rate in this work is defined as the ratio between the number of particles that generate ions detectable by mass 
spectrometry when the D/I laser has fired versus the total number of particles sized in the same time period. 
The hit rate with SPAMS was at 43% for Foster® NEXThaler® and 81% for Seretide® Diskus®. The different hit rates 
for the two different DPI products is dependent on several factors: A higher dosage strength in the product will 
generally result in an increase in the hit rate, if the API has relatively good absorption of the desorption/ionization 
laser. Excipients in a formulation, such as (fine) lactose or MgSt, will significantly decrease the hit rate because of 
dilution. 
Interestingly, the hit rate for Foster® NEXThaler® (43%) is relatively high when comparing the dosage strength to 
Seretide® Diskus® and knowing there are fine excipient particles in the formulation. In Seretide® Diskus® a lactose 
type with a very narrow particle size distribution of approximately 50-100 μm was used by the manufacturer [298] 
thus minimizing the number of fine lactose particles present in the formulation to form agglomerates. In the 
experiments reported here, a pre-separator was used to cut off particles with an aerodynamic diameter above 10 μm. 
Thus, the hit rate for Seretide® Diskus® was very high since nearly all of the particles with an aerodynamic diameter 
below 10 μm were API particles. A possible explanation why the hit rate is reduced to 81% in Seretide® Diskus® could 
be that during DPI actuation some smaller lactose particles may be formed through particle collision, abrasion and 
shear forces. Last but not least, the ionization efficiency of each API itself plays an important role. 
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Figure 37: Mass spectrum of a single FP particle from Seretide® Diskus®. 
 
Figure 38: Mass spectrum of a single SX particle from Seretide® Diskus®. 
 
Figure 39: Mass spectrum of co-associated particles of FP and SX from Seretide® Diskus®. 
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Figure 40: Mass spectrum of a single BDP particle from Foster® NEXThaler®. 
 
Figure 41: Mass spectrum of a single FF particle from Foster® NEXThaler®. 
 
Figure 42: Mass spectrum of co-associated particles of BDP and FF from Foster® NEXThaler®. 
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Figure 43: Averaged mass spectrum of pure lactose monohydrate. 
 
Figure 44: Averaged mass spectrum of pure MgSt. 
The pharmaceutical performance of both products has been reported [35]. The delivered dose, fine particle mass 
(FPM), fine particle fraction (FPF, % loaded dose) determined by NGI/HPLC are presented in Table 9. Additionally, 
similar data is presented for the extra-fine FPM (particles <2 μm in size) for each API in both products. 
Table 9: Pharmaceutical performance of Seretide® Diskus® and Foster® NEXThaler® at a flow rate of 60L/min, total 
inhalation volume, 4 L. Data adapted from [35]. 
Product API Loaded 
dose [μg] 
Delivered Dose 
[%LD] 
FPM 
<5μm 
[μg] 
FPF 
<5μm 
[%LD] 
eFPM <2μm 
[μg] 
eFPF  
<2μm 
[%LD] 
Seretide® 
Diskus® 
FP 250 92 52.9 21 29.9 12 
SX 50 96 9.3 19.3 2.4 5 
Foster® 
NEXThaler® 
BDP 100 88 58.4 58 46.6 46 
FF 6 80 3.4 56 2.3 38 
 
It can be seen from Table 9 that even though both products are established commercial products, the pharmaceutical 
performance is markedly different with Foster® NEXThaler® not only generating a higher FPF (<5 μm) but also, 
interestingly, a higher relative eFPF (<2 μm). Such a relatively high fine particle fraction has been assigned to the 
presence of the breath-actuated mechanism in Foster® NEXThaler® by Chiesi [299]. In a very recent published article 
by Farkas et al. [299] it is reported that the breath-actuated mechanism in Foster® NEXThaler® leads to a reduction of 
emission of larger particles (lower upper airway deposited doses) and an increase in the available therapeutic fine 
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particle fraction resulting in a significantly higher lung dose. The breath-actuated mechanism is delaying the emission 
of the drug until the inhalation flow rate of the patient is sufficiently high to detach the drug particles from their 
carriers. The generation of such a high FPF would also indicate that the interparticulate interactions are such that they 
allow a very high level of detachment. It has been demonstrated as well that the breath-actuated mechanism is capable 
to provide a reproducible and similar emitted dose and FPF of FF and BDP when activated using inhalation profiles 
of asthmatic patients. The results decreased when a capsule inhaler was employed [300]. 
Several DPI have been commercialized containing the two excipients lactose monohydrate and magnesium stearate 
[19], but there is to date no public information for any pharmaceutical performance or rationale, such as stability, 
processing or manufacturing for choosing this dual excipient approach in commercial products. It has been reported 
that MgSt can act as a force control agent and modify the performance of DPI formulations [194]. It is interesting to 
note that the FPM (<5 µm) of the capsule based mono therapy product Seebri® Breezhaler®, which also contains the 
excipients lactose monohydrate and MgSt, is reported to exhibit a FPFLD of 40-66% based on a loaded dose of 50 µg 
of glycopyrronium [301]. These levels of FPFLD are comparable with those reported for Foster® NEXThaler®, albeit 
with different APIs. 
Although it has been reported that MgSt can behave as an effective force control agent to potentially improve product 
performance [15, 194, 195], any apparent differences in performance may also be due to the particle size of the APIs 
and lactose monohydrate, manufacturing process, dosing and API/excipient ratios etc. 
The SPAMS APSD and chemical composition of particles in the aerosolized DPI doses results for Seretide® Diskus® 
and Foster® NEXThaler® are presented in Figure 45 and Figure 46, respectively. The APSD results summary of data 
generated from SPAMS is presented in Table 10. It can be seen from Table 10 that for Seretide® Diskus® and Foster® 
NEXThaler® the number of API particles determined with the SPAMS technique is in general agreement with the 
reported impaction data (Table 9). The number of particles measured with SPAMS displays for both tested products 
a similar proportionality to loaded dose as cascade impaction tests (co-associated particles influenced the ratio only 
minimal) (Table 11). Furthermore, the SPAMS results seem to confirm the results obtained with the cohesive-adhesive 
balance (CAB) technique as the FF performance is extremely high (FF is slightly cohesive with respect to lactose) 
[225]. 
Table 10: SPAMS APSD results for Seretide® Diskus® and Foster® NEXThaler® at a flow rate of 60L/min, total inhalation 
volume, 4 L. Number of particles measured in total. Average (n=3) of 10240 particles ± SD. 
Product API(s) Loaded dose 
(μg) 
Number of 
particles 
<5 μm 
Number of 
particles 
<2 μm 
Seretide® Diskus® 
FP 250 3805 ± 105 488 ± 21 
SX 50 998 ± 29 76 ± 6 
Co-associated particles (FP+SX) - 2743± 63 594 ± 34 
Foster® 
NEXThaler® 
BDP 100 2865 ± 79 1121 ± 28 
FF 6 181 ± 9 142 ± 5 
Co-associated particles 
(BDP+FF) 
- 8 ± 1 3 ± 0 
 
It can be seen in Figures 37-42 that the SPAMS technique has appropriate specificity and is capable of identifying the 
2 APIs in the APSDs of each of the formulations. However, in terms of compositions of the particles/particulates in 
the APSDs it appears that the interactions between the 2 APIs in both products are very different. Both APSDs 
containing single API, however Seretide® Diskus® appears to contain a significant number of co-associated drug 
particles compared to NEXThaler®. This result, like the differences in the pharmaceutical performance, is somewhat 
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unexpected and could be a consequence of the presence and the way MgSt is used in the formulation in Foster® 
NEXThaler®. Besides the manufacturing and processing with the MgSt in the Foster® formulation, there are a number 
of other contributing factors such as the API properties, lactose monohydrate properties and the breath actuated 
mechanism (in Foster® NEXThaler®). It should be noted that in each product two totally different sets of APIs with 
different dosage strengths are contained (Foster® NEXThaler®: 100 mcg BDP and 6 mcg FF / Seretide® Diskus®: 250 
mcg FP and 50 mcg SX). 
 
Figure 45: APSD Seretide® Diskus® DPI (250/50 mcg) obtained by SPAMS (n=3 DPI actuations; error bars represent 
one standard deviation). The plot shows the distribution of number of particle co-associations (FP+SX), pure FP and pure 
SX. 
Figure 45 illustrates the APSD of the two APIs in Seretide® Diskus® and suggests that the APIs exist as single API 
particles or as co-associated API particles. The APSD histogram shows the fractionation of the “hit” particles and the 
collected data demonstrates that there are a high number of co-associated particles (37%) emitted (Table 11). 
 
Figure 46: APSD of Foster® NEXThaler® (100/6 mcg) obtained by SPAMS (n=3 actuations; error bars represent one 
standard deviation). The plot shows the distribution of number of particle co-associations (BDP+FF), pure BDP and pure 
FF. 
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Figure 46 shows the APSD determined by SPAMS of the two APIs BDP and FF in Foster® NEXThaler® as single 
API particles or co-associated API particles. It is clearly evident that there are significant differences between the two 
tested products. In contrast to Seretide® Diskus® there appears to be only a negligible number of co-associated API 
particles (<1%) in Foster® NEXThaler® with the vast majority of the particles being present as single API particles 
(FF) or in co-association with MgSt in case of BDP (Table 11 and Figure 40). 
Table 11: Percentage of individual particles measured in the DPI products (10’240 particles per run). 
[%] Seretide® Diskus® [%] Foster ® NEXThaler® 
FP 51.3 BDP 92.6 
SX 11.8 FF 7.0 
FP-SX co- 
associated 
36.9 
BDP-FF co- 
associated 
0.4 
 
Table 12 shows the mean aerodynamic diameter (MAD, number average from SPAMS APSD measurements) 
measured with SPAMS. Generally, the MAD of the individual APIs and co-associated particles in Foster® 
NEXThaler® seem to be much smaller than these from Seretide® Diskus®. Similarly, the overall MAD of the Foster® 
NEXThaler® DPI was measured to be much smaller than Seretide® Diskus®. 
Table 12: Median aerodynamic diameter (MAD [um], number average from SPAMS APSD measurements) calculated 
from the DPI products measured by SPAMS. 
 Seretide® Diskus®  Foster ® NEXThaler® 
FP 3.1 BDP 2.3 
SX 3.7 FF 1.5 
FP-SX co- 
associated 
3.0 
BDP-FF co 
associated 
2.5 
Overall 3.1 Overall 2.1 
 
For Seretide® Diskus®, the API particulates in the aerosolized dose may consist of 6 simplistic particulate states: APIFP 
(single particles and assemblies), APISX (single particles and assemblies), APIFP-APISX assemblies, APIFP-lactose 
assemblies, APISX-lactose assemblies and APIFP-APISX-lactose assemblies. Normally lactose and MgSt do not give 
any mass spectral signals when using a D/I laser wavelength of 248 nm (Figure 43 and Figure 44). In this case, only 
the size of the particle is then recorded and it is classified as a “miss”. 
This study has shown that SPAMS can detect MgSt if it is (co-)associated with API. A large peak at m/z +24 for Mg+ 
is present in the mass spectrum of an API particle that also contains or is associated with MgSt. In addition to using 
mass spectrometry to determine the API APSD contents, it was also used to investigate the chemical composition of 
any MgSt in the single API particles in APSD of Foster® NEXThaler®. The results are presented in Figure 6 and 7 for 
BDP and FF, respectively. It can be seen from Figure 6 that the large peak at m/z 24 is present in single BDP particles, 
but not in the FF particles. This was compared to a pure BDP pMDI measured with SPAMS where no peak at m/z 24 
was measured (data not shown). 
It has been reported that the formulation in Foster® NEXThaler® is constituted of a coarse lactose (212–355 μm) 
blended with a micronized lactose/MgSt mixture [35, 302]. Even though quantification of the relative Mg-content is 
not possible, it is clear from this study that MgSt is in some way ‘associated’ with BDP, but apparently not with FF 
in the Foster® NEXThaler®. However, it cannot be ascertained whether the MgSt has simply ‘transferred’ to the BDP 
particles during actuation, storage or processing. It has also been reported that if any additional MgSt is added in any 
other part of the manufacturing process to either the carrier or API itself, such as in co-milling [303] or mechanofusion 
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[23] of API and MgSt, also leads to improved fine particle performance. Last but not least, the device itself can play 
an important role in aerosolization and de-agglomeration mechanisms of the product as mentioned before. 
It is clear from the composition selected APSD profiles (impactor and SPAMS results) that the aerosolized formulation 
in Foster® NEXThaler® not only exhibits a higher NGI generated FPFLD but may also be engineered/manufactured 
with MgSt in such a way as to reduce the level of co-association between APIs, with MgSt also contributing to this 
effect. This is in stark contrast with the Seretide® formulation which has a lower FPFLD and does not contain MgSt 
and has very high levels of co-association. Adding fine lactose to the blend as an excipient will presumably reduce 
the level of co-association by acting as a diluent. But adding lactose might increase the likelihood of particle co-
association between fine lactose APIs which are adhesive with respect to lactose (such as for example FP) and thus 
increase particle size. Any reduction in co-association and/or API/excipient agglomeration will decrease the 
aerodynamic particle size distribution of the particulates, which is observed in the Foster® NEXThaler® both using an 
impactor and the SPAMS measurements. 
Importantly, if the generation of a relatively high eFPF is possible in a DPI, as observed with the NEXThaler®, then 
these particles may reach the lower part of the airways. This has been reported for the pMDI version of Foster [304]. 
It also appears that an effort was made to limit the interactions of API in the Foster® NEXThaler® DPI formulation to 
achieve a high eFPF. A pre-treatment of the APIs and/or the carrier with a force control agent can furthermore facilitate 
drug detachment overall and thus increase in vitro aerosol performance [15, 23, 195]. 
This study demonstrates that combination DPIs, which are developed using “force control” agents such as MgSt in 
addition to carriers such as lactose monohydrate, may exhibit improved relative pharmaceutical performance, as 
measured by FPF. This effect is in addition to the function of the force control agent MgSt on single API formulations 
which has been demonstrated extensively in literature. Additionally, the increasing use of MgSt in other commercial 
products, such as in Anoro® Ellipta®, Relvar® Ellipta® or Seebri® Breezhaler®, suggest that the use of MgSt with 
lactose monohydrate is in part also responsible for enhanced pharmaceutical performance and becoming a standard 
approach in the development of DPI products [301, 305]. 
Conclusions 
There are distinct differences in the relative in vitro pharmaceutical performance of Foster® NEXThaler® and Seretide® 
Diskus®. Foster® NEXThaler® generates a higher fine particle fraction for both APIs (FPF <5 μm) and furthermore 
also emits a significantly higher relative eFPF (extra fine particle fraction <2 μm). SPAMS was able to successfully 
distinguish and characterize the two different formulations in the range of 0-10 μm where a much higher number of 
particles with a small MAD were detected from Foster® NEXThaler® compared to Seretide® Diskus®. Furthermore, 
SPAMS showed that both products emit APIs in different relative particulate states and particulates with distinctly 
different characteristics, suggesting that the interactions between the APIs and excipients in both tested combination 
products are very different. The Seretide® APSD profile contained a relatively high number of co-associated API 
particles of FP and SX. As there is no fine lactose in the Seretide® Diskus® formulation, the co-associated particles 
are formed of APIs without any excipient particles involved. The Foster® NEXThaler® formulation only exhibited a 
negligible number of co-associated API particles of BDP and FF. Interestingly, large peaks for the presence of 
magnesium stearate (m/z=+24) were detected in the mass spectra of beclomethasone dipropionate in Foster® 
NEXThaler®. This would suggest that the BDP particles in Foster® NEXThaler® are somehow co-associated with 
MgSt (but not with FF). It is possible that in the manufacturing process BDP was processed (co-milled) together with 
MgSt to improve dispersion mechanics. Another explanation may be that the BDP or the lactose carrier are receiving 
a MgSt-coating that would prevent the co-association or agglomeration of the particles and moreover facilitate 
detachment from carrier. This would then result in high in vitro performance (eFPF) and a relatively fine APSD profile 
compared to a product not engineered in this way like the Seretide® formulation. It is not possible to explain this as 
being simply due to the presence of MgSt. However, since MgSt has been described as being a FCA in DPI 
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formulations, it is possible that this ternary excipient is indeed capable of affecting the interparticulate forces in DPI 
formulations resulting in high in vitro performance. 
These studies suggest that the SPAMS technique may be used to investigate the nature of API particulates and provide 
feedback control for the level of particle co-association (API-API or API-excipient) in early-phase development of 
inhaled products. A SPAMS with separate desorption and ionization lasers firing at a different wavelengths could 
potentially detect co-associations not only between APIs, but also between API and excipients (lactose or force control 
agents) [283]. This makes the SPAMS technique an attractive additional technique in the field of pharmaceutical 
aerosol analysis and complementary to the current standard of impactor/HPLC-analysis. 
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4. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol 
Performance in Dry Powder Inhaled Formulations 
 
Jetzer et al. Journal of Pharmaceutical Sciences (2018) 107:984-998 
Abstract 
The potential of the force control agent (FCA) magnesium stearate (MgSt) to enhance the aerosol performance of 
lactose-based dry powder inhaled (DPI) formulations was investigated in this study. Two different blending methods 
of lactose and MgSt have been examined. Excipient-blends were manufactured either by high-shear or low-shear 
blending lactose carrier with different amounts of MgSt in the range from 0-10% (w/w). Fluticasone propionate (FP) 
and salmeterol xinafoate (SX) were used as model APIs. The excipient blends were investigated with analytical 
techniques including time-of-flight secondary ion mass spectrometry (ToF-SIMS) and Single Particle Aerosol Mass 
Spectrometry (SPAMS). Particle size, morphology and surface properties were evaluated. The in vitro aerosol 
performance in terms of aerodynamic particle size distribution (APSD) and fine particle fraction (FPF) of the FP and 
SX DPI formulations were evaluated with the Next Generation Impactor (NGI) and also with SPAMS using a 
Breezhaler® inhalation device. The distribution of MgSt on the lactose carrier in the blends was visualized and found 
to depend strongly on the blending method. This affected drug particle detachment from the carrier and thus impacted 
aerosol performance for FP and SX. Compared to blends without FCA, low-shear blending of MgSt increases the FPF 
of the model drug SX, while high shear blending significantly increased FPF of both SX and FP. The interactions 
between drug and carrier particles were substantially affected by the choice of blending technique of MgSt with 
lactose. This allows detailed control of aerosol performance of a DPI by an adequate choice of the blending technique. 
SPAMS successfully demonstrated that it is capable to distinguish changes in DPI formulations blended with different 
amounts of MgSt and additional information in terms of dispersibility of fine particles could be generated. 
Introduction 
Dry powder inhalers (DPIs) are a widely used method of aerosol drug delivery for the local treatment of respiratory 
diseases. DPI products commonly consist of large carrier particles (usually alpha-lactose monohydrate) and a 
relatively small amount (0.05–10%) of micronized active pharmaceutical ingredient (API) having a particle size 
typically below 6 μm. The addition of a carrier particle has the effect of preventing agglomeration of cohesive APIs, 
improving the respirable fraction by facilitating drug aerosol formation, and acting as a bulking agent increasing 
powder flowability for uniform filling [7]. Extensive research in the field of DPI formulations has been conducted in 
the past 40 years; however, the development of DPI formulations still presents multiple challenges [138]. Deposition 
of an aerosol particle in the respiratory tract depends on many factors but the most important parameter in a DPI 
formulation is the particle size of the drug substance, which has to be tailored to give deposition at the desired locations 
within the lung [167]. Particle size analysis is required to assure the performance and reproducibility of the final 
dosage forms and drug delivery systems [306]. A variety of factors such as particle size and size distribution, shape, 
surface morphology (roughness) and surface energy can be critical, of which many are directly or indirectly connected 
with each other [171, 172, 178, 181, 307, 308]. In addition to the formulation composition and material properties, the 
choice of blender, order of mixing of ingredients, the process parameters and storage also play an important role [7, 
143, 181, 182, 309]. 
The addition of lactose fines and/or functional additives such as magnesium stearate (MgSt) as a ternary force control 
agent (FCA) make DPI systems even more complex [14-16, 20, 310]. Even a small amount of formulation components 
can potentially have a big influence on the performance of the DPI product due to their impact on surface 
characteristics. They play an important role in particle interactions between excipient and API. Particle co-associations 
can occur between API and excipient, but also between two or more APIs in a formulation and may affect the in vitro 
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and possibly clinical performance of combination products [30, 38, 277]. The presence of fine lactose particles in a 
DPI formulation improves the formulation performance in terms of delivered dose and fine particle fraction up to 
some extent. Numerous articles on the topic of adding lactose fines to coarse carrier with different blending methods 
have been published over the last years [15, 16, 20]. Surface modifications of carrier particles have been reported to 
improve inhalation performance of DPI formulations [308, 311]. Blending lactose together with a FCA such as MgSt 
prior to adding the API has been shown to modify the performance of pharmaceutical inhaled products [15, 16]. A 
number of researchers are investigating the role of FCA’s in pharmaceutical inhaled products with different analytical 
techniques. Various application processes such as mechanofusion and particle smoothing have been used to apply 
different FCAs on carrier particles [13, 15, 16, 184, 194]. 
Mechanofusion is a term used for various intensive mechanical dry coating processes. During the mechanofusion 
mixing process, a very thin coating layer of a material is applied onto a solid surface through high compression and 
shear forces. Therefore, it can be used to alter the surface characteristics of a host material without using any solvent 
[184]. 
The engineering of lactose carrier surfaces using the particle smoothing process resulted in significant differences in 
surface morphology when compared with the starting material. The mixing process has been proposed to decrease 
surface irregularities by filling FCA into surface flaws hence eliciting a relative smoothing of the lactose particle 
surface due to plastic deformation and/or a surface polishing effect by the FCA coating layer. This was measured by 
a significant reduction in surface area and roughness and was observed with AFM surface topography images [13, 22, 
24]. 
Processed lactose carriers with FCAs have been investigated with different analytical techniques. Inverse gas 
chromatography (IGC) was used to determine total surface energy distributions [17]. Surface energies of excipient-
blends prepared by high- and low-shear mixing have not been compared so far. Studies with atomic force microscopy 
(AFM) generated information about the surface properties and especially surface roughness of processed carriers in 
the past [13]. Nevertheless, a thorough mechanistic understanding of the role of FCA’s in DPI formulations is still 
largely missing. 
It has been recognized from previous work that there is a need to establish the nature and extent of carrier surface 
coatings, and for a detailed study of the relationship between the extent and nature of the coating and the particle 
interactions as well as bulk powder characteristics. This can be very difficult to achieve because of technological 
challenges of characterizing such thin coating layers on the surface of particles that can be in the range of only 
nanometers. Conventional techniques such as Raman spectroscopy penetrate the coating layer and measure both, the 
coating layer and the host particles. Time-of-flight secondary ion mass spectrometry (ToF-SIMS) is a highly sensitive 
analytical technique that provides chemical information regarding elemental, isotopic and molecular structure from 
the first few layers of small particles [24, 312]. Therefore, ToF-SIMS was used in this study to further investigate 
particle coating and MgSt distribution of carriers. 
For evaluation of the in vitro aerosol performance of inhaled pharmaceutical products, the current state of the art is 
the use of cascade impaction [250], typically with chemical analysis using high performance liquid chromatography 
(HPLC), to characterize the aerodynamic particle size distribution (APSD) and fine particle fraction (FPF) of the drug. 
While highly quantitative for the total concentration of API delivered, this technique does not yield any information 
regarding the interactions of the various product components (active(s), excipients) with each other within the 
formulation. SPAMS is an analytical technique where the aerodynamic diameters and chemical compositions of many 
individual aerosol particles are determined in real-time. The SPAMS technique and its advantages have been published 
recently [30, 277]. SPAMS is a promising method to explore effects in DPI formulations due to the fact that the APSD 
of the total number of particles (excipient and API) in the formulation is determined simultaneously. 
85 
The fundamental attractive forces/mechanisms of interaction between particles in DPI formulations are classified as 
van der Waals, electrostatic and capillary forces [7, 196]. Techniques such as IGC, colloid probe and AFM enable the 
measurement of interparticulate or surface forces at the individual particle level, but due to the lack of understanding 
of the actual form of bodies in contact such as the contact area and coordination number, the exact description of the 
powder formulation and the correlation of measured forces with aerosol performance are still challenging. Besides the 
mentioned adhesion/cohesion forces, friction and mechanical interlocking also play important roles in power flow and 
deaggregation [197]. 
The aim of this study was to investigate the impact of the FCA MgSt on the mechanism of interaction and physico-
chemical characteristics of the DPI carrier particles and the performance of active substances in pulmonary 
formulations using engineered excipient blends. A variety of analytical techniques, including for the first time SPAMS 
and ToF-SIMS, were employed. Blends with the cohesive drug fluticasone propionate (FP) [279] and the adhesive 
drug salmeterol xinafoate (SX) [225] were manufactured containing 0-10% (w/w) MgSt in the excipient-blend by 
high- and low-shear mixing. A formulation of FP or SX with untreated lactose (0% MgSt) was used as a reference. 
Particle size, morphology and surface properties were assessed and the aerosol performance in terms of APSD and 
FPF of the DPI formulations was evaluated with cascade impaction studies with the NGI and analyzed with SPAMS. 
Materials and Methods 
Materials 
Micronized FP and SX were supplied by Sandoz. Inhalation grade lactose monohydrate (Respitose® ML001) was 
purchased from DFE Pharma (Netherlands) and inhalation grade magnesium stearate (MgSt) from Peter Greven 
(Germany). 
DPI Formulation Preparation 
Batches with a total amount of 50 g of powder (excipient and drug) were manufactured. For the high-shear excipient-
blends, inhalation grade lactose and MgSt (0-10% w/w) were blended in a Collette MicroGral 2 L (GEA Pharma 
Systems, Switzerland) for 16 minutes at 1400 rpm. The low-shear excipient-blend was mixed for 16 min at 34 rpm in 
a Turbula® T2F mixer 2 L (Willy A. Bachofen AG, Switzerland). In both cases, excipient-blends were mixed together 
with the API in a Turbula mixer at 34 rpm for 16 min (low-shear blending method). The final powder was filled 
manually into size 3 Hydroxypropyl methylcellulose (HPMC) capsules (QualiCaps, Spain) containing a dosage 
strength of 200 mcg API per capsule. The FP capsules were stored at 25°C and 55% relative humidity for a period of 
7 days prior to the experiments. The SX capsules were not conditioned because SX showed previously poor stability 
when exposed to temperature and humidity. Thus, the in vitro performance of SX is highly affected by the conditioning 
of the product [309]. 
The content uniformity of manufactured DPI capsules was measured by analyzing the quantity of active in 25 mg ± 
0.1 mg samples. Drug content was analyzed by HPLC. Relative standard deviation between samples was calculated 
to assess the homogeneity of the different blends. 
Scanning Electron Microscopy (SEM) 
The particle morphology of the different powder blends was investigated using scanning electron microscopy (SEM, 
Zeiss Supra 40, Germany) at 6 keV. The samples were prepared by careful transfer onto double-adhesive carbon tape, 
and a thin gold layer was deposited on the sample surface using a Leica EM ACE600 (Leica, Germany) prior to 
imaging. 
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Time-of-flight Secondary Ion Mass Spectrometry (ToF-SIMS) 
Time-of-flight secondary ion mass spectrometry (TOF.SIMS 5, ION-TOF, Germany) was used to detect the chemical 
composition of surfaces by scanning the sample with a focused ion beam of Bi3+ primary ions in spectrum mode using 
the ion beam with an extractor voltage of 10 kV. The area scanned was 500 x 500 micrometers. The samples were 
prepared on pieces of silicon wafers with dimensions of 10 x 10 mm. Double sided carbon tape was adhered to the 
silicon and covered with aluminum backed tape, with the adhesive side up. The powders were then spread over the 
surface and the excess shaken off. The samples were then fixed on to the ToF-SIMS plate and inserted into the ToF-
SIMS vacuum chamber. Negative and positive spectra were measured in spectrum mode. Each sample was measured 
three times on different areas. 
ToF-SIMS is a mass spectrometric technique that provides detailed information on the chemical composition of the 
uppermost monolayers of a surface. The Time-of-Flight detection system offers the parallel detection of all elements, 
isotopes, full molecules and molecular fragments present at the surface, with a high mass resolution and an ultra-high 
sensitivity, down to the ppm range. The acquisition of images can be achieved by scanning the relevant area with a 
lateral resolution in the range of up to 100 to 200 nm (theoretically) with a complete spectrum recorded at every pixel 
(256x256 pixels in our measurements) of the image. Layer-by-layer erosion is also possible, allowing the profiling of 
chemical species in the depth of the sample, with a depth resolution in the nanometer range.  
The areas and m/z of the peaks used in determination of the relative amounts of magnesium (m/z 23.99) are given 
following the images. The relative amounts of magnesium stearate to lactose were calculated using all three fragments 
CH3O+, C2H5O+ and C3H5O2+, which were present in the spectrum of lactose but not in the spectrum of magnesium 
stearate. 
The relative amounts of magnesium were calculated from: 
Area Mg
(Area Mg +  Area of peak assigned to lactose)
 
This gives a value of 1 when only magnesium stearate is present. Additionally, the spectra were normalized against 
total ion count. 
Specific Surface Area 
The specific surface area of the powders was determined by the BET method based on nitrogen adsorption using a 
Quadrasorb SI (Quantachrome Instruments, USA). Adsorption isotherms at P/P0: 0.01, 0.02, 0.03, 0.04, 0.05, 0.07, 
0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 and 0.9 were used. 
Laser Light Diffraction Measurements 
Laser light diffraction (LLD) analysis for particle size distribution (PSD) measurements was always performed using 
a Sympatec RODOS (Sympatec GmbH, Germany) dry dispersion system equipped with an R5 lens at 3bar. 
Density Measurements 
The density of the materials used in this study was determined with gas pycnometry (ULTRAPYC 1200e, 
Quantachrome Instruments, USA) according to the Pharmacopoeia Europea 8.0 (2.9.23) 
DPI Analysis by Next Generation Impactor (NGI) 
The deposition of the dry powder formulations was investigated using an NGI equipped with a pre-separator filled 
with 15 mL of solvent (Acetonitrile: Water: TFA, 58: 42: 0.1 v/v/v). All measurements were conducted at 55% RH 
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and ambient temperature (23 ± 2ºC). The cup trays of the impactor were coated with Brij® reagent (1% v/v solution 
of Glycerol in Ethanol). The capsules were actuated in a Breezhaler® inhalation device (Novartis, Switzerland) at a 
flow rate of 90 L/min for 2.7 sec (USP pressure drop of 4kPa). The amount of powder deposited on the different 
collection cups was recovered by extracting each cup with solvent. The remaining powder in the capsule, device, 
powder deposited in the throat and pre-separator was also collected. After dissolution of the particles, HPLC analysis 
was performed. In this study the mean of three individual determinations was taken for a given NGI result. 
FP and SX were analyzed using HPLC coupled with an UV-detector. The samples were eluted with an isocratic 
method with Acetonitrile: Water: TFA (58: 42: 0.1 v/v/v) as mobile phase, through an ACT ACE 3 C18,100 × 4.6 
mm, 3 μm column (ACE, UK). A wavelength of 225 nm was used for detecting FP and SX. The peaks eluted at 
approximately 7.1 min (FP) and 2.0 min (Salmeterol at 2.0 min; xinafoate at 2.9 min). The flow rate through the HPLC 
system was 1.5 mL/ min. Data acquisition was carried out with Chromeleon. (LOD: 0.01 ug/mL for both FP and SX; 
LOQ: 0.03 ug/mL for SX and 0.04 ug/mL for FP; R2 0.9995). 
Single Particle Aerosol Mass Spectrometry (SPAMS) / DPI Testing by SPAMS 
A detailed introduction into Single Particle Aerosol Mass Spectrometry is published in Morrical et al. [30]. 
A SPAMS 3.0 (Livermore Instruments, USA) was used for this study. The experimental setup of the SPAMS 
instrument and sample testing has been described earlier by Morrical et al. [30] and Jetzer et al. [248]. For the 
calibration of the SPAMS instrument in the region of 0.1-10 μm, polystyrene (PLS) microspheres (Thermo-Fisher 
Scientific, USA) were used. The dry powder formulations samples were acquired using a Breezhaler® inhalation 
device actuated via an induction port through a pre-separator into the relaxation chamber. The induction port was 
connected to a pre-separator (Copley Scientific, UK), which was filled with 15 mL of water and then connected to the 
4L relaxation chamber. This assembly of pre-separator and relaxation chamber was then fitted to the SPAMS inlet. 
The primary purpose of the pre-separator was to filter out coarse lactose carrier particles (>10 μm) to prevent clogging 
of the SPAMS inlet interface. The sampling chamber allows for dilution of the particles and flow rate matching. The 
SPAMS interface deliberately size biases in favor of larger particles and this bias was not accounted for in this work. 
Nevertheless, even the biased aerodynamic particle size distribution (APSD) histograms can be informative given that 
they all have the same bias [248]. The actuation of the DPIs was made with a 2.7 seconds draw of air into the relaxation 
chamber, at a flow rate 90 L/min (i.e. 4 liters of air drawn). The same number of particles was analyzed for each 
sample run (ca. 10’000 individual particles each). SPAMS experiments were alternated with background blank runs 
for one minute each. 
Preliminary experiments have been performed to investigate optimal parameters for pMDI and DPI measurements by 
SPAMS [30, 247, 277]. Both FP and SX have shown previously good absorbance at a wavelength of 248 nm [278]. 
Therefore, the desorption/ionization laser was set to fire at a wavelength at 248 nm. In the configuration being 
operated, the SPAMS was able to analyze up to 64 particles per second (laser repetition rate 64 Hz). The laser energy 
was maintained at around 12 mJ per pulse to obtain a high and consistent hit rate. It is important to note that the 
SPAMS interface is known to size bias in favor of larger particles and that that bias was not accounted for in this work 
[313]. 
Results and Discussion 
General Physical Characterization 
The PSD of the carrier has a significant influence on the performance of a DPI formulation, especially the fraction 
with a size below 10 μm that is counted as the “inhalable fraction”. Typically more than 90 volume percent of the 
lactose carrier particles are within 50 and 200 μm. While only a small fraction has a size below 10 μm [12, 314]. 
Density, particle size data and specific surface area (BET) for all materials are given in Table 13. 
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Table 13: Materials used and measured key characteristics. 
Material Denotation Density [g/cm3] D10 [μm] D50 [μm] D90 [μm] BET [m2/g] 
Fluticasone propionate FP 1.32 0.9 1.9 4.1 9.76 
Salmeterol xinafoate SX 1.11 0.7 1.4 2.9 6.99 
Respitose® ML001 Lactose 1.53 6.6 57.8 170.3 0.63 
Magnesium stearate MgSt 1.05 1.6 6.1 21.3 16.61 
 
In Figure 47 and Figure 48, high- and low-shear excipient-blends with differing MgSt-content and the lactose carrier 
itself are shown for comparison. With a MgSt-content up to 1%, the behavior of the PSD curves does not change 
significantly compared to the starting material. Adding 10% MgSt to the excipient mixture changed the shape of the 
curve: A significantly higher number of smaller particles in the range of 2-10 μm are present. The PSD curve is roughly 
trimodal with both applied blending methods for the 10% MgSt excipient-blends. 
 
Figure 47: Particle size distribution of high-shear excipient-blends. 
 
Figure 48: Particle size distribution of low-shear excipient-blends. 
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Characteristic parameters of PSD of processed excipient-blends are listed Table 14. While the x10, x50 and x90 values 
slightly increase for high-shear blends (except Lactose 10% MgSt), the values slightly decrease for low-shear blends 
both compared to lactose untreated (Table 13 and Table 14). These findings suggest that the high-shear mixing process 
is applying MgSt on the lactose carrier surface and therefore increasing the particle size. With an MgSt-content of 
10%, the particle sizes are much lower for both used blending methods due to the introduction of a high number of 
small MgSt particles in the excipient-blend. 
Table 14: Particle size distribution of the excipient-blends (mean, n=3). 
High-shear x10 [µm] x50 [µm] x90 [µm] Low-shear x10 [µm] x50 [µm] x90 [µm] 
Lactose 0.1% MgSt 7.57 63.36 176.28 Lactose 0.1% MgSt 5.85 50.44 159.29 
Lactose 0.5% MgSt 9.07 69.17 181.62 Lactose 0.5% MgSt 5.24 47.66 156.32 
Lactose 1% MgSt 7.40 61.81 171.76 Lactose 1% MgSt 5.24 49.76 164.12 
Lactose 10% MgSt 2.65 35.41 152.74 Lactose 10% MgSt 2.45 22.29 130.61 
 
In order to examine changes in surface morphology of lactose before and after mixing with MgSt, scanning electron 
micrographs (SEM) were taken of all the powders. Representative SEM micrographs of the formulations are shown 
in Figure 49, Figure 50 and Figure 51. 
The untreated lactose consists of large irregular shaped particles together with an amount of fine lactose particles. 
Some small particles were observed to adhere onto the surface of larger particles or to exist as agglomerates. Flat and 
smooth surfaces with sharp edges were clearly seen in SEM of untreated lactose. Pure MgSt particles were small (<20 
μm size) and existed as multilayered flakes (Figure 49). When lactose was high-shear mixed with MgSt, the edges of 
larger particles became noticeably more rounded, and the characteristic MgSt flakes were not obviously visible (Figure 
50). The SEM images of the excipient-blends containing a lower amount of MgSt (0.1-0.5%) were similar and did not 
differ from the untreated lactose. In contrast, the presence of small flakes and agglomerates were observed in both 
excipient-blends containing 1 and 10% MgSt, suggesting an excess of MgSt was present (arrows). The carrier particles 
seem to be well covered with fines, forming a thin layer on the carrier surface. In the 10% MgSt sample, the fine 
particle aggregates appear to be very dispersed and only loosely attached to the carrier particles. The surfaces of 
Lactose 0.5, 1 and 10% MgSt were visually rougher than the samples without MgSt (Figure 50). Interestingly, this is 
in strong contrast with what was observed with mechanofusion where the surface was significantly smoother after 
treatment [315]. 
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Figure 49: SEM images of raw materials untreated lactose, MgSt, FP and SX. 
Lactose untreated Magnesium stearate 
Fluticasone propionate Salmeterol xinafoate 
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Figure 50: SEM images of high-shear excipient-blends. 
Lactose 0.1% MgSt (high-shear) Lactose 0.5% MgSt (high-shear) 
Lactose 1% MgSt (high-shear) Lactose 10% MgSt (high-shear) 
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Figure 51: SEM images of low-shear excipient-blends. 
In Figure 51, SEM images of the low-shear excipient-blends are shown. The edges of larger lactose particles did not 
change and characteristic MgSt flakes are clearly visible. In the excipient-blend containing 10% MgSt, the coverage 
of the carriers is patchy with aggregates of fine particles. A lot of larger particle agglomerates are visible (arrows). 
Time-of-flight Secondary Ion Mass Spectrometry (ToF-SIMS) Measurements 
The images were constructed from the spectra and cover an area of 500x500 µm. They show an overlay of the signal 
at m/z 23.99 assigned to Mg+ in the magnesium stearate and the signal at m/z 73.04 assigned to C3H5O2+ in lactose. 
The reference samples (Lactose untreated and pure MgSt) give an indication of the residual signal detected at 23.99 
for the lactose sample and at 73.04 for the magnesium stearate (Figure 52). The images constructed from the peak at 
23.99 are shown in red and those from the peak at 73.04 are shown in green. For the untreated lactose sample, the 
signal mapping of C3H5O2+ was clearly observed (Figure 52). In contrast, there was no Mg+-signal detected for the 
untreated lactose sample. This indicates that any Mg+-signal detected for the processed excipient-blend sample, would 
come from the MgSt coating or MgSt agglomerates present. 
The ToF-SIMS mapping of different signals on the various powder samples are shown in Figure 53. For the processed 
lactose samples with various MgSt content, the C3H5O2+ signals could still be observed to some extent (Figure 53). 
When the MgSt content was increased, the density of the C3H5O2+ signals (lactose) observed were relatively reduced 
while the density of the Mg-signals increased markedly. Regions that are red therefore represent positions where the 
coating of magnesium stearate is too thick to allow the lactose to be detected. Yellow regions show the presence of 
both lactose and magnesium stearate. Layer-by-layer erosion (profiling of depth of the sample) was not possible in 
the tested samples because the sample surface was too rough. 
Lactose 0.1% MgSt (low-shear) Lactose 0.5% MgSt (low-shear) 
Lactose 1% MgSt (low-shear) Lactose 10% MgSt (low-shear) 
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ToF-SIMS images showed ion signals for MgSt all over the measured area in the high-shear excipient-blends with 
high MgSt content (Figure 53). We conclude that MgSt must be evenly distributed on the lactose surface (overlay of 
MgSt and lactose) in a thin layer of MgSt that is covering the lactose surface. A fully coherent coverage may have 
been formed on the carrier surface, but it is possible that it is thinner in thickness than the ToF-SIMS penetration 
depth. Therefore, the lactose signal is still detected. While in the low-shear excipient-blend, MgSt agglomerates were 
detected by ToF-SIMS imaging as small intense spots (Figure 53). Low-shear blending did not induce any surface 
coating of the lactose with MgSt. The overlay of MgSt and lactose shows only some intense spots with ion signals 
indicating MgSt agglomerates. 
With increasing MgSt-content in the high-shear excipient-blend, the relative amount on the lactose surface covered 
by MgSt increases (Table 15). Around 1% MgSt results in nearly full coverage (relative coverage 0.92) of the carrier. 
Interestingly Zhou et al. [24] investigated lactose coverage with X-ray Photoelectron Spectroscopy (XPS) in blends 
with MgSt manufactured by mechanofusion and were reaching much lower coverages (8.5% ± 0.2 for 0.1% MgSt-
content; 75.0% ± 0.3 for 1% MgSt-content; 75.1% ± 0.1 for 5% MgSt-content) than were achieved in our formulations 
with the applied high-shear blending technique. The presence of MgSt as a coating layer on the lactose surface in the 
high-shear blend might change the interaction forces between API and lactose carrier substantially. 
Table 15: Relative amounts of Magnesium in reference, high-shear and low-shear excipient-blend samples 
Sample Mg/(Mg+CH3O) Mg /(Mg+C2H5O) Mg /(Mg+C3H5O2) 
Lactose 0.0009±0.0002 0.0010±0.0002 0.0005±0.0001 
MgSt 0.99±0.01 0.98±0.01 0.98±0.01 
High-shear Mg/(Mg+CH3O) Mg /(Mg+C2H5O) Mg /(Mg+C3H5O2) 
Lactose 0.1% MgSt 0.53 ± 0.01 0.54 ± 0.01 0.36 ± 0.01 
Lactose 0.5% MgSt 0.80 ± 0.03 0.80 ± 0.03 0.68 ± 0.04 
Lactose 1% MgSt 0.92 ± 0.002 0.91 ± 0.002 0.85 ± 0.006 
Lactose 10% MgSt 0.97 ± 0.004 0.96 ± 0.003 0.94 ± 0.005 
Low-shear Mg/(Mg+CH3O) Mg /(Mg+C2H5O) Mg /(Mg+C3H5O2) 
Lactose 0.1% MgSt 0.011 ± 0.0005 0.012 ± 0.0006 0.006 ± 0.0004 
Lactose 0.5% MgSt 0.11 ± 0.008 0.12 ± 0.008 0.08 ± 0.005 
Lactose 1% MgSt 0.17 ± 0.009 0.19 ± 0.01 0.11 ± 0.007 
Lactose 10% MgSt 0.44 ± 0.01 0.47 ± 0.009 0.30 ± 0.006 
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Figure 52: ToF-SIMS micrographs at scanning area of 500μm × 500μm for Lactose untreated (top) and pure magnesium 
stearate (bottom). 
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Figure 53: ToF-SIMS micrographs at scanning area of 500μm × 500μm for: 
(1) Lactose 0.1% MgSt (high-shear) (5) Lactose 1% MgSt (high-shear) 
(2) Lactose 0.1% MgSt (low-shear) (6) Lactose 1% MgSt (low-shear) 
(3) Lactose 0.5% MgSt (high-shear) (7) Lactose 10% MgSt (high-shear) 
(4) Lactose 0.5% MgSt (low-shear) (8) Lactose 10% MgSt (low-shear) 
Aerosol Performance of DPI Formulations by SPAMS and NGI for FP blends 
Figure 54 shows a comparison of SPAMS APSD histograms of total particles (API, fine lactose and MgSt) for three 
different FP blends with lactose untreated, lactose with 0.1 and 0.5% MgSt-content (high-shear), respectively. By 
adding MgSt to the formulation, the APSD profile shifts to a higher number of smaller particles with a higher number 
of particles in the size range from 0-1.7 μm diameter. By increasing the MgSt-content from 0.1 to 0.5% (w/w), the 
number of smaller particles increases even more and the size distribution shift is more pronounced. 
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Figure 54: SPAMS Aerodynamic particle size distribution histogram of three FP blends with lactose untreated, 0.1 and 
0.5% MgSt (high-shear), respectively. The plot shows the total number of particles measured (active substance FP and 
excipients). 
 
Figure 55: SPAMS Aerodynamic particle size distribution histogram of three FP blends with lactose untreated, 0.1 and 
0.5% MgSt (high-shear), respectively. The plot shows the distribution of the active substance FP only. The size bins were 
scaled to the ratio of the hit rate in order to have a comparison between the different formulations. 
The APSD histogram of particles containing FP in the two high-shear manufactured formulations and the reference 
formulation without MgSt is shown in Figure 55. The size bins in Figure 55 were scaled in order to compare the three 
formulations with each other. It can be seen that there is a significant increase in number of FP particles with a small 
particle size in the range from 0-1.7 μm for the formulations containing 0.1 and 0.5% MgSt, respectively. Interestingly, 
the same shift observed in the total number of particles (Figure 54) was also detected for the API FP following the 
0
400
800
1200
1600
0
.3
0
.5
0
.7
0
.9
1
.1
1
.3
1
.5
1
.7
1
.9
2
.1
2
.3
2
.5
2
.7
2
.9
3
.1
3
.3
3
.5
3
.7
3
.9
4
.1
4
.3
4
.5
4
.7
4
.9
5
.1
5
.3
5
.5
5
.7
N
u
m
b
e
r 
o
f 
P
a
rt
ic
le
s
Aerodynamic diameter [μm]
FP Lactose untreated FP Lactose 0.1% MgSt (high-shear) FP Lactose 0.5% MgSt (high-shear)
0
200
400
600
0
.3
0
.5
0
.7
0
.9
1
.1
1
.3
1
.5
1
.7
1
.9
2
.1
2
.3
2
.5
2
.7
2
.9
3
.1
3
.3
3
.5
3
.7
3
.9
4
.1
4
.3
4
.5
4
.7
4
.9
5
.1
5
.3
5
.5
5
.7
N
u
m
b
e
r 
o
f 
p
a
rt
ic
le
s
Aerodynamic diameter [μm]
FP Lactose untreated FP Lactose 0.1% MgSt (high-shear) FP Lactose 0.5% MgSt (high-shear)
97 
same pattern. SPAMS is indicating that the high-shear blends containing the FCA MgSt have a much higher 
dispersibility compared to the reference formulation without MgSt. 
In Figure 56, a series of SPAMS APSD histograms of three FP blends is compared: two low-shear excipient-blends 
(0.1% and 0.5% MgSt) and the reference formulation without MgSt. It is clearly evident that there are significant 
differences between the high- and low-shear blends and also the reference formulation. While the APSD of the high-
shear manufactured blend shifts to a higher number of smaller particles (0-1.7 μm), the APSD of the low-shear 
formulation seems to have no or a very slight shift to a larger particle size. A much lower number of particles with a 
size below 1.7 μm are present. The increase in number of particles in the region of 2.1 μm is probably due to MgSt 
agglomerates. The histogram of Figure 57 indicates that low-shear mixing of the excipient-blend does not increase the 
dispersibility of the manufactured FP formulation. 
 
Figure 56: SPAMS Aerodynamic particle size distribution histogram of three FP blends with lactose untreated, 0.1 and 
0.5% MgSt (low-shear), respectively. The plot shows the total number of particles measured (active substance FP and 
excipients). 
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Figure 57: SPAMS Aerodynamic particle size distribution histogram of three FP blends with lactose untreated, 0.1 and 
0.5% MgSt (low-shear), respectively. The plot shows the distribution of the active substance FP only. The size bins were 
scaled to the ratio of the hit rate in order to have a comparison between the different formulations. 
Figure 58 shows NGI histograms of FP formulations. For the high-shear formulation of FP with 0.5% MgSt the NGI 
profile shows a decrease in drug deposited in the pre-separator compared to the reference formulation. There is a 
considerable increase in deposition of FP in NGI Cups 2-8 (cutoff 6.48-0.28 μm) for the high-shear formulation. While 
in the low-shear formulation there seems to be poor drug detachment from larger lactose carrier particles and therefore 
a higher deposition in the pre-separator. This results in lower performance. The drug detachment from the carrier is 
significantly different between the formulations manufactured with the two blending techniques. 
  
Figure 58: NGI profiles of FP formulations. 
To further illustrate the impact of application of MgSt and high shear blending, the fine particle fraction (FPF, particles 
with a diameter <5 μm) of FP, calculated as a percentage of total recovery, is shown in Table 16. The FPF generally 
increases with the addition of MgSt for the high-shear blends. However, there seems to be a maximum or optimal 
amount around 0.5% MgSt for the FP high-shear formulation. Introducing more MgSt into the system beyond 0.5% 
did not further improve the performance of FP in terms of FPF. The tested formulations with an amount of 0.5% MgSt 
increased roughly 8% in FPF. This observation is in agreement with the theory of unsaturated “active sites” on the 
carrier [316]. The more MgSt is introduced into the system, the less interaction between large carrier particles and 
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drug. Therefore, the likelihood to form smaller agglomerates between drug and fine lactose is increased and the amount 
of liberated drug substance is higher. The FPF did not increase for the low-shear formulations at the MgSt 
concentrations evaluated. Only at a MgSt-content of 10%, the FPF increased slightly compared to lactose untreated. 
However, there is an excess of small carrier particles which could explain the increase in FPF (Table 14) [317]. 
Table 16: Fine particle fraction (% of declared content) of FP formulations obtained by NGI 
High-shear FPF [%] StDev [%] Low-shear FPF 
[%] 
StDev [%] 
FP Lactose untreated 24.4 0.2 FP Lactose untreated 24.4 0.2 
FP Lactose 0.1% MgSt 26.3 0.2 FP Lactose 0.1% MgSt 22.0 1.2 
FP Lactose 0.5% MgSt 32.2 0.8 FP Lactose 0.5% MgSt 22.3 0.5 
FP Lactose 1% MgSt 29.5 1.2 FP Lactose 1% MgSt 23.6 1.0 
FP Lactose 10% MgSt 32.5 0.6 FP Lactose 10% MgSt 26.1 1.3 
 
Aerosol Performance of DPI Formulations by SPAMS and NGI for SX blends 
In Figure 59 and Figure 61, a comparison of SPAMS APSD histograms of total particles (API, fine lactose and MgSt) 
for SX blends with lactose untreated, lactose with 0.1 and 0.5% MgSt-content are shown with high shear and low 
shear blending, respectively. By adding MgSt to the formulation with both, high- and low-shear mixing, the APSD 
profile shifts to a higher number of smaller particles similar to the effect in the FP high-shear formulations (Figure 
54). A higher number of particles in the size range from 0-2.3 μm diameter are present. By increasing the MgSt-
content from 0.1 to 0.5% (w/w), the number of smaller particles increases and the size distribution shift is more 
pronounced. Fewer particles with an aerodynamic diameter larger than 6.1 μm were detected in the SX high-shear 
formulations with SPAMS. 
 
Figure 59: SPAMS Aerodynamic particle size distribution histogram of three SX blends with lactose untreated, 0.1 and 
0.5% MgSt (high-shear), respectively. The plot shows the total number of particles measured (active substance SX and 
excipients). 
The APSD histogram of SX particles only is shown in Figure 60. The size bins were scaled in order to compare the 
three formulations with each other on the same scale. It can be seen that there is a significant increase in number of 
SX particles with a small particle size in the range from 0-2.3 μm for the formulations containing 0.1 and 0.5% MgSt, 
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respectively. SPAMS data indicates that the high- and low-shear (Figure 62) manufactured SX blends containing the 
MgSt have a higher dispersibility compared to the reference formulation without MgSt. 
 
Figure 60: SPAMS Aerodynamic particle size distribution histogram of three SX blends with lactose untreated, 0.1 and 
0.5% MgSt (high-shear), respectively. The plot shows the distribution of the active substance SX only. The size bins were 
scaled to the ratio of the hit rate in order to have a comparison between the different formulations. 
 
Figure 61: SPAMS Aerodynamic particle size distribution histogram of three SX blends with lactose untreated, 0.1 and 
0.5% MgSt (low-shear), respectively. The plot shows the total number of particles measured (active substance SX and 
excipients). 
Figure 62 shows the APSD histogram of SX low-shear formulations compared to the reference. Interestingly, the low-
shear SX formulations show also a higher number of smaller SX particles (in the range from 0-1.9 μm), but this is not 
as pronounced as what is observed with the high shear blends where the increase in particles <1.5 µm is higher. 
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Figure 62: SPAMS Aerodynamic particle size distribution histogram of three SX blends with lactose untreated, 0.1 and 
0.5% MgSt (low-shear), respectively. The plot shows the distribution of the active substance SX only. The size bins were 
scaled to the ratio of the hit rate in order to have a comparison between the different formulations. 
In Figure 63, NGI APSD histograms of SX formulations are shown. Introducing MgSt in the formulation by high-
shear mixing increased the deposition in NGI cups 3-8 for SX particles significantly. With MgSt present in the 
formulation, the deposition of SX in the pre-separator and Cups 1-2 is greatly decreased. A higher deposition in the 
device was observed for the high-shear formulations containing MgSt. This could be related to electrostatic forces 
built up during capsule spinning (triboelectrification) during actuation, as this has been observed in previous studies 
[318]. Adding more MgSt resulted in a further increase in the device deposition. The performance in terms of FPF for 
SX reached a maximum when 0.1% MgSt (w/w) was added by high-shear mixing in the excipient-blend (Table 17). 
A higher amount of MgSt did not further improve the performance of SX. 
Surprisingly, the deposition of SX also increased when adding MgSt to the excipient-blend by low-shear mixing 
(Figure 63). The deposition significantly increased in NGI cups 3-6 for SX particles while the deposition was 
significantly decreased in the device, throat and pre-separator. High-shear mixing seemed to influence the deposition 
of SX also on the lowest NGI stages (Cups 6-8) while low-shear mixing the excipient-blends seemed to influence the 
deposition mainly in NGI Cups 3-5. This could be an indication that small agglomerates of fine excipient and drug 
are formed after actuation of the low-shear SX formulations. 
We suggest that the adhesive compound SX seems to be rather loosely distributed in the blend and the cohesive FP is 
forming agglomerates with itself. Comparing the reference formulations of FP and SX, the performance of SX was 
already much higher than the one of FP (Table 16 and Table 17). The performance of SX was improved by MgSt 
independently of the blending method used. It can be hypothesized that SX is preferentially distributed on MgSt rather 
than on lactose and therefore the blending technique has a very limited influence on SX aerosol performance. 
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Figure 63: NGI profiles of SX formulations. 
The FPF of the SX formulations is summarized in Table 17. The tested high-shear formulations with MgSt increased 
up to 18% in FPF. Interestingly, the FPF for the SX low-shear blends also increased with the amount of added MgSt. 
While the maximum in FPF was reached at a MgSt-content of 0.1% in the high-shear formulations, the maximum in 
FPF was reached at 0.5% MgSt in the low-shear formulations. A higher amount of MgSt in the low-shear formulation 
was necessary to increase the performance of SX in terms of FPF similar to the high-shear formulation. Too much 
MgSt seems to decrease the performance. Larger agglomerates of fine excipients and drug may be formed which 
deposit in the throat, pre-separator and upper NGI stages. 
Table 17: Fine particle fraction (% of declared content) of SX formulations obtained by NGI 
High-shear  FPF [%] StDev [%] Low-shear  FPF 
[%] 
StDev [%] 
SX Lactose untreated 39.2 1.3 SX Lactose untreated 39.2 1.3 
SX Lactose 0.1% MgSt 56.7 1.3 SX Lactose 0.1% MgSt 43.4 0.2 
SX Lactose 0.5% MgSt 54.2 0.7 SX Lactose 0.5% MgSt 56.3 2.0 
SX Lactose 1% MgSt 54.0 0.3 SX Lactose 1% MgSt 49.5 3.5 
SX Lactose 10% MgSt 45.9 4.2 SX Lactose 10% MgSt 50.1 1.7 
 
The results collected with SPAMS and NGI indicate that there is higher dispersibility of fine particles with an 
aerodynamic diameter below 5 μm when adding the FCA MgSt to the excipient blend by high-shear mixing. It has 
been observed from the SEM that the MgSt is modifying the lactose carrier surface. This modification is in such way 
that attractive forces, such as van der Waals or electrostatic forces, between drug and carrier and also between fine 
excipient and coarse excipient are reduced [319]. This leads to easier detachment of drug and also fine excipient from 
the coarse carrier. As a consequence, the amount of liberated drug substance increases [16]. 
The amount of MgSt added to the blend also played an important role in the DPI formulations. Introducing more MgSt 
into the system did not always result in a further increase of the aerosol performance in terms of FPF for the 
formulations (both high- and low-shear blends) although a higher amount of MgSt seems to cover more of the lactose 
surface area and should thus decreases interaction forces even more when applied on the lactose by high-shear mixing. 
The data suggests that the optimal amount of MgSt added by high-shear mixing was 0.5% for FP and 0.1% for SX. 
For the SX low-shear formulation 0.5% MgSt seemed to be optimal. This could be related to the different affinity of 
the APIs themselves to the lactose or MgSt. It can be hypothesized that above a certain concentration of MgSt in the 
excipient blend, different effects may influence the aerosol performance. Beyond a certain level of coverage on the 
carrier surface, there is no additional benefit to adding excess MgSt. 
The drug-to-carrier interparticulate forces must be weak enough to allow substantial drug detachment during the 
inhalation process while strong enough to maintain powder blend homogeneity. Particle interactions and 
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aerosolization are prone to change when surface characteristics of the drug or carrier particles such as surface energy 
[320, 321], crystallinity [322, 323], hydrophobicity [311], coating with an FCA [23, 324, 325], additives [326, 327] 
or electrostatic behaviour [328], are changed. Reduced surface energy and low surface heterogeneity are often desired 
features for aerosol formulation optimization. In the case of our high-shear formulations there is a significant change 
of surface characteristics as the outermost surface consists more of MgSt and not of lactose anymore after the high-
shear mixing process has been applied to the blend. The drug-to-carrier interaction has now changed from lactose-
API to MgSt-API. Adding more MgSt by high-shear mixing seems to further weaken the interaction between drug 
and carrier. With a higher amount of MgSt added by high-shear blending, ToF-SIMS imaging detected a higher 
relative amount of MgSt and thus we conclude a higher surface coverage. This may result in a reduced surface energy 
and altered electrostatic behaviour. Measurements with IGC by Das et al. did explain that the dispersive surface energy 
of MgSt is significantly lower compared to lactose [17]. In the high-shear formulations, the carrier surface is more 
randomly covered with a thin coating layer of MgSt as it has been demonstrated with ToF-SIMS imaging. During 
powder mixing, drug particles are distributed between the surface of carrier and fines, forming weak agglomerates of 
drug and fines that can be dispersed and disaggregated easily during aerosolization as “soft-agglomerates” [1, 38]. 
Experiments using the SPAMS technology could show that high-shear blending of lactose carrier with MgSt improved 
the dispersibility of the manufactured FP and SX formulations. 
Furthermore, the interparticulate forces can also change by altering physicochemical properties of drug or carrier 
particles such as size [226, 329], size distribution [230, 330], morphology [331-333], surface roughness [334], 
elastic/plastic deformity [335], drug/carrier ratio [316] and drug/fine ratio [179]. The addition of MgSt to the 
formulations resulted in apparent changes in particle size, size distribution, morphology, surface roughness and 
drug/fine ratio as can be seen in Table 14, Figure 47, Figure 48, Figure 50 and Figure 51. The particle size distribution 
is one of the determining factors for powder adhesion and resuspension, which will affect the powder processing and 
aerosolization. It may also influence the aerodynamics and particle deposition in the respiratory tract. The particle 
morphology may alter the true contact area and coordination number between particles. Improved aerosol performance 
can be related to smaller drug–carrier contact area. We hypothesize that the modification in surface roughness in our 
high-shear blends is also reducing the true contact area between drug and carrier and therefore we have an increased 
in vitro aerosol performance [13, 178]. In the high-shear formulations an excess of fine and very fine particles could 
be detected with SPAMS. Meanwhile, in the FP low-shear formulations, a much lower number of smaller particles 
were detected. It has been proposed that “high-energy active sites” exist on coarse lactose carrier particles [15, 167, 
193, 307]. The drug/carrier ratio and drug/fines ratio may be involved in saturation of “active sites” on the particle 
surface and/or a redistribution of agglomerates, so that an optimum drug/carrier and drug/fine ratio exists. The addition 
of ternary fines such as MgSt or lactose preferentially binds to these “active sites”, forcing the drug to the weaker 
binding site, thus drug particles are more easily liberated from the surface of the carrier particles after actuation. If 
this hypothesis is true, the “active sites” should be saturable, and the order of mixing of drug, carrier, and fines would 
result in performance difference [7, 176]. The “active site” theory could possibly explain the effects in the SX low-
shear formulations and various competing effects such as the saturation of activated areas on the carrier surface or the 
formation of drug–fines agglomerates for easier lift-off could offer an explanation for the observed behaviour [21, 
186, 193, 316]. The affinity between API and carrier is also substantially different for FP and SX. FP is a cohesive 
drug and tends to form agglomerates with itself while the adhesive drug SX is rather fine dispersed in the blend. This 
was observed in Figure 58 and Figure 63 where in the FP low-shear blend a high deposition in the pre-separator 
indicated the formation of larger agglomerates. While in the SX low-shear blend a much lower deposition in the pre-
separator was observed and thus a higher deposition in the NGI stages. 
Conclusions 
The intensity of the blending technique is demonstrated in this work to affect the distribution of MgSt covering the 
lactose carrier. This covering/distribution was shown to significantly influence the in vitro aerosol performance (as 
evidenced in ToF-SIMS images). The underlying mechanism of particle interaction between API and the carrier seems 
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to be substantially different for high- and low-shear formulations. This provides the basis for a modification in particle 
interactions from drug-lactose to drug-MgSt (in high-shear) which then seems to be responsible for the improved 
performance (enhanced particle detachment from carrier due to lower interaction forces). 
The blending method applied to pre-blend the excipients strongly impacts the APSD and FPF of FP. For SX, the 
important factor seemed to be the presence of MgSt in the blend since both blending techniques were nearly equally 
effective to increase the aerosol performance. SPAMS and NGI independently show an increase of the number of 
fines as result of the addition of MgSt by high-shear mixing, indicating a reduction of interaction between the actives 
and the lactose carrier particles. Low-shear mixing of the excipient-blend did not increase the performance of FP. 
However, low-shear mixing the excipient-blend did increase the FPF of the cohesive drug SX in our formulations. 
Nearly equal aerosol performances could be achieved for SX with both blending techniques applied to pre-blend the 
excipients. The aerosol performance of SX could be increased much more by adding MgSt compared to the 
performance of FP. This may be influenced by the properties of the APIs themselves and their interaction with the 
carrier surface (lactose or MgSt). The observed effects could possibly be explained with the “active site” and “soft-
agglomerate” hypotheses. 
Using NGI and SPAMS it is possible to distinguish changes in the formulation of DPI powders blended with different 
amounts of MgSt. The results from SPAMS can be correlated to NGI results. Valuable additional information in terms 
of dispersibility of fine particles in the formulations could also be obtained with SPAMS. SPAMS provides much 
finer particle resolutions compared to NGI cut-off stages (fine details of APSD). This gives a good understanding 
what happens with fine and very fine particles. Furthermore, SPAMS is also more sensitive for smaller particles down 
to 0.1um as with this technique the aerodynamic diameter of single particles is measured. Meanwhile the NGI relies 
on particle mass which is very low for fine particle sizes. In addition, SPAMS provides additional information on 
excipients and co-associations of particles in DPI formulations [248]. 
We hypothesize that other adhesive or cohesive APIs might show a similar behaviour in terms of in vitro aerosol 
performance as the model compounds used in this study when utilizing the proposed blending techniques. To confirm 
this further studies are necessary. This study yielded additional evidence for the mechanism of MgSt action in DPI 
formulations. 
For future work it would be interesting to explore, if other FCAs can have a similar effect when using the excipient 
high-shear mixing method. There is high possibility for association of FP or SX (or both) with lactose and/or MgSt 
and future work would involve development of techniques that could further differentiate and identify the particles 
generated. Using an upgraded SPAMS setup with a desorption and ionization laser firing at a different wavelength, 
SPAMS could potentially detect co-associations not only between APIs, but also between API and excipients (lactose 
and FCA). 
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5. Investigation of Electrostatic Behavior of Dry Powder Inhaled Model 
Formulations 
 
Jetzer et al. submitted to Journal of Pharmaceutical Sciences (November 2018) 
Abstract 
The accumulation of electrostatic charge on drug particles and excipient powders arising from interparticulate 
collisions or contacts with other surfaces can lead to agglomeration and adhesion problems during the manufacturing 
process and application of dry powder inhaler (DPI) formulations. The objective of the study was to investigate the 
role of triboelectrification to better understand the influence of electrostatic charge on the performance of DPIs with 
two capsule based devices constructed to be dimensionally the same but with different materials. Another goal was to 
investigate strategies to reduce electrostatic charge build up during the manufacturing process and study the processes 
involved in this phenomenon. Electrostatic charge measurements showed that there is a significant difference in 
electrostatic charge generated between tested formulations and devices. This affects particle detachment from carrier 
and thus significantly impacts aerosol performance. Conditioning fluticasone DPI capsules at certain temperature and 
humidity conditions reduced electrostatic charges acquired during manufacturing. Conditioning salmeterol DPI 
capsules at same conditions seemed disadvantageous for their aerosol performance due to increasing capillary forces 
and solid bridge formation due to water absorption. The presented results provide increased knowledge and 
understanding of the role of electrostatic forces in influencing DPI formulation performance. 
Introduction 
Dry powder inhalers (DPIs) are well established for delivering pharmaceutical aerosols to the lungs. They commonly 
consist of coarser carrier particles (usually α-Lactose monohydrate; >30 µm) and micronized drug particles (<5 µm) 
[7]. The addition of a carrier particle has the effect of improving the respirable fraction through the prevention of 
agglomeration of cohesive active pharmaceutical ingredients (APIs) and improving powder flowability, which 
facilitates metering and drug aerosol formation and uniform filling [3]. To reach the deeper parts of the lung, the small 
drug particles have to detach from the carrier particles [4]. The fundamental attractive forces/mechanisms of 
interaction between drug and carrier particles in DPI formulations can be summarized as van der Waals, electrostatic 
and capillary forces [7, 196]. Besides the mentioned adhesion/cohesion forces, friction and mechanical interlocking 
also play important roles in powder flow and deaggregation [197]. The drug-to-carrier interparticulate forces must be 
weak enough to allow substantial drug detachment during the inhalation/aerosolization process while strong enough 
to maintain powder blend homogeneity. The performance of DPI formulations is therefore a function of the relative 
magnitudes of cohesive (drug–drug) and adhesive (drug–excipient) interparticulate forces. Particle interactions and 
aerosolization are prone to change when surface characteristics of the drug or carrier particles such as surface energy 
[320, 321], crystallinity [322, 323], hydrophobicity [336], coating with a force control agent (FCA) [14, 23, 24], 
additives [20, 195] or electrostatic charge [337], are changed. 
The accumulation of electrostatic charge in DPI particles can occur during formulation preparation, when the API is 
sieved and blended with coarser carrier particles, and during processing, when the formulation may be transported or 
stored, filled into capsules or blister strips or transferred to a powder reservoir device. During these different 
manufacturing processes as particles are disturbed and agitated they undergo collisions with themselves and the 
surfaces with which they come into contact. During such collisions particles will become charged via the mechanism 
of triboelectrification, which may result in a bipolar charge distribution [206, 207]. Since triboelectrification arises 
from interactions between surfaces, the composition of equipment surfaces will directly affect both the polarity and 
magnitude of particle tribocharging. This is due to the fact that different materials have different abilities to transfer 
electrons from or to a surface depending on their relative abilities to donate or accept electrons. Therefore, interactions 
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between particles and different material surfaces may result in different charge levels and polarity in the powder [199]. 
This can potentially affect the physical structure of the blend and result in processing problems such as adhesion to 
container surfaces, agglomeration, poor flow behavior, reduced API recovery, loss of content uniformity and manual 
handling difficulties [208]. The presence of charge on a DPI formulation, which may not decay quickly with time, can 
result in variable formulation performance. 
To achieve a tailored API particle size (<5 μm) for a successful delivery to the lungs requires secondary processing of 
primary API crystals using highly energetic comminution techniques, such as air-jet micronization [338]. Although 
an accumulation of electrostatic charge on APIs during micronization is not commonly reported in literature, it is a 
well-known issue observed in industrial manufacturing sites. The impact and breaking apart of the API crystals within 
the mill during micronization and subsequent transfer to a storage container results in a high level of static charge 
build up on the API particles, making them difficult to handle and process [143]. 
In addition to a build-up of electrostatic charge during manufacturing and processing, DPI formulations also undergo 
triboelectrification upon aerosolization within an inhaler device. During drug dispersion in a DPI, interactions between 
the powder, air turbulence and inhaler device surface build up electrostatic charge in the aerosol cloud and along the 
inner walls of the device itself, which are made primarily from hard, insulative, plastics. Particles deagglomerate from 
each other, fluidize and enter the air stream. The particles circulate within the internal cavity of the inhaler where they 
also undergo numerous interparticulate collisions and collisions with the inner surfaces of the device. Modelling with 
computational fluid dynamics by Shur et al. reported that the velocity of the airstream travelling through the device 
can influence the particle impact velocities and frequency that govern the extent of triboelectrification [339]. Other 
factors influencing the extent of electrostatic charge during DPI aerosolization include; the deaggregation mechanism 
of the device, device material, capsule material, physico-chemical and electrical properties of the particles, humidity 
and temperature [205, 209]. The resultant electrostatic interactions between the particles may affect the extent of 
deaggregation of the API from the carrier and also the attraction to and deposition of drug on the walls of the device 
which in turn will affect the DPI performance. The group of Byron et al. investigated the net charge of pharmaceutical 
aerosols before and after aerosolization with a Faraday-pail [189]. Studies using an electrical low-pressure impactor 
(ELPI) provided the measurement of charge in various particle size fractions of the aerosol [318]. O’ Callaghan et al. 
reported evidence that the static charge generated on plastic aerosol devices resulted in significant drug retention 
within the device [340, 341]. All these studies showed that many types of DPI aerosols carry a significant amount of 
electrostatic charge that may affect in vivo deposition of fine aerosol particles in the lungs [9, 342]. 
Interparticluate forces can vary within different temperature and relative humidity (RH) settings or storage duration 
depending on the material properties of the product. The in vitro aerosol performance or drug dispersion changes 
during storage or can therefore be modified through conditioning of the DPI capsules. A number of previous studies 
investigated the influence of storage humidity on the dispersion of DPI formulations [309, 343-345]. 
Extensive research has been conducted on aerosol characteristics of DPIs such as particle size and mass output, but 
their electrostatic properties have not been studied comprehensively up to date [199, 209, 337, 346]. This study aims 
to better understand the influence of electrostatic charge on the performance of DPI formulations. The objective of 
the study was to investigate the electrostatic behavior of different custom manufactured DPI formulations with two 
identical devices constructed of different materials; plastic and metal. A custom made dynamic electrostatic charge 
measurement device (flow-through Faraday pail) and an electrostatic charge decay meter were used to analyze the 
electrostatic properties of the DPI formulations. Another goal was to investigate strategies to reduce electrostatic 
charge build up during the manufacturing process and study the processes involved in this phenomenon. 
A standard inhalation device made of Acrylonitrile butadiene styrene (ABS) plastic and a custom inhalation device 
made of titanium were used to compare device material properties and simulate a state where presumably less 
electrostatic charge is built up in the metal device due its being a conductive material with less propensity to 
tribocharge. The radical change in materials was done to generate insights in electrostatic charge generation during 
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capsule spinning and aerosolization in the inhalation device (i.e. unit dose capsule inhaler), its dependence on the 
material properties of the device and its effect on the aerosol performance. Furthermore, several formulation process 
related electrostatic effects on in vitro aerosol performance (such as: two different APIs, presence of a force control 
agent (magnesium stearate), blending method and powder conditioning/storage) have been examined. 
The results of this study are expected to provide a valuable insight into how changes of material properties during 
storage and aerosolization can affect electrostatic particle interactions of drug-carrier and drug-device, and 
consequently the in vitro aerosol performance of carrier-based DPI formulations. 
Materials and Methods 
Micronized fluticasone propionate (FP) and salmeterol xinafoate (SX) were supplied by Sandoz. Inhalation grade 
lactose monohydrate (Respitose® ML001) was purchased from DFE Pharma (Netherlands) and inhalation grade 
magnesium stearate (MgSt) from Peter Greven (Germany). Density, particle size data and specific surface area (SSA; 
Brunauer-Emmett-Teller theory) for all materials are given in Table 18. 
Table 18: Materials used in this study and measured key characteristics. 
Material Denotation Density [g/cm3] D10 [μm] D50 [μm] D90 [μm] SSA [m2/g] 
Fluticasone propionate FP 1.32 0.9 1.9 4.1 9.76 
Salmeterol xinafoate SX 1.11 0.7 1.4 2.9 6.99 
Respitose® ML001 Lactose 1.53 6.6 57.8 170.3 0.63 
Magnesium stearate MgSt 1.05 1.6 6.1 21.3 16.61 
 
Specific Surface Area 
The specific surface area (SSA) of the powders was determined by the BET method (Brunauer-Emmett-Teller theory) 
based on nitrogen adsorption using a Quadrasorb SI (Quantachrome Instruments, USA). Adsorption isotherms at P/P0: 
0.01, 0.02, 0.03, 0.04, 0.05, 0.07, 0.1, 0.15, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 and 0.9 were used. 
Laser Light Diffraction Measurements 
Laser light diffraction (LLD) analysis for particle size distribution (PSD) measurements was always performed using 
a Sympatec RODOS (Sympatec GmbH, Germany) dry dispersion system equipped with an R5 lens at 3bar. 
Density Measurements 
The density of the materials used in this study was determined with gas pycnometry (ULTRAPYC 1200e, 
Quantachrome Instruments, USA) according to the Pharmacopoeia Europea 8.0 (2.9.23) 
DPI Formulation Preparation 
Batches with a total amount of 50 g of powder (excipient and drug) were manufactured. For the high-shear excipient-
blend, inhalation grade lactose and MgSt (0.5% w/w) was blended in a Collette MicroGral 2 L (GEA Pharma Systems, 
Switzerland) for 16 min at 1400 rpm. The low-shear excipient-blend was mixed for 16 min at 34 rpm in a Turbula® 
T2F mixer 2 L (Willy A. Bachofen AG, Switzerland). In both cases, excipient-blends together with the API were 
sieved and then mixed in a Turbula mixer at 34 rpm for 16 min (low-shear blending method). The final powder was 
filled manually (25 mg per capsule) into size 3 hydroxypropyl methylcellulose capsules (HPMC, QualiCaps, Spain) 
containing a dosage strength of 200 mcg API per capsule. All formulation manufacturing, processing and testing 
parameters are given in Table 19. 
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The content uniformity of manufactured DPI capsules was measured by analyzing the quantity of active in 25 ± 0.1 
mg samples. Drug content was analyzed by high performance liquid chromatography (HPLC). Relative standard 
deviation between samples was calculated to assess the homogeneity of the different blends. 
Table 19: DPI formulation manufacturing parameters used in this study. 
 Pre-blending 
Excipient-blend 
Blending with 
API 
Filling Conditioning Actuation/Testing 
High-shear 
formulations 
Lactose + MgSt 
(high-shear) 
Excipient-blend 
+ FP or SX 
(low-shear) 
HPMC 
Capsules 
(by hand) 
Not conditioned 
(tested immediately 
after manufacturing 
and filling) 
 
Standard ABS plastic 
device 
 
Conditioned at 25°C, 
55% RH for 7 days 
Custom made titanium 
device 
Low-shear 
formulations 
Lactose + MgSt 
(low-shear) 
Excipient-blend 
+ FP or SX 
(low-shear) 
HPMC 
Capsules 
(by hand) 
Not conditioned 
(tested immediately 
after manufacturing 
and filling) 
 
Standard ABS plastic 
device 
 
Conditioned at 25°C, 
55% RH for 7 days 
Custom made titanium 
device 
 
DPI Capsule Conditioning 
Capsules were either not conditioned (tested immediately after manufacturing and filling) or stored in a clima chamber 
(CTS Clima chamber QK 10/660 EI, CTS-QS-Technik AG, Switzerland) chamber at 25°C and 55% relative humidity 
(RH) for a period of 7 days prior to the experiments for conditioning (Table 19). Previous studies have been performed 
to investigate optimal parameters for DPI capsule storage. Capsules were kept in open petri dishes. 
Inhaler Devices used in this Study 
A standard capsule based inhalation device inhalation device made of ABS plastic and a custom made inhalation 
device made of pure titanium with the exact same dimensions were used to compare device material properties 
(titanium device Figure 64 left). 
 
Figure 64: Left: Custom made (capsule based) inhalation device made of titanium with grounding wire. Right: Schematic 
of a standard capsule based inhalation device made of ABS plastic. 
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DPI Analysis by Next Generation Impactor (NGI) 
The deposition of the dry powder formulations was investigated using an NGI equipped with a pre-separator filled 
with 15 mL of solvent (Acetonitrile: Water: TFA, 58: 42: 0.1 v/v/v). All measurements were conducted at 55% RH 
and ambient temperature (23 ± 2ºC). The cup trays of the impactor were coated with Brij® reagent (1% v/v solution 
of Glycerol in Ethanol). The capsules were actuated either in a standard plastic inhalation device or in a grounded 
titanium inhalation device at a flow rate of 90 L/min for 2.7 sec. The amount of powder deposited on the different 
collection cups was recovered by extracting each cup with solvent. The remaining powder in the capsule, device, 
powder deposited in the throat and pre-separator was also collected. After dissolution of the particles, HPLC analysis 
was performed. In this study the mean of three individual determinations was taken for a given NGI result. 
FP and SX were analyzed using HPLC coupled with an UV-detector. The samples were eluted with an isocratic 
method with Acetonitrile: Water: TFA (58: 42: 0.1 v/v/v) as mobile phase, through an ACT ACE 3 C18,100 × 4.6 
mm, 3 μm column (ACE, UK). A wavelength of 225 nm was used for detecting FP and SX. The peaks eluted at 
approximately 2.0 min for Salmeterol, xinafoate at 2.9 min and FP at 7.1 min. The flow rate through the HPLC system 
was 1.5 mL/ min. Data acquisition was carried out with Chromeleon. 
Electrostatic Charge Decay of Powders 
Electrostatic properties of powders were characterized using a charge decay time analyzer (JCI155v5, Chilworth 
Technology Ltd., UK). Samples (ca. 2g) were placed in the sample holder to form an even layer. A positive corona 
discharge of 9.0 kV was applied to the sample for a duration of 0.02 s. The data analysis was commenced at 0.07 s 
after the corona discharge, and the rate of charge decay was measured until 10% of the initial charge was reached. 
Five measurements were taken for each sample at 55% RH and ambient temperature (23 ± 2ºC). 
Dynamic Emitted Electrostatic Charge (DEEC) Measurement 
Dynamic emitted electrostatic charge (DEEC) measurements were performed using an in-house designed dynamic 
Faraday cage with an isolated mesh screen inside that is isolated from external fields (Figure 65). Actuated particles 
fly through the screen and impart a charge that is detected by a JCI 178 charge measuring unit electrometer (Chilworth 
JCI 178 Charge Measurement Device) to record the electrostatic charge that the powder generated on the mesh screen. 
The DEEC device was connected to a vacuum pump (Copley Scientific, USA). Five Capsules of each formulation 
were actuated in each device at a flow rate of 90 L/min for 2.7 sec and taken as a DEEC result. The measurements 
were performed at 55% RH and ambient temperature (23 ± 2ºC). A diagram and image of the experimental setup of 
the dynamic Faraday cage is shown in Figure 65. 
 
  
Figure 65: Schematic and photo of flow through Faraday pail for the measurement of the electrostatic emitted dose of DPI 
formulations. 
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Dynamic vapor sorption (DVS) 
Dynamic vapor sorption (DVS) was used to assess the moisture sorption characteristics of the raw materials. Sorption 
profiles were determined using a DVS (Surface Measurement Systems Ltd., UK). Approximately 50mg of sample 
was weighed into the sample cell and subjected to a 0–95% relative humidity (RH) sorption cycle, over 10% (RH) 
increments. Equilibrium sorption at each humidity was determined by a change in mass to time ratio of ≥0.001 dm/dt. 
Results and Discussion 
Moisture Sorption Characteristics of the Raw Materials 
 
Figure 66: Dynamic vapor sorption profiles for pure lactose, pure magnesium stearate, fluticasone propionate and 
salmeterol xinafoate. 
Representative moisture sorption isotherms for all raw materials are shown in Figure 66. A clear difference in moisture 
sorption for magnesium stearate and the other three materials was observed. The water sorption isotherm for 
magnesium stearate follows a sigmoidal class L3 curve, suggesting multilayer water sorption onto the surface [347]. 
Magnesium stearate seems to take up around 8-10x the amount of moisture compared to the other materials. Lactose, 
FP and SX do not seem to take up a significant amount of moisture below 65% of relative humidity. 
Charge Accumulation by Corona Charging: Maximum Electrostatic Potential 
Corona discharge has been used extensively as a method for assessing the electrostatic properties of various materials 
ranging from thin films [348] and fibers [349] to polymers [350] and powders [351]. The technique is believed to 
provide results comparable with tribocharging experiments [207, 352]. 
To assess the charging behavior of each material, the maximum electrostatic potential (Vmax) of each powder was 
measured. The maximum charge provides an indication of the ability of the powder to become electrostatically charged 
under specific applied corona charging conditions. Figure 67 shows the maximum surface potential detected (Vmax) 
for each tested sample. 
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Figure 67: Maximum electrostatic potential (Vmax) of different powders and materials used in this study charged by positive 
corona discharge (22°C, 50%RH; n=5 ±SD). 
As shown in Figure 67, each sample accumulated a distinct level of charge under the same conditions. The ABS 
plastic, pure MgSt and FP acquired the highest overall charge while SX, HPMC capsules, pure lactose and the mixed 
excipient-blends containing MgSt acquired much lower overall charge. It should be noted, that HPMC and lactose 
contain similar structures. 
The ability of FP to charge was in the range of approximately 352 V while SX charged up much lower at only a Vmax 
of around 223 V. The ability of electrostatic charging of SX was therefore closer to that of lactose (Vmax 193 V). Figure 
67 could potentially indicate that the SX would likely tribocharge much less than the FP at selected experimental 
conditions. 
The tested samples can be ranked in a corona charge holding series in the order of increasing ability to accumulate 
and hold charge as follows: 
ABS Plastic > MgSt > FP > SX > high-shear excipient blend > Lactose > low-shear excipient blend > HPMC Capsules 
A recent study by Biegaj and coworkers indicated that the electrostatic properties are directly related to the surface 
functional group chemistry, with hydrophobic and electronegative groups accumulating greater quantities of charge 
than hydrophilic groups. Florine-rich surfaces, such as fluticasone accumulate much greater charge upon tribocharging 
than hydroxyl-rich surfaces as for example in salmeterol [207]. This seems to be in line with the findings in the present 
study. 
Interestingly, the ABS plastic shows a very high propensity to build up electrostatic charge, although it is commonly 
used as a material for medical inhaler devices. This material is highly insulative and therefore completely non-
conductive. The volume resistivity of ABS plastic is >1016 Ohm.cm; below 105 Ohm.cm a material is considered as 
conductive; above 109 Ohm.cm a material is considered as an electrical insulator [353]. The volume resistivity of 
lactose is 104 Ohm.cm, and the resistivity of HPMC is approximately 106 Ohm.cm. This indicates that both materials 
are at least somewhat conductive. In contrary, pure MgSt is known to be very hydrophobic and can accumulate very 
high amounts of electrostatic charge, similar to ABS plastic, which suggests a high volume resistivity. However, its 
volume resistivity is not known in literature. 
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Electrostatic Charge Decay 
An electrostatic charge decay test unit was used to characterize and compare the charge decay kinetics of the 
formulation components (FP, SX, lactose, MgSt, HPMC capsules and device material) under controlled laboratory 
conditions of 22°C and 50% RH following application of a constant corona charge voltage of 9kV across each test 
sample. The charge decay results are shown in Figure 68. 
 
Figure 68: Comparison of charge decay curves (at 22°C, 50% RH) for materials used in this study. 
It can be concluded from Figure 68 that MgSt, FP and SX are uniquely placed with respect to charge retention relative 
to the other formulation components. They all dissipate the charge extremely slowly. However, it should be noted, 
that the SX dissipates faster than FP and MgSt and furthermore, it accumulates a much lower amount of charge. In 
contrast, the charge decay of lactose, the lactose-MgSt low-shear excipient blend and HPMC capsules is extremely 
fast within only a few seconds (to 0 V). 
As expected, the decay kinetics behavior of the lactose-MgSt high-shear excipient-blend is dominated by the presence 
of MgSt on the lactose surface. As demonstrated in previous work, the magnesium stearate is not coating surface of 
the lactose particles in the low-shear blend [146], the surface mainly consists of lactose, and the electrostatic charge 
can be distributed and dissipated much faster through the lactose. 
The device material (ABS plastic) dissipates charge quite slowly compared to lactose and HPMC capsules and is 
comparable to the MgSt and FP. The ABS plastic reaches the overall highest charge potential of all tested samples. 
The results suggest that any residual charge related performance issues of the drug product would originate mainly 
from the drug substance, MgSt or device material. Lactose and HPMC Capsules dissipate the charge extremely fast. 
Although it has been described earlier that corona discharge has been used extensively as a method for assessing the 
electrostatic properties of various materials and the technique is believed to provide results comparable with 
tribocharging experiments, there are still some unknown variables and differences that cannot be simply explained. It 
is important to note that during tribocharging much lower electrostatic charges are generated as compared to corona 
charging [207]. When using corona charging for these measurements, a constant positive corona discharge of 9.0 kV 
was applied to the sample for a duration of 0.02 seconds. These measurements are very useful for characterizing the 
raw materials when they are used to predict tribocharging. Additional factors should also be considered such as 
material against which the powder is in frictional contact with and also the duration of the tribocharging event. 
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Influence of Relative Humidity on Electrostatic Charge Decay Rate 
Triboelectrification is considered as a surface phenomenon and can therefore be influenced by several external 
parameters such as for example temperature and relative humidity [354]. Typically, higher moisture content in the 
surrounding environment results in a reduction in the absolute charge generated during the tribocharging process [355, 
356] but it also will have an impact on how long a charge can remain on a surface before being neutralized. This can 
then have an impact on how long a charged powder will remain charged, depending on the environmental conditions. 
Experiments were conducted on the different blends in this study looking at the charge decay rate as a function of 
relative humidity (%RH) to gain understanding about the role %RH plays in charge decay rates that could impact 
aerosol performance. 
Figure 69 illustrates the decay time required for the charge to decrease to 10% (t1/10) of its initial level, for the samples 
tested with a corona discharge of 9.0 kV. This data quantifies how quickly powder surfaces lose charge when subjected 
to a corona charging method. 
 
Figure 69: Charge decay of FP and SX Lactose 0.5% MgSt (high-shear) formulations at different relative humidity levels 
as a result of negative corona discharge (average n=3). 
In general, an increase in relative humidity resulted in a decrease in the charge relaxation times for all samples tested 
using a corona discharge method. This general observation agrees with previously published data on the effect of 
humidity on charge decay kinetics [356, 357]. However, there is a significant difference in charge decay time highly 
depending on the API in the formulation. As seen in Figure 69, the fluticasone formulation exhibited much slower 
charge decay kinetics below relative humidity of 50% RH, while the charge on the salmeterol formulation still 
dissipated very fast (less than 100 sec) even down to 30% RH. This observation also seems to be in line with previous 
investigations that electrostatic properties of powders are directly related to the surface functional group chemistry of 
the sample measured [207]. Both the fluticasone and salmeterol formulations have very rapid charge decay kinetics 
above 50% RH. The charge decay times for different surfaces became more similar and therefore the surface chemistry 
itself became less pronounced at higher humidity levels. Interestingly, the excipient-blend for both formulations was 
manufactured with a high-shear blending method to apply a thin MgSt coating on the lactose surface [146], but the 
charge decay kinetics seemed to be mainly dominated by the API properties and not by the excipient-blend, which 
was not entirely expected as MgSt on its own showed very slow charge decay kinetics and a high propensity to 
accumulate electrostatic charge previously in Figure 67 and Figure 68. 
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It has been previously discussed in literature that charge relaxation properties could not only be dependent on the 
existing surface moisture but could also be a function of the interactions with water and ions present in the surrounding 
environment. An overall reduction in electrostatic charge by moisture is also associated with a lowering in surface 
resistivity, because of water molecules physically adsorbing on the surface. More specifically, the presence and 
adsorption of [OH(H2O)n]− and [H(H2O)n]+ ions on the surface have been identified to contribute towards a reduction 
of charge [358]. A preferential adsorption of either type of water ion, depending on the surface type, has been observed 
by Burgo et al. [359]. This indicates indeed, that water plays an important role as a source and sink of ions in the 
surface electrostatic phenomenon [359-361]. 
Electrostatic Behavior and In Vitro Aerosol Performance of FP DPI Formulations 
For DPI formulations two main causes can lead to a build-up of electrostatic charge: (A) the manufacturing process 
(micronization, sieving, mixing, filling, transport and storage) and (B) the actuation of the device (tribocharging during 
aerosolization process). For capsule based DPIs, the electrostatic forces present or acquired on drug and excipient 
powders during the manufacturing process or capsule spinning in the inhaler device can cause agglomeration with 
other particles, reduced deagglomeration of drug particles from carrier or adhesion of particles to device surfaces with 
a resulting impact on dispersion properties of DPI products. The formulation and/or its components can be 
electrostatically charged during the various API and final product manufacturing process steps, leading to a change in 
the electrostatic forces between particles and surfaces and potentially resulting in a higher retention of the powdered 
formulation on the capsule itself and device surfaces when tested shortly after manufacture. As the charge decays, the 
electrostatic forces within the formulation decline resulting in an increased dispersion efficiency of the formulation 
upon actuation from the delivery system. 
It would be expected that triboelectric charging during device actuation is highly dependent on the type of material 
the particles are undergoing frictional contact with. Measurements of triboelectric charging of the powder plume 
expelled from the inhaler were performed to assess the electrostatic behavior of model powders and DPI formulations 
and the potential influence of charge on aerosol performance (FPF). Dynamic electrostatic charge measurements were 
performed with a custom made device described in the methods section. Measurements for pure lactose and pure MgSt 
are shown in Figure 70. Using a standard plastic device made of ABS plastic, emitted pure lactose particles are charged 
slightly negative/close to zero (capsule filled with pure lactose) while pure MgSt particles are charged strongly 
positively (capsule filled with pure MgSt). When changing the device type to a grounded titanium device, pure lactose 
changed from slightly negative charge to positive while MgSt remained positively charged. 
  
Figure 70: Dynamic charge measurement of pure lactose and pure MgSt with standard ABS plastic device (left) and 
grounded titanium device (right). 
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Measurements of the dynamic emitted electrostatic charge (DEEC) showed significant differences between the various 
FP formulations tested with a standard ABS plastic device (Figure 71 and Table 20). The FP is again to have a very 
high propensity for acquiring and retaining electrostatic charge as determined from its maximum acquired potential 
(Vmax) and charge decay measurements. 
In an attempt to reduce electrostatic charge acquired during the powder manufacturing process to optimize aerosol 
performance, capsules were conditioned at 25°C and 55% RH in order to dissipate the charge. In general, an increase 
in relative humidity resulted in a significant decrease in the dynamic electrostatic charge for all of the samples tested 
in this study. This general observation agrees with our data and previously published data on the effect of humidity 
on charge decay kinetics [205, 207]. For all tested FP formulations, the measured charge was significantly lower 
(closer to zero) after the conditioning step (tested with the standard ABS plastic device). A strong relative difference 
(Δ) in the range of 1-2 nC was measured between conditioned and not-conditioned FP DPI capsules with the 
unconditioned capsules generating higher electrostatic charges when using a standard plastic device (Table 20 and 
Figure 71). However, no significant effect before and after conditioning could be detected when using the titanium 
device. Table 20 shows that the effect of humidity on charge decay rate is different for different powder formulations. 
 
Figure 71: Dynamic electrostatic charge measurement with standard ABS plastic device for FP formulations before and 
after conditioning (n=5 capsules shot ±SD). 
The results in Figure 71 show that the addition of MgSt to a FP lactose formulation changes the overall polarity of the 
powder with low-shear mixing having a positive and high charge upon actuation. This might be because with low-
shear MgSt is still present as discrete particles in the formulation, which will charge up during tribocharging. Since 
MgSt is an electrical insulator and is not in direct contact with conductive surfaces and has minimal contact surface 
with the lactose and API particles it will therefore strongly retain charge (based on slow charge decay measured for 
pure MgSt, Figure 68). However, when applied through high-shear blending [146], the thin layer of MgSt (<10 nm) 
is in direct contact with lactose, which could act as an effective sink (based on the rapid charge decay measured for 
lactose, Figure 68) for the charge, thus lowering the overall impact of having MgSt in the formulation. Values in a 
similar range have been measured by Byron and coworkers for the APIs budesonide and salbutamol sulfate using 
similar measuring techniques [189]. 
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Table 20: DEEC measurement of FP formulations before and after conditioning (n=5 ± SD). 
 
ABS plastic device Titanium device 
Formulation Charge [nC] SD Δ Charge [nC] SD Δ 
FP Lactose untreated - not conditioned -1.63 0.9  2.85 0.66  
FP Lactose untreated - conditioned -0.26 0.84 1.37 2.58 0.64 0.27 
FP Lactose 0.5% MgSt (high-shear) - not conditioned 1.55 0.21 
 0.68 0.28  
FP Lactose 0.5% MgSt (high-shear) - conditioned 0.62 0.01 0.93 0.8 0.22 0.12 
FP Lactose 0.5% MgSt (low-shear) - not conditioned 5.3 0.76  3.09 0.23  
FP Lactose 0.5% MgSt (low-shear) -conditioned 3.2 0.41 2.1 2.75 0.35 0.34 
 
Many of the theoretical models developed to describe charge transfer and triboelectrification assume that charged 
species are only transferred from one material to another resulting in a unipolar charge distribution for each material 
present during the contact [362]. But during the manufacture of respiratory drug products, particles will undergo 
multiple collisions with many different types of materials such as stainless steel (equipment for micronizing and 
blending), gelatin or hydroxypropylmethyl cellulose (HPMC) used for capsules and plastic and/or metal components 
of the inhaler. Excipient-excipient, excipient-API and API-API collisions will also lead to charge transfer [363]. While 
the overall net charge of the powder will remain constant, due to the different types of collisions involved some 
particles will become positively charged and some will become negatively charged, resulting in a bipolar charge 
distribution within the powder where the particles will be both positively and negatively charged at the same time. 
Furthermore, different particle sizes will charge differently. [364].This can be difficult to assess accurately using 
conventional methods of measuring net charge as net charge only provides a sum of the positive and negative charges 
present [365, 366]. Bipolar charge can be measured using an electrical low pressure impactor (ELPI). Since the MgSt 
prefers to charge positively and the FP prefers to charge negatively, it may also be possible that the overall charge of 
such a formulation is neutral (or close to zero) and this could then be advantageous for powder dispersion mechanics 
and thus aerosol performance. The bipolar charge then depends on multiple factors, such as the number of particles 
involved, their size and identity. 
 
Figure 72: Dynamic electrostatic charge measurement with grounded titanium device for FP formulations before and after 
conditioning (n=5 capsules shot ±SD). 
Measuring the dynamic electrostatic charge using the titanium device shows a reduction in electrostatic charge 
compared to the standard plastic device for both the high- and low-shear blends containing MgSt in the non-
conditioned state. Furthermore, there was no more significant difference detected before and after conditioning for all 
FP formulations (Figure 72). Interestingly, the charge generated using the titanium device for the blends containing 
MgSt (conditioned and not-conditioned) were at the same levels as the electrostatic charge levels generated for the 
same formulations using the standard plastic device with conditioned capsules. 
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For the FP Lactose untreated formulation there was a shift from negative to positive overall charge with the difference 
in device contact material (ABS plastic-titan). An important aspect in addition to the magnitude of the charge seems 
to be the polarity of the electrostatic net charge generated. Negative charge has been described in literature to decay 
much slower than positive electrostatic charge [359]. (Small) Negative electrostatic charge also seems to be 
disadvantageous for aerosol performance (FP Lactose untreated). Furthermore, generating high positive electrostatic 
charge also results in lower aerosol performance (Figure 73). 
Comparing the electrostatic charge built up in the two tested devices, it was detected that there is a lower amount of 
electrostatic charge generated when actuating the capsule in the grounded titanium device. This difference in charge 
indicates that a significant amount of charge in the powder is from triboelectrification in the device itself. A significant 
amount of electrostatic charge is also depending on the materials in the formulation. Another interesting finding was 
also that there was no longer a significant difference in electrostatic charge between conditioned and un-conditioned 
samples when using the grounded titanium device (Δ relative difference). These findings seem to be in line with what 
Elajnaf and coworkers concluded that the effect of humidity on charge decay kinetics can be further affected by the 
nature of the contacting surface, as differing extents of charge reduction could be observed when the same powder 
interacted with metal or plastic surfaces [355]. 
Assuming that a significant amount of electrostatic charge is generated due to tribocharging in the device upon 
aerosolization of the formulation and not during formulation manufacturing at least for FP, then another hypothesis 
for the increase in aerosol performance could also be that adding moisture by conditioning the DPI capsules is 
modifying (decreasing) the way in which tribocharging occurs in the device. An overall reduction in electrostatic 
charge by moisture is associated with a lower surface resistivity, because of water molecules adsorbing on the surface 
[358, 359]. This would mean that less tribocharging can be occurring after conditioning of the capsules due to the 
presence of moisture in the formulation and capsule shell. In contrast to the standard ABS plastic device, the grounded 
titanium device presumably only generates low amounts of tribocharging, and the difference in electrostatic charge 
before and after conditioning of the DPI capsules might be negligible as the moisture effect is almost irrelevant. 
Comparing the dynamic electrostatic measurements for FP to the in vitro aerosol performance determined with cascade 
impaction testing (Figure 73) it seems evident that the electrostatic behavior has a considerable influence on the 
performance for the FP formulations tested in this study. After conditioning the capsules at given conditions, the in 
vitro aerosol performance was improved in all tested FP formulations when using a plastic device. 
The impact of the observed electrostatic effects on the in vitro aerosol performance in terms of fine particle fraction 
(FPF, % of declared content) of the fluticasone formulations after manufacturing and after storage for seven days 
under controlled conditions at 25°C and 55% RH are given in Figure 73. 
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Figure 73: Fine Particle Fraction (FPF; % of declared content; ± SD) of Fluticasone Propionate DPI formulations before 
and after conditioning at 25°C/55% RH for 7 days obtained by NGI (n=3 capsules). 
A consistent and reproducible change in FPF was observed before and after conditioning of the FP DPI capsules. In 
vitro data show that a significant increase in performance was determined for the fluticasone formulations when 
actuating with an ABS plastic device for unconditioned DPI formulations. The FP formulations increased about 6% 
(abs.) (Lactose untreated), 11% (Lactose 0.5% MgSt high-shear) and 3% (Lactose 0.5% MgSt low-shear) in FPF after 
conditioning of 7 days using the ABS plastic device. Interestingly, no significant difference was observed before and 
after conditioning when actuating the FP capsules with the grounded titanium device. These observations for the 
plastic device go in hand with a significant reduction of electrostatic charge (Δ) as can be seen from Table 20, Figure 
71 and Figure 72. The titanium device showed no change from unconditioned to conditioned and this can reflect the 
lack of change in FPF. 
Figure 74 and Figure 75 show plots of the electrostatic charge (determined from the dynamic charge measurement) 
against fine particle fraction (determined by NGI measurement) of fluticasone formulations before and after 
conditioning. The measurements for Figure 74 were obtained with the ABS plastic device while for Figure 75 the 
titanium device was used. It can be clearly seen that the tested formulations exhibiting a total electrostatic charge < 
±1 nC results in higher in vitro aerosol performances. In Figure 75 it can also be seen that the presence of MgSt and 
the use of the high-shear blending technique results in lower electrostatic charge and higher aerosol performance. 
Overall, the electrostatic charging behavior for the fluticasone formulations using the titanium device seems to be also 
less variable compared to the ABS plastic device (Figure 74).  One thing that seems to apparent from Figure 11 is that 
the overall polarity of the powder is significant and that less negative charge seems to be more detrimental to in vitro 
performance than the equivalent positive charge for FP formulations.   
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Figure 74: Electrostatic charge vs. fine particle fraction of fluticasone propionate tested with an ABS plastic 
inhalation device (before and after conditioning). 
 
Figure 75: Electrostatic charge vs. fine particle fraction of fluticasone propionate tested with a titanium 
inhalation device (before and after conditioning). 
  
Figure 76: Aerodynamic particle size distribution of fluticasone high-shear formulations before and after conditioning 
(25°C/55% RH for 7 days) obtained with NGI (APSD; average n=3 capsules ± SD). Actuation with standard ABS plastic 
device (left) and grounded titanium device (right). 
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Figure 76 shows the NGI APSD histograms for the FP Lactose 0.5% MgSt (high-shear) formulation before and after 
conditioning using either the plastic device or the grounded titanium device. It could be determined that there was no 
difference in the APSD profile before and after the conditioning period when using the grounded titanium device. 
However, there were apparent differences measured when using a plastic device. A significant reduction in drug 
deposition was observed in the capsule, inhaler device and pre-separator. This resulted in a large shift to smaller 
particle size and better drug detachment from larger carrier. The deposition in NGI stages 2-8 was significantly 
increased. 
The blending technique also seems to have an impact on the interparticulate electrostatic forces. High-shear blending 
of MgSt seems to modify the carrier surface so that electrostatic forces, between drug and carrier and also between 
fine excipient and coarse excipient, are much reduced as witnessed by the increase in fine particles observed for FP 
with NGI (Figure 73). The modification of particle interaction from drug-lactose to drug-MgSt (in high-shear) seems 
to be responsible for the improved performance (enhanced particle detachment from carrier due to lower interaction 
forces). Low-shear blends with FP seem to have a reduced drug detachment, even after conditioning, from the carrier 
due to high interactive forces such as van der Waals or capillary forces (non-electrostatic forces) and also electrostatic 
forces (as witnessed in this study) and therefore a lower FPF. 
Electrostatic Behavior and In Vitro Aerosol Performance of SX DPI Formulations 
Measurements of the dynamic emitted electrostatic charge (DEEC) for the SX formulations are shown in Figure 77 
(ABS plastic device), Figure 78 (grounded titanium device) and Table 21. All tested SX formulations seemed to exhibit 
weak electrostatic forces. SX does not have the same propensity to charge as FP and in fact seems to dissipate 
electrostatic charge relatively effectively. This was observed as SX had quite a low propensity for acquiring 
electrostatic charge as determined from its maximum acquired potential (Vmax) around only 220 V as compared to the 
highly electrostatic compound FP around 350 V. Furthermore, there was no difference in dynamic emitted electrostatic 
charge detected before and after conditioning (p>0.05) of the SX DPI formulations when using the plastic device 
(Table 21). 
Measuring the dynamic electrostatic charge using the titanium device shows a shift from positive to negative overall 
charge for the MgSt-blends with the difference in device contact material. Interestingly, there was also no significant 
(p>0.05) change between conditioned and un-conditioned samples (Δ relative difference). All formulations tested with 
the plastic had a dynamic electrostatic charge around +1.1nC. Using the grounded titanium device, the formulations 
containing MgSt exhibited an average dynamic charge around -1.4nC while the Lactose formulation had an average 
dynamic charge around +1.3nC. The conditioning step did not seem to influence the electrostatic charging behavior 
of SX (relative difference Δ in the range of 0.02 nC after conditioning). 
All three SX formulations exhibited a relatively high in vitro aerosol performance (as compared to the highly 
electrostatic FP) as could be verified with NGI (Figure 73). This could also be attributed to the weak electrostatic 
interaction forces measured in the SX formulations. 
Table 21: DEEC measurement of SX formulations before and after conditioning (n=5 ± SD). 
 ABS plastic device Titanium device 
Formulation Charge [nC] SD Δ Charge [nC] SD Δ 
SX Lactose untreated - not conditioned 1.08 0.21  1.54 0.45  
SX Lactose untreated - conditioned 1.06 0.34 0.02 1.15 0.32 0.39 
SX Lactose 0.5% MgSt (high-shear) - not conditioned 1.11 0.39  -1.55 0.36  
SX Lactose 0.5% MgSt (high-shear) - conditioned 1.08 0.6 0.03 -1.22 0.16 0.33 
SX Lactose 0.5% MgSt (low-shear) - not conditioned 1.15 0.21  -1.36 0.31  
SX Lactose 0.5% MgSt (low-shear) - conditioned 1.14 0.18 0.01 -1.36 0.66 0 
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Figure 77: Dynamic electrostatic charge measurement with ABS plastic device for SX formulations before and after 
conditioning (n=5 capsules shot ±SD). 
 
Figure 78: Dynamic electrostatic charge measurement with grounded titanium device for SX formulations before and after 
conditioning (n=5 capsules shot ±SD). 
 
Figure 79: Fine Particle Fraction (FPF; % of declared content; ± SD) of Salmeterol Xinafoate DPI formulations before and 
after conditioning at 25°C/55% RH for 7 days obtained by NGI (n=3 capsules). 
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In vitro aerosol performance data show that storage at the conditions used did affect the FPF of salmeterol with a 
considerable decrease after storage. The SX formulations decreased around 3% (Lactose untreated), 16% (Lactose 
0.5% MgSt high-shear) and 11% (Lactose 0.5% MgSt low-shear) in FPF when conditioned at 25°C and 55% RH for 
7 days and actuated with a plastic inhaler device. This is in stark contrast to the FP formulations, where a significant 
increase in performance was observed after storage when actuating the FP capsules with the ABS plastic device. The 
decrease in aerosol performance for SX formulations using a plastic device was determined to be much more 
pronounced if MgSt was present in the formulation. The decrease of 3% in performance for the SX Lactose untreated 
formulation seems to be negligible. This might be due to the ability of MgSt to take up a much higher amount of 
moisture than the other formulation components (Figure 66). A hypothesis could be that due to a higher water uptake 
there is an increased likelihood to form water bridges in these formulations. Further studies are necessary to learn 
more about this phenomenon. 
 
Figure 80: Electrostatic charge vs. fine particle fraction of salmeterol xinafoate tested with an ABS plastic 
inhalation device (before and after conditioning). 
 
Figure 81: Electrostatic charge vs. fine particle fraction of salmeterol xinafoate tested with a titanium inhalation 
device (before and after conditioning). 
Figure 80 and Figure 81 show plots of the electrostatic charge (determined from the dynamic charge measurement) 
against fine particle fraction (determined by NGI measurement) of salmeterol formulations before and after 
conditioning. The measurements for Figure 74 were obtained with the ABS plastic device while for Figure 75 the 
titanium device was used. The amount of electrostatic charge built-up using an ABS plastic device does not seem to 
differ between the tested salmeterol formulations as can be seen in Figure 80. The in vitro aerosol performance seems 
to be more dependent on the presence of MgSt in the formulation and on humidity exposure rather than on electrostatic 
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charge. Overall, only lower amounts of electrostatic charge in the range of +/-1.5 nC were measured for SX 
formulations.  From the results in Figure 81, it seems that the addition of MgSt results in a negative charge relative to 
contact with titanium device material in presence of salmeterol. 
  
Figure 82: Aerodynamic particle size distribution of salmeterol low-shear formulations before and after conditioning 
(25°C/55% RH for 7 days) obtained with NGI (APSD; average n=3 capsules ± SD). Actuation with standard ABS plastic 
device (left) and grounded titanium device (right). 
Figure 82 shows the NGI APSD histograms for the SX Lactose 0.5% MgSt (high-shear) formulation before and after 
conditioning using either the standard plastic device or the grounded titanium device. It could be determined that there 
was no significant (p>0.05) difference in the APSD profile before and after the conditioning period when using the 
grounded titanium device. Similar to the FP formulation in Figure 76 there were apparent differences measured when 
using a plastic device. However, a significant reduction in drug deposition was observed in NGI stages, while the 
deposition in the capsule, mouthpiece/throat and pre-separator was significantly increased. The conditioning period 
resulted in a shift to larger particle size and decreased drug deagglomeration from carrier. 
Hygroscopicity is the intrinsic tendency of a material to take on moisture from its surroundings. It is affected by the 
crystallinity of the material and the particle morphology. Hygroscopic drugs such as SX present a greater risk of 
physical and chemical instability while more lipophilic APIs such as FP are expected to have only a very limited water 
uptake [367]. Moisture uptake and loss due to changes in relative humidity can result in local dissolution and 
recrystallization of the API, leading to irreversible aggregation through solid bridge formation [8], which can 
negatively influence aerosol generation and thus decrease lung deposition [343]. This water uptake can alter adhesive 
and cohesive properties or even increase particle size substantially. Hygroscopic growth has implications for the 
equilibrium moisture content of the particles in the dosage form prior to aerosol generation and it can cause chemical 
or physical instability of the product in some cases [368]. A number of excipients can modify the hygroscopic 
properties of a drug. Previous studies have also evaluated the influence of storage humidity on the dispersion of DPI 
formulations [309, 369, 370]. Young et al. observed that the fine particle fraction (FPF) of some APIs decreased at 
elevated humidity while other APIs exhibited an increased in vitro aerosol performance when stored at different 
humidity conditions [370]. 
Currently it is not fully understood why there is no drop in performance for the conditioned SX formulations with 
MgSt when using the titanium device. In this study it could be demonstrated that the dynamic emitted electrostatic 
charge is different depending on the device material. Although both the ABS plastic and titanium device have the 
exact same dimensions, it was observed that the surface of the titanium device is much rougher compared to the 
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smooth surface of the injection molded ABS plastic device. Further studies are necessary to investigate an effect of 
device surface roughness on drug deagglomeration and particle-particle or particle-wall collisions. A difference in 
device surface roughness might lead to different spinning properties (e.g. turbulence) due to a presumably smaller 
contact area of capsule and device surface. 
Conclusions 
The results of the present study highlight that electrostatic forces and interactions play a significant role in dry powder 
inhaled formulations. Large differences in the electrostatic charging behavior were observed. Fluticasone propionate 
seems to have a high propensity to electrostatically charge, while salmeterol xinafoate only showed a negligible 
electrostatic charging behavior. FP drug particles tend to acquire and carry much higher electrostatic charges compared 
to SX particles and excipients (with the exception of pure MgSt). APIs may also possess a larger variety of elements, 
including halogen containing functionalities such as in FP. Therefore they may be more electrically resistive, which 
makes them more prone to acquiring charge. This ability of acquiring large charges could be potentially magnified 
even further when coupled with typically small particle sizes of APIs, as these tend to accept greater charges compared 
with large particles. Most of the common excipients used in DPI formulations, such as lactose monohydrate, possess 
hydroxyl groups on the surface and do not experience significant charge accumulation. Other formulation components 
like the HPMC capsules did not charge significantly in comparison to other excipients such as MgSt. 
DPI formulation conditioning at certain temperature and humidity levels can be used to reduce electrostatic charges 
built up during the manufacturing process. This could be demonstrated by measuring the dynamic charge before and 
after storage of FP formulations. This process is highly dependent on the propensity of the API to accumulate 
electrostatic charge. APIs that have a low propensity to build up electrostatic charge, such as salmeterol xinafoate, 
may not benefit from this conditioning process. In fact, for SX, a conditioning step and exposing the drug product to 
humidity was found to be disadvantageous in terms of aerosol performance. Capillary interactions seemed to lead to 
agglomeration and poor drug dispersion. Another hypothesis might be that conditioned DPI capsules are simply 
tribocharging less because they contain a higher amount of moisture. An overall reduction in electrostatic charge by 
moisture is associated with a lowering in surface resistivity, because of water molecules adsorbing on the surface. 
This would mean that less tribocharging can be generated after conditioning of the capsules due to the presence of 
moisture in the formulation. Since this study did not evaluate the performance of the formulations after prolonged 
storage, the impact of any change generated during the manufacture of DPIs during stability has yet to be evaluated, 
with obvious simplications for any shelf-life. 
Device material also seemed to be an important factor for DPI performance. ABS plastic, which is commonly used as 
material for medical inhaler devices, showed a very high propensity to build up electrostatic charge. Its bulk resistivity 
and insulative properties are well known in literature. Measuring the dynamic charge when using a grounded titanium 
device showed that less triboelectric charge was built up during the aerosolization process for FP capsules which in 
turn resulted in higher aerosol performance. SX capsules generated only low amounts of electrostatic charge 
independently of the device material. 
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CHAPTER 3: UNPUBLISHED DATA 
1. Detection of Particle Co-associations using Raman Microscopy 
The combination of the long-acting β2-agonists and inhaled corticosteroids has shown enhanced efficacy compared 
with concurrent administration of the two drug classes from individual inhalers at the same dose. A possible 
explanation for this increased effect is a higher degree of co-deposition of the two drugs from the combination inhaler 
compared with the component drugs administered separately [38, 101, 106, 256, 263]. 
The goal of this project was to use Raman laser spectroscopy, a technique capable of identifying individual drug 
particles, together with the nearest neighbor function methodology, to determine whether there is any co-association 
between drug particles. Raman laser spectroscopy was applied to particles deposited on the stages of a Next Generation 
Impactor (NGI). This method is capable of identifying individual drug particles and presents images where particles 
are color coded. Previously this technique has been shown to highlight deposition of beclomethasone and salbutamol 
from a Ventide® metered dose inhaler in a study by Fraser Steele et al. [371]. The ratios of salbutamol-beclomethasone 
identified by Raman spectroscopy were found to be similar to that of the quantified amounts, but an assessment of co-
deposition was not made. A similar approach has also been used by the group of Theophilus et al. to analyze a 
Seretide® MDI formulation. Concurrent samples of salmeterol xinafoate and fluticasone propionate were taken from 
stage 4 of an Andersen Cascade Impactor. This plate was considered to represent the dose delivered to the central 
airways [270]. 
However, after preliminary tests using commercial and proprietary model DPI formulations (data not shown) it was 
concluded that the particle concentration on the impactor stage was too high (even after actuating only one capsule) 
and it was impossible to disambiguate whether particle co-associations were formed before (during manufacturing, 
aerosolization or in the aerosol cloud) or upon particle impaction on the plate. The sampling method was likely to bias 
the results. Collecting a sample on stage 4 of the NGI at particle concentrations similar to those reported is expected 
to result in powder piles accumulating under the nozzles on the impactor stage (Figure 83). 
 
Figure 83: NGI collection cups with characteristic deposition pattern after actuation of a DPI formulation. 
Therefore, determining the chemical composition of individual particles with a technique measuring particles in an 
aerosol cloud in real-time such as SPAMS should yield more definitive data [248]. Nevertheless, drug particles from 
combination inhalers could still be deposited individually at the same location in the lungs and exhibit their 
complementary effects. 
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2. Determination of the Carrier Surface Coverage with Magnesium Stearate using 
Raman Microscopy 
It has been recognized from previous work that there is a need to establish the nature and extent of carrier surface 
coatings, and for a detailed study of the relationship between the extent and nature of the coating and the particle 
interactions as well as bulk powder characteristics. This can be very difficult to achieve because of technological 
challenges of characterizing such thin coating layers on the surface of particles that can be in the range of only 
nanometers. Conventional techniques such as Raman spectroscopy penetrate the coating layer and measure both, the 
coating layer and the host particles (see Figure 84). Time-of-flight secondary ion mass spectrometry (ToF-SIMS) is a 
highly sensitive analytical technique that provides chemical information regarding elemental, isotopic and molecular 
structure from the first few layers of small particles [24, 312]. Therefore, ToF-SIMS was used in this study to further 
investigate particle coating and MgSt distribution of carriers. 
   
Figure 84: Raman spectroscopy micrographs of excipient-blend mixtures. Left: Lactose 0.5% MgSt (high-shear); Middle: 
Lactose 5% MgSt (high-shear); Right: Lactose 10% MgSt (high-shear). Color codes: Blue = Lactose; Yellow = MgSt. 
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3. Combination Dry Powder Inhalation Formulations of Fluticasone Propionate and 
Salmeterol Xinafoate 
The guidelines for the treatment of patients with COPD (GOLD) mention the use of long-acting beta2-receptor 
agonists (LABA) in combination with inhaled corticosteroids (ICS) whenever the patient’s treatment with ICS alone 
is insufficient. In this manner, the two fundamental processes of the disease can be addressed simultaneously 
(bronchoconstriction and inflammation). The co-administration of ICS/LABA for chronic obstructive pulmonary 
disease has resulted in reduced mortality compared to either drug administered alone. It was discovered that the co-
administration of the two types of drugs in the same formulation resulted not only in increased patient convenience, 
but also showed improved β2-adrenoceptor and glucocorticoid receptor function, as well as a reduction in 
inflammation due to the synergistic effects [101, 106]. For this effect to occur, both drugs need to be present on the 
same cell in the airways. It has been shown to reduce exacerbations, hospitalization, emergency department visits and 
health care costs [372, 373]. A possible explanation for this increased effect is a higher degree of co-deposition of the 
two drugs from the combination inhaler compared with the respective drugs administered separately. Administration 
of the two drugs via the same inhaler would lead to an increased likelihood of co-deposition compared with the 
administration via two separate inhalers. This is because natural variation in inspiratory maneuvers, causing different 
deposition patterns within the lung between inhalations from two separate inhalers, is avoided when both drugs are 
delivered in a single breath. It is possible that the opportunity for synergistic action is further enhanced in the 
combination formulation by co-deposition of FP and SX particles in the airways as a result of particle co-association 
during the manufacturing process or aerosolization event [248]. 
Several combination product development programs are currently underway. Additionally, there is a great interest in 
the development of ‘generic’ combination inhalers combining for example corticosteroids with long-acting β2-
agonists such as in Advair® Diskus® (SX with FP). The equivalence of two products is usually assessed in vitro, by 
comparing drug deposition using parameters such as the mass median aerodynamic diameter (MMAD), geometric 
standard deviation (GSD), fine particle dose (FPD) and fine particle fraction (FPF) (FPD and FPF are often defined 
as the amount or proportion of particles with an aerodynamic diameter <5 μm). However, it is currently thought that 
changes to the particle size distribution within the range of 1–5 μm may affect the drug’s site of deposition within the 
lungs, and thus possibly producing significant clinical differences. In vitro, this may be assessed by comparing drug 
deposition within a multi-stage cascade impactor on a stage-by-stage basis. Guidance by the European Medicines 
Agency (EMEA) has been introduced defining a step-wise approach to demonstrating bioequivalence between 
different inhalation products [374, 375]. The ‘innovator’ and the ‘generic’ product must be equivalent (within ± 15%) 
when tested at all flow rates with respect to all individual stage depositions or at least 4 justified grouped stages [263]. 
Only limited work has been done up to date investigating drug deposition when aerosolized from combination versus 
single-active formulation. Despite the potential similarities in FPD and FPF values between the single-active and 
combination products, difference in stage-by-stage deposition may be found which might explain the reported clinical 
differences between the two types of products. 
The aim of this study was to investigate the particle detachment from carrier, dispersion mechanisms and particle co-
associations of active pharmaceutical ingredients (APIs) in model combination products. Up to the present, only 
limited assessments have been carried out on the nature of particle of the delivered dose emitted from the device. 
Another goal of this work was to compare the in vitro aerosol performance and stage-by-stage deposition of dry 
powder inhaled formulations aerosolized from single-active FP and SX with the respective FP–SX combination 
formulations. 
3.1 In Vitro Aerosol Performance of Combination DPI Formulations by NGI 
A detailed study of the influence and mechanism of the force control agent magnesium stearate in FP and SX mono 
DPI formulations can be found in Jetzer et al. [146]. 
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In Figure 85, the in vitro aerosol performance in terms of fine particle fraction (FPF) of three FP-SX combination DPI 
formulations is shown. Figure 86 shows the FPF of the respective FP and SX mono DPI formulations. Co-formulation 
of the two active ingredients in lactose monohydrate dry powder blends lead to substantial changes in aerosol 
performance (FPF) and the APSD profiles of the active ingredients compared to their mono formulations. When 
comparing mono and combination formulations, it can be seen that the combination of FP and SX in the same DPI 
formulation resulted in an increase of approximately 10% in FPF for SX compared to their in vitro performance 
administered alone. Meanwhile the FPF of FP did not change. Adding 0.5 % MgSt to the combination formulation by 
high-shear mixing further increased the FPF of SX for about 8% and also increased the FPF of FP (around 11% 
compared to lactose untreated). Adding 0.5% MgSt to the combination formulation by low-shear mixing did not 
influence the performance of FP, however it did increase the performance of SX. While these effects are well 
understood from a pharmaceutical process development point of view, there is only limited mechanistic understanding 
of what physical processes and interactions between the particles are responsible for phenomena such as 
compound/compound interactions (particle co-associations) in a formulation. 
 
Figure 85: Fine Particle Fraction of the tested FP-SX Combination DPI Formulations obtained by NGI (n=3 DPI actuations; 
error bars represent one standard deviation). Capsules were not conditioned. 
  
Figure 86: Fine Particle Fraction of the tested FP and SX mono DPI Formulations obtained by NGI (n=3 DPI actuations; 
error bars represent one standard deviation). Capsules were not conditioned. 
Figure 87-Figure 90 show the NGI stage-by-stage profiles from the FP-SX mono and combination formulations. It is 
clearly evident that there are significant differences between the particle depositions in the various stages of the 
formulations with differing blending technique. Both drugs FP and SX, show a significant increase in deposition of 
fine particles in the impactor stages (NGI Cup 2 to Cup 8) when adding MgSt to the excipient-blend by high-shear 
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mixing as well as a significant decrease in drug deposition in the pre-separator. This suggests better detachment from 
coarse carrier resulting in a higher deposition in the NGI stages (and hence a higher FPF). The plots show significant 
differences between mono and combination formulations. 
 
Figure 87: NGI profiles of FP in FP-SX combination DPI formulations (n=9 capsules actuated; error bars represent one 
standard deviation). 
 
Figure 88: NGI profiles of FP mono DPI formulations (n=9 capsules actuated; error bars represent one standard deviation). 
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Figure 89: NGI profiles of SX in FP-SX combination DPI formulations (n=9 capsules actuated; error bars represent one 
standard deviation). 
 
Figure 90: NGI profiles of SX mono DPI formulations (n=9 capsules actuated; error bars represent one standard deviation). 
The Mass Median Aerodynamic Diameter (MMAD) and Geometric Standard Deviation (GSD) measurements of the 
aerodynamic particle size distributions of all FP-SX formulations are shown in Table 22. Interestingly, the MMADs 
of both FP and SX in the mono products were detected to be larger than the ones in the combination products (for 
both, lactose untreated and high-shear formulations). While there was no difference in MMAD between mono and 
combination formulations for the low-shear blends. The MMAD for the high-shear combination formulation was 
detected to be the smallest. It is important to note that even though significant differences in MMAD for these 
formulations were measured using the standard pharmacopoeial methodology, this does not necessarily mean they 
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will have significant differences with respect to regional deposition, since their median values may be considered 
similar (ca. 3–4 μm). 
Table 22: Mass Median Aerodynamic Diameter (MMAD) and Geometric Standard Deviation (GSD) of the FP and SX 
mono and combination Formulations calculated from NGI. 
 MMAD (μm) GSD  
MONO DPI PRODUCTS FP SX FP SX 
Lactose untreated 4.71 2.97 1.84 2.23 
FP and SX Lactose 0.5% MgSt (high-shear) 4.33 2.13 1.93 2.13 
FP and SX Lactose 0.5% MgSt (low-shear) 4.71 2.34 1.80 2.04 
 MMAD (μm) GSD  
COMBINATION DPI PRODUCTS FP SX FP SX 
FP-SX Lactose untreated 4.58 2.67 1.87 2.12 
FP-SX Lactose 0.5% MgSt (high-shear) 3.58 2.12 1.89 2.15 
FP-SX Lactose 0.5% MgSt (low-shear) 4.70 2.69 1.83 2.12 
 
3.2 In Vitro Aerosol Performance of Combination DPI Formulations by SPAMS 
The hitrate for the combination products was at 64% for FP-SX Lactose untreated, 36% for FP-SX Lactose 0.5% 
MgSt (high-shear) and 54% for FP-SX Lactose 0.5% MgSt (low-shear). The hit rate for the different formulations can 
depend on several factors as described by Jetzer et al. [248, 249]. Excipients in a formulation, such as lactose and/or 
MgSt, will significantly decrease the hit rate. 
 
Figure 91: Aerodynamic particle size distribution of FP-SX Combination formulations obtained by SPAMS (n=3 DPI 
actuations). The plot shows the distribution of total particles (API + excipients). The bars in this plot are normalized with 
the hitrate of each formulation. 
Figure 91 shows a comparison of SPAMS APSD histograms of total particles (API, fine lactose and fine MgSt) for 
FP-SX combination formulations. By adding MgSt to the formulation by high-shear mixing, the APSD profile 
increases to a much higher number of smaller particles in the size range from 0-3.9 μm diameter. The high-shear 
mixing process used in this study seems to lead to comminution of larger MgSt agglomerates to (very) fine MgSt 
particles. Therefore, a much higher number of particles is present compared to the reference formulation. While in the 
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low-shear mixing process, not enough shear forces to break the agglomerates are applied to the blend. Only a very 
small increase in number of particles in the region of 1.5-3.7 μm can be seen due to the addition of MgSt (Figure 91). 
The Median Aerodynamic Diameter (MAD) measurements of the aerodynamic particle size distributions of processed 
and unprocessed FP-SX formulations are shown in Table 23. Generally, the MADs for the low-shear formulation were 
detected to be coarser than those from the high-shear formulations. Therefore it was concluded that there may be an 
agglomeration of API and excipient (possible MgSt). The MAD for the high-shear combination product was 
determined to be the smallest. These findings would explain the increased performance of this particular formulation. 
Table 23: Median aerodynamic diameter (MAD) calculated from the FP-SX combination DPI products measured by 
SPAMS. 
MAD [um] Total FPSX FP SX Unassigned 
FP-SX Lactose untreated 1.89 2.32 2.40 1.71 1.90 
FP-SX Lactose 0.5% MgSt (high-shear) 2.03 2.26 2.12 1.89 2.13 
FP-SX Lactose 0.5% MgSt (low-shear) 2.05 2.46 2.44 1.90 2.27 
 
The particle co-associations and interactions in combination products may influence the ratio and MAD of the APIs 
in a formulation. It is possible that a certain particle size of each API preferentially forms heterogeneous agglomerates 
as reported by Jetzer et al. [248]. Because DPI formulations also contain excipients such as lactose, it seems likely 
that pure particles (FP or SX) and co-associated particles (FPSX) are made of agglomerates of API and excipient, 
resulting in larger particle size. 
Figure 92-Figure 94 show the APSD of APIs in FP-SX Lactose untreated, FP-SX Lactose 0.5% MgSt (high-shear) 
and FP-SX Lactose 0.5% MgSt (low-shear) combination formulations, respectively. Both, mono API particles and co-
associated API particles are plotted. The APSD histograms show the fractionation of the “hit” particles. The collected 
data demonstrates that a considerable fraction of all particles emitted contained both APIs in co-association (25-33%). 
Due to the dosage strength of 200/200 mcg and given the much smaller particle size of SX compared to FP used in 
this study (Jetzer et al. [146]), many more SX particles are present in the formulations. A higher number of pure SX 
particles (about 58-66%) were detected than pure FP particles (7-9%). Only a very small fraction of particles (< 2%) 
could not be identified, most likely due to insufficient ionization. 
 
Figure 92: Aerodynamic particle size distribution of FP-SX Lactose untreated obtained by SPAMS (n=3 capsule actuations; 
error bars represent one standard deviation). The plot shows the distribution of number of particle co-associations (FPSX), 
pure FP, pure SX and unassigned particles. The bars in this plot are normalized with the hitrate of the tested formulation. 
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In the reference formulation (FP-SX Lactose untreated), 28% of all hit particles contained FP and SX in co-association 
as can be seen in Figure 7. A majority of FP particles (81%) also contained SX. 
 
Figure 93: Aerodynamic particle size distribution of FP-SX Lactose 0.5% MgSt (high-shear) obtained by SPAMS (n=3 
capsule actuations; error bars represent one standard deviation). The plot shows the distribution of number of particle co-
associations (FPSX), pure FP, pure SX and unassigned particles. The bars in this plot are normalized with the hitrate of 
the tested formulation. 
In the FP-SX Lactose 0.5% MgSt (high-shear) formulation the highest percentage of particle co-associations of FP-
SX (33%) were detected. A lower number of smaller particles (0.3-1.5 μm) were detected compared to the reference 
and low-shear formulations. This is most likely a result of the fine particles forming particle co-associations which 
results then in the higher number of particles in the range from 1.9-3.1 μm. Also, a much lower number of particles in 
the range from 5.5-6.7 μm were measured. 
 
Figure 94: Aerodynamic particle size distribution of FP-SX Lactose 0.5% MgSt (low-shear) obtained by SPAMS (n=3 
capsule actuations; error bars represent one standard deviation). The plot shows the distribution of number of particle co-
associations (FPSX), pure FP, pure SX and unassigned particles. The bars in this plot are normalized with the hitrate of 
the tested formulation. 
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Figure 95 shows the overlay of co-associated particles of FP-SX in the combination products (Lactose untreated, 
Lactose 0.5% MgSt (high-shear) and Lactose 0.5% MgSt (low-shear). A much higher number of FP-SX co-associated 
particles are present in the Lactose 0.5% MgSt (high-shear) formulation with the highest number of particles in the 
range of 1.7-3.3 μm. Also the MAD for the three formulations seems to be quite different. 
 
Figure 95: Overlay of aerodynamic particle size distribution of co-associated particles of FP-SX in the combination products 
(Lactose untreated, Lactose 0.5% MgSt (high-shear) and Lactose 0.5% MgSt (low-shear)). The bars in this plot are 
normalized with the hitrate of the tested formulation. 
MADs determined by SPAMS for co-associated particles of FP and SX were found to be slightly different in the tested 
combination formulations (Table 23 and Figure 95). Interestingly, the MAD was detected the smallest for the FPSX 
Lactose 0.5% MgSt (high-shear) formulation with 2.26 μm while 2.32 and 2.46 μm for the Lactose untreated and low-
shear formulation, respectively. 
Adding 0.5% MgSt by high-shear mixing to the excipient-blend increased the number of particle co-associations about 
5% compared to the reference formulation without MgSt. Low-shear mixing of the lactose-MgSt excipient-blend did 
not influence the ratio of particle co-associations in the tested formulations. The combination of FP and SX in one 
formulation resulted in an enhanced in vitro aerosol performance compared to either drug tested as mono formulation. 
The addition of MgSt by high-shear mixing to the excipient-blend could further increase the performance of the 
combination DPI products to some extent. Adding MgSt by low-shear mixing did not alter the aerosol performance 
compared to no MgSt in the formulation. 
Table 24: Percentage of individual particles measured in the formulations (10’240 particles per run). 
[%] FPSX FP SX Unassigned 
FP-SX Lactose untreated 27.5 8.6 62.9 1.0 
FP-SX Lactose 0.5% MgSt (high-shear) 32.6 7.8 58.1 1.5 
FP-SX Lactose 0.5% MgSt (low-shear) 25.8 8.6 64.5 1.1 
 
Looking at the aerosol populations in their entireties, significant levels of API particle co-associations were detected 
in all tested combination products (Table 24). Around 33% of all particles in FP-SX Lactose 0.5% MgSt (high-shear) 
were found to contain both APIs. A significantly lower percentage of pure SX particles (58%) were measured in this 
particular formulation. The levels of particle co-association of FP and SX in the other tested formulations did not 
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differ much. Low-shear mixing the excipient-blend did not seem to affect the number of drug particle co-associations 
in the tested formulations. 
Table 25: Percentage distribution of total FP and SX in the formulations in co-associated or pure state in the tested 
combination products. 
[%] 
FP-SX Lactose 
untreated 
FP-SX Lactose 
0.5% MgSt (high-shear) 
FP-SX Lactose 
0.5% MgSt (low-shear) 
FP co-associated 76 81 75 
SX co-associated 30 36 29 
FP pure 24 19 25 
SX pure 70 64 71 
 
Most of the FP (around 80%) was detected to be in co-association with SX. While still a very large fraction (around 
70%) of SX was found to be made of pure particles. A possible explanation for this effect is the dosage strength and 
particle size distribution of the raw materials (FP and SX). The SX was much finer than the FP. Therefore many more 
SX particles overall are present in the formulations. 
The deposition of FP and SX from single-active versus combination formulations on an NGI stage-by-stage basis was 
determined to be significantly different. Both APIs in the combination products appear to affect the deposition of each 
other. Concentration-related trends may be observed when expanding this study with different dosage strengths of FP 
and SX. However, no firm conclusions can be drawn to date why such differences in drug deposition are happening 
in the combination formulations. More studies are necessary to investigate important factors such as the particle size 
distributions of the two drugs, the effect of dosage strength, particle interactions and the drug-carrier interaction area 
and cohesive-adhesive balance on in vitro aerosol performance of combination DPI formulations. 
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CHAPTER 4: GENERAL CONCLUSIONS 
For many decades DPI products have been successfully developed using a variety of formulation strategies including 
drug-only or powder mixture approaches containing only one single excipient (alpha lactose monohydrate). Single 
excipient based formulations continue to be used in approved commercial DPI products today. Novel dual excipient 
formulation strategies containing ternary materials such as the force control agent magnesium stearate are now 
considered to be a somewhat standard formulation approach as witnessed in the latest DPI product approvals. 
Scientific literature is claiming that the addition of magnesium stearate may improve the fine particle dose 
performance characteristics of DPI formulations [189-191]. 
The understanding of the particle-particle interactions and determination of DPI formulation in vitro aerosol 
performance are key requirements for the rational and effective research and development of novel formulations. The 
present thesis aimed at improving the mechanistic understanding of particle interactions in engineered dry powder 
inhaled formulations (adhesive mixtures) using advanced analytical tools such as single particle aerosol mass 
spectrometry (SPAMS). 
The SPAMS technique was identified to be able to distinguish small changes in DPI and pMDI formulations. A range 
of model formulations blended with different amounts of the force control agent magnesium stearate with various 
APIs was successfully investigated. Valuable reproducible additional information in terms of dispersibility of fine 
particles in the formulations could also be obtained with SPAMS. The SPAMS instrument sizes emitted particles from 
an inhaler in the size range from ca. 0-10 µm. This means that also information about fine excipients (e. g. lactose 
fines or force control agents) in the tested formulation is generated and can therefore be evaluated for a better 
understanding of the product. 
The development of a precise, accurate, robust analytical test methodology is a key part in the development and quality 
control of inhalation drug products. SPAMS as an additional or alternative technique to the current compendial cascade 
impaction test methods should meet all these goals and also the comparability of its measurements must be 
demonstrated (as well as repeatability and reproducibility [247]). The aerodynamic particle size distribution profiles 
(APSD) of pMDI and DPI products were obtained using SPAMS and then compared to those obtained by the 
Aerodynamic Particle Sizer and NGI. In addition, the transmission efficiency of SPAMS as well as potential size bias 
of APSD measurements that might result from a size dependent transmission profile were evaluated. This study 
demonstrated the application of SPAMS for the analysis of pharmaceutical aerosols in real-time for semi-quantitative 
analysis. It could be shown that the SPAMS can generate useful APSD measurements for both pMDI and DPI 
products. The APSD results generated using SPAMS can be transformed and compared to APSD data generated using 
cascade impactors. However, a consistent anomaly of particle transmission in the SPAMS in the region of 2-3 µm was 
found. 
Measurements of the commercially available combination pMDI and DPI products Seretide® and Advair® Diskus® 
using the SPAMS technique showed that a significant fraction of the emitted drug particles fluticasone propionate and 
salmeterol xinafoate can form co-associated particles with other APIs (and maybe excipients) in the same formulation. 
Unique mass spectral fragmentation patterns can be recognized and assigned for each API using the SPAMS data 
analysis software. SPAMS also revealed which particle size fractions are most likely forming these co-associations. 
Measurements with SPAMS have demonstrated that particle co-associations between drug product components can 
be evaluated in a way that is inaccessible via cascade impaction techniques. A deeper understanding about product 
performance and particle interactions can be gained, providing valuable information for combination products. Using 
SPAMS it could be demonstrated that the degree of particle co-association can be manipulated by the choice of 
formulation and manufacturing approach for DPIs. It is possible that in the manufacturing process drugs or carrier can 
be processed together with a force control agent such as magnesium stearate to improve dispersion mechanics. A 
possible explanation may be that the drug or the carrier receive an MgSt-coating that would prevent the co-association 
or agglomeration of the particles and moreover facilitate detachment from carrier. This results in high in-vitro 
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performance (and furthermore very high extra fine particle fraction of particles <2 µm) and a relatively fine APSD 
profile compared to products not engineered in this way. 
The choice and intensity of the blending technique of the excipient mixture was found to affect the distribution of the 
force control agent magnesium stearate covering the lactose carrier. This covering/distribution was shown to 
significantly influence the in vitro aerosol performance (as evidenced using the ToF-SIMS technique). The underlying 
mechanism of particle interaction between API and the carrier seems to be substantially different for high- and low-
shear formulations. This provides the basis for a modification in particle interactions from drug-lactose to drug-MgSt 
(in high-shear) which then seems to be responsible for the improved performance (enhanced particle detachment from 
carrier due to lower interaction forces). SPAMS and NGI techniques independently showed an increase of the number 
of fines as result of the addition of MgSt by high-shear mixing, indicating a reduction of interaction between the 
actives and the lactose carrier particles. Low-shear mixing of the excipient-blend did not increase the performance of 
FP. However, low-shear mixing the excipient-blend did increase the FPF of the adhesive drug SX in our formulations. 
Nearly equal aerosol performances could be achieved for SX with both blending techniques applied to pre-blend the 
excipients. The aerosol performance of SX could be increased much more by adding MgSt compared to the 
performance of FP. 
In carrier based mixtures for inhalation a proper balance has to be obtained between the stability of the blend during 
storage and handling, and dispersibility during inhalation. This requires control of the interparticulate forces in the 
mixture in order to prevent segregation on the one hand and insufficient dispersion of drug particles in the required 
aerodynamic size distribution from the blend on the other. Storage and conditioning of DPI capsules at controlled 
temperature and humidity levels showed to have a significant effect on the separation of drug and carrier particles. 
Significant differences were observed between adhesive and cohesive model compounds (with respect to lactose). The 
present study highlights that electrostatic forces and interactions play a key role in dry powder inhaled formulations. 
Large differences in the electrostatic charging behavior were observed. Fluticasone propionate seems to have a high 
propensity to electrostatic charging, while salmeterol xinafoate only showed a negligible electrostatic charging 
behavior. Most of the common excipients used in DPI formulations, such as lactose monohydrate, do not seem to 
experience significant charge accumulation. Other formulation components like the HPMC capsules did not charge 
significantly in comparison to other excipients such as MgSt. Conditioning of certain APIs was found to be helpful to 
dissipate electrostatic charge which in turn increased aerosol performance. Significant differences were also observed 
when using different device materials: the standard inhaler device made of ABS plastic showed to generate a high 
amount of tribocharge while a grounded titanium device (made of pure titanium; with same dimensions) showed to 
build up lower electrostatic charges. 
The effects of DPI formulation variables on drug dispersion performance can be explained by changes in three overall 
factors: (1) The size distribution of the drug particles (including drug/drug and drug/fine-lactose agglomerates or 
degree of particle co-associations) as they detach from the carrier surface; (2) The interaction forces between drug and 
carrier; (3) The properties of the APIs (e. g. physico-chemical properties, ability to tribocharge, behavior when 
exposed to temperature or humidity, cohesive/adhesive balance with respect to the carrier). 
In summary, this thesis combines improvements to the analytical methodologies such as SPAMS with the systematic 
investigation of dry powder inhalation drug product formulations to advance the understanding of in vitro aerosol 
characteristics of formulations at a fundamental mechanistic level. It also highlights the relevance of electrostatic 
forces in DPI formulation in vitro aerosol performance. The improved conception of the interplay between variables 
in the formulation and dispersion mechanics of adhesive mixtures resulting from this thesis may stimulate the effective 
implementation of quality by design approaches to dry powder inhalation product development. In addition, it may 
facilitate and speed up the development of generic or more efficiently dispersing products with the advantage to lower 
the dosage strength and ultimately reduce unwanted side effects for patients. 
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CHAPTER 5: FUTURE OUTLOOK 
One of the most important goals for the further development of dry powder inhalation should be the improvement of 
efficacy of such inhalers. Despite of a gradual increase in the total lung deposition over the past decades from less 
than 10% (!) to 20-40% for currently marketed inhalers, still less than half of the dose becomes available to the site of 
action (or site of absorption). In general, the performance of a DPI system can be improved by establishing a better 
balance between the three types of forces shown in Figure 96: (a) interparticulate forces in the powder formulation, 
(b) dispersion forces generated in the DPI and (c) deposition forces in the respiratory tract [137, 138]. 
 
Figure 96: Desired balance for optimal DPI therapy between the interparticulate forces in the powder formulation, the 
dispersion forces generated by the inhaler device and the deposition forces in the respiratory tract during inhalation. 
Adapted from [138]. 
In DPI formulation research and development, several challenges still remain despite many years of effort put in the 
understanding of mechanisms of powder dispersion. For adhesive mixtures some relevant variables, like moisture 
content or roughness have extensively been described, but there is insufficient knowledge of the mixture properties 
and the processes occurring during the mixing process that affect the final performance of the mixture. The extent to 
which particles de- and re-agglomerate and distribute over the carrier surface and to which the interparticulate forces 
are increased by inertial and frictional forces during blending are difficult to measure and require the introduction of 
new techniques. 
Most studies in the literature investigate and discuss the understanding and controlling of the factors that determine 
the interparticulate forces in dry powder formulations. They aim to improve the dispersion of the powder during 
inhalation [6, 8, 136, 172, 228, 309, 310, 317, 324, 332, 376]. The inhaler design as an important factor in powder 
dispersion has mostly been neglected in many studies until just recently [377, 378]. So far, most studies still focus on 
studying the performance of existing devices or investigating the effect of small design modifications thereon [339, 
379-381] as well as understanding the mechanisms of powder dispersion [382-384]. The design of new inhaler 
technology is hardly studied. Peer reviewed publications dealing with computational fluid dynamics-assisted new DPI 
developments are still quite rare although most pharmaceutical companies make use of this technique by now. With 
the availability of such new techniques in combination with an increased understanding of the mechanisms of powder 
dispersion, better integrated device-formulation development becomes possible. One of the challenges is to design 
optimally tuned combinations of the powder formulation and the dispersion principle. In this respect it is highly 
regrettable that still many consultancy agents or plastic manufacturers continue developing inhaler concepts for the 
market, initially not knowing for which types of formulation these concepts will be used. Part of the newly developed 
devices, or existing devices used for new powder formulations are still low resistance capsule based DPIs [111, 129, 
133, 163, 385, 386]. This has the disadvantage that powder properties need to be optimized with respect to both 
emptying of the capsules and good dispersion. If the drug formulation is an adhesive mixture, the carrier material 
providing best flow properties for discharge of the capsules may not always be the first choice from a dispersion point 
of view. 
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Cascade impaction testing requires mastery of a complex technique before consistent results can be achieved. NGI-
testing results in a large demand on resources in terms of laboratory personnel and solvents, the measurements are 
very time-consuming and results are typically returned days or even weeks later [29, 30]. There is, therefore, high 
interest in the development and routine use of more rapid techniques that might have particular application for routine 
product quality testing as well as in product development applications in which many similar impactor measurements 
are often necessary [31]. The SPAMS technique is an attractive additional technique in the field of pharmaceutical 
aerosol analysis and complementary to the current standard of impactor/HPLC-analysis. The results of this thesis 
indicate that the SPAMS technique is very well able to distinguish between small changes in the formulation of various 
DPI powders (and also pMDIs). The results from SPAMS can be correlated to NGI results. Valuable additional 
information in terms of dispersibility of fine particles in the formulations can also be obtained with SPAMS. SPAMS 
provides much finer particle resolutions compared to NGI cut-off stages (fine details of APSD). It is also more 
sensitive for smaller particles down to 0.1 μm as with this technique the aerodynamic diameter of single particles is 
measured. Meanwhile the NGI relies on particle mass which is very low for fine particle sizes. In addition, SPAMS 
also may be used to investigate the nature of API particulates and provide feedback control for the level of particle 
co-association (API-API or API-excipient) in early-phase development of inhaled products [248].  
The Analysis of organic compounds in aerosol particles using real-time single particle techniques is difficult because 
of the extensive fragmentation that occurs in the laser desorption/ionization step [243]. The current setup of the 
SPAMS 3.0 instrument contains a one-step desorption/ionization excimer laser using a krypton-fluoride gas mixture 
(KrF) firing at a wavelength of 248 nm [246]. In an effort to avoid extensive fragmentation and make the identification 
of the analyte compounds easier, a modification to the SPAMS to allow for a two-step laser desorption/ionization 
would potentially make identification of analytes less problematic than the current single laser system. Such an 
upgrade to the SPAMS instrument would be highly valuable for the analysis of pharmaceutical aerosols. An upgraded 
SPAMS with separate desorption and ionization lasers firing at a different wavelength could potentially detect co-
associations not only between APIs, but also between API and excipients (lactose or force control agents) in the future 
if an appropriate ionization wavelength were selected (for example 193 nm using an argon-fluoride (ArF) gas mixture) 
[283]. This might shed more light on particle dispersion mechanisms of complex DPI systems. 
For the development of generic versions of established DPI or pMDI products, the SPAMS technique might help 
generic drugmakers to better analyze and characterize innovator products with regards to dispersion mechanics, 
particle interactions and co-associations in the formulation. Such an approach might also speed up the development 
of generic drugs and therefore ultimately reduce costs for the pharmaceutical industry, patients and healthcare systems. 
Several generic versions of for example Advair® Diskus®/Seretide® are currently under development [387]. 
Additional future work would be to explore, if other force control agents than magnesium stearate can have a similar 
effect when using the excipient high- or low-shear mixing method. Alternate blending or coating techniques could be 
explored to apply such a force control agent on the carrier surface. Another attractive area of research could also be 
to further probe the treatment of drug particles instead of processing only the carrier particles. In this way, the degree 
of drug-drug/drug-excipient particle co-association could be controlled. This would enable to target the different 
regions of the human lung by controlling (if a co-association is desired) or even preventing such a formation of 
agglomerates. Such a formulation approach would potentially result in very high in vitro aerosol performance and 
therefore ultimately might lead to high lung deposition in patients. Combined with a two-step laser 
desorption/ionization SPAMS system this could provide more insight into particle deagglomeration and dispersion 
mechanics in dry powder inhaled formulations of adhesive mixtures. 
Although product development focuses on minimizing variability across all aspects of the product, it is also important 
to understand there is an inherent variability among patients, who differ both in their oropharyngeal and airway 
anatomies and in their breathing profiles. Overcoming this variability is a key challenge in inhaled product 
development. Differences in lung deposition because of anatomical variability can be addressed through design of 
powder and device combinations that enable aerosols that largely bypass the mouth and throat. 
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LIST OF ABBREVIATIONS 
ABS  Acrylonitrile butadiene styrene 
AFM  Atomic force microscopy 
API  Active pharmaceutical ingredient 
APS  Aerodynamic particle sizer 
APSD  Aerodynamic particle size distribution 
BDP  Beclomethasone dipropionate 
BUD  Budesonide 
CAB  Cohesive-adhesive balance 
CFC  Chlorofluorocarbon 
COPD  Chronic obstructive pulmonary disease 
DPI  Dry powder inhaler 
FCA  Force control agent 
FF  Formoterol fumarate 
FP  Fluticasone propionate 
FPF  Fine particle fraction 
GINA  Global initiative for asthma 
GOLD  Global initiative for chronic obstructive pulmonary disease 
HFA  Hydrofluoroalkanes 
HPLC  High performance liquid chromatography 
HPMC  Hydroxypropyl methylcellulose 
IGC  Inverse gas chromatography 
ICS  Inhaled corticosteroids 
LABA  Long-acting β2-agonist 
LOD  Limit of detection 
LOQ  Limit of quantification 
MgSt  Magnesium stearate 
NGI  Next generation impactor 
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pMDI  (pressurized) metered dose inhaler 
RH  Relative humidity 
SABA  Short-acting β2-agonists 
SCF  Supercritical fluid 
SD  Standard deviation 
SEM  Scanning electron microscopy 
SPAMS  Single particle aerosol mass spectrometry 
SS  Salbutamol sulphate 
SX  Salmeterol xinafoate 
ToF-SIMS Time-of-flight secondary ion mass spectrometry 
XPS  X-ray photoelectron spectroscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
